Cancer

744

Cancer Tumor biology

donor kidneys - Long term experiences with 40 transplants. Transplantation 1997, 63:233-237. Brooks BK, Levy MF, Jennings LW, Abbasoglu O, Vodapally M, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB: Influence of donor end recipient gender on the outcome of liver transplantation. Transplantation 1996, 62:1784-1 ?87. Brown RS, Lomberdero M, Lake JR: Outcome of patients with renal Insutfl¢lency undergoing liver or liver-kidney transplantation. Transplantation 1996, 62:1788-1793, Burbach GJ, Rianzle U, Neuhaus R, Hopf U, Metzger WG, Pratschke J, Neuhsus P: Intravenous or intramuscular enti-HBs ImmunoglobuIin for the prevention of hepatitis B reinfection after orthofopic liver trsnspientstlon. Transplantation 1997, 63:4?8-480, Candines D, Msrk W, Kaever V, Miysteke T, Koysmada N, Hechenleitner P, Hancock W~N: Immunomodulatory effects of the alkaloid slnomenine In the high responder ACI-to-Lewls cardiac ellograft model. Transplantation 1996, 62:1855-1860. Cosi FG, Qiu WZ, Henry ML, Falkenhain ME, Elkhammas F_~ Davies F_.A,Bumgerdnar GL, Ferguson RM: Factors related to the donor organ are major dstermlmints of renal ellograft function end survivsl. Transplantation 1996, 62:1571-1576. Dijoseph JF, Ruhiar E, Armarong J, Sherr M, Sehgal SN: Therapeutic blood levels of slmlimus (rapamycin) in the sllografted rat. Transplantation 1996, 62:1109-1112. Egaws H, Berquist W, Garciakennedy R, Cox K, Knlesly AS, Esquivel CO: Rapid development of hepatocelluiar slderosis after liver transplantation for neonatal hernochromstosis. Transplantation 1996, 62:1511-1513. Feral G, Gochat P, Serrebeeuvals F, Vialtel P, Chevalllet C, Cuzin B, Bouviar R, Lachaux A: MIzodblne as an eltemstiva to azathidpdne in pediatric renal transplantation [Letter]. Transplantation 1996, 62:1701-1702. Fast LD: Recipient CD8(+) cells are responsible for the rapid elimination of sllogeneic donor lymphoid cells. J Immunol 1996, 15Y:4606-4810. Fischer 1", Miller M, Bottsilverrnan C, Lichfin A: Posttransplsnt lymphoprcliferstlve disease after cardiac transplantation - Two unusual vsdsnts with predominantly piasmecytoid features. Transplantation 1996, 62:1687-1690. Rechner SM, Modlin CS, Sen'ann DR Goldfsrb DA, Papsjcik D, Mastroianni B, Goormestic M, Novick AC: Determinants of chronic renal allograft rejection in cyclosporine-trested recipients. Transplantation 1996, 62:1235-1241. Gainer AL, Kod0utt GS, Rsjotts RV, Wamock GL, Elliott JF: Successful biollstic trsmiformatlon of mouse pancreatic islets while presenting cellular function. Transplantation 1996, 61:1567-1571. Goggins WC, Rsher RA, Kimball PM, Wolfe L, Hill BE, • PietruszkaTD, Shiffman ML, Sanyal AJ, Luketic VAC, Hem JM, Posner MP: The impact of s positive crossmstch upon outcome after liver transplsntstlon. Transplantation 1996, 62:1794-1798. Hammed P, Welnlich D, Hertl .A, ThalhsmerJ: A non-expressed transgene as s cell marker for the Investigation of cellular traffic after splenic sutotrenspientstlon. J Immunol Methods 1996, 194:131-139. Hariheran S, Smith RD, Viam R, First MR: Diabetic nephropathy after renal transplantation - Clinical and pathologic features. Transplantation 1996, 62:632-635. Hausan B, Muller P, Bahra M, Ramsamooj R, Hewitt CW: Donor pretreatment with intravenous prostacyclin versus inhaled nitric oxide in experimantsl lung transplantation. Transplantation 1996, 62:t 714-1719. Heckiostteicher B, Wosnik A, Kirschfink M: Protection of pordne endothelial cells from complement-mediated cytofoxicny by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor t~)e 1 - Analysis in a pig-to-human in vitro model relevant to hyperecuta xenogrsft rejection. Transplantation 1996, 62:1693-1696. Haneine W, Switzer WM: Highly sensitive and specific polymerase chain reaction assay= for detection of bsboon and pig cells following xenotrensplantation In humans. Transplantation 1996, 62:1360-1362. Imagsws DK, Dawson S, Hclt CD, Kirk PS, Kaldss FM, Shackieton CR, Seu P, Rudich SM, Kinkhabwsla MM, Marlin R Goldstein LI, Murray NGB, Terasaki I=1, Busuttil RW: Hyperlipldemis after liver trsmipiantstion - Natural history and tre=d='nent wRh the hydroxy-mathylglutsryl-coenzyme a reductsse inhibitor pravaststin. Transplantation 1996, 62:934-942.

Imagswa DK, Olthoft KM, Yersiz H, Shackleton CR, Colquhoun SD, Shaked A, Busuttil RW: Rapid en bloc technique for pancreas-liver procurement - Improved usdy liver function. Transplantation 1996, 61:1605-1609. Jonnalagsdda S, Veerabagu MP, Rskels J, Kusne S, Randhsws P, Rabinovitz M: Candida elbicans ostaomyelltis in a liver transplant recipient - A case report and review of the literature. Transplantation 1996, 62:1182-1184. Kaplen B, Wang 7_, Abeoessis MM, Fryer JP, Stuart FP, Kaufman DB: Frequency of hyperkelernia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. Transplantation 1996, 62:1174-1175. Kerahner RP, Fitzsimmons WE: Relationship of FKS06 whole blood concentrations end efficacy end toxicity altar liver and kidney transplsntation. Transplantation 1996, 82:920-926. Kukkonen S, Heikkiia L, Verkksia K, Msttila S, Toivonen H: Abnormal in viva response to sodium nitroprusside after porcine single lung transplantation. Transplantation t 996, 61:1435-1439. Lee S, Dsilva M, Wang YCt, Man L, Nozawa M, Yea CH, Wolf P, Chung WS, Hs J, Cho C, Kim S, Youngkin T, Yoder T, Gittes RF: Sequential isologous organ transplantation in inbred rots - Pancreatlcnduodenal transplants. Transplantation 1997, 63:20-25. Lorante L, Aller MA, Aries JL Arias J: Complement: A cascade with neuro, immune, and endocrine functions [Letter]. Transplantation 1996, 91:1424-1425. Maher SE, Kermann K, Min W, Hughes CCW, Pober JS, Bothwell ALM: Porcine endothelial CD86 is s major costimulator of xenogenslc human T cells - Cloning, sequencing, and functional expression in human endothelial cells. J Immuno/1996, 157:3836-3844. Malyszko J, Mslyszko JS, Pswlak K, Mysliwie¢ M: The coagulo-lytic system and endothelial function in cyclospodne-trestsd kidney allogrsft recipient. Transplantation 1996, 62:628-830. Marsman WA, Wiesner RH, Rodriguez L, Bstts KP, Porayko MK, Hay JE, Gores GJ, From RAF: Use of fatty donor liver is associated with diminished eady patient and graft survival. Transplantation 1996, 62:1246-1251. Mcsherry C, Jackson A, Hertz MI, Boltman R, Savik K, Reinsmoen NL: Sequential measurement of podpheral blood allogenelc microchimedsm levels and association with pulmonary function. Transplantation 1996, 92:1811-1818. Melendez HV, Dhswan A, Mialivergani G, Rels M, Heaton ND, Pritcherd J, Mowat A: Liver transplantation for Lengorhens' sell histiocyfusls - A case report and literature review. Transplantation 1996, 62:1167-1171. Muhm M, Zuckermann A, Prokesch R, PammerJ, Hiasmsyr M, Haider W: Eady onset of pulmonsry mucormycosls with pulmonary vein thrombosis in a heart transplant recipient. Transplantation 1996, 62:1185-118?. Oriordan K, Blei A, Ran MS, Abecassis M: alpha 1-antltrypsln dsticiency-essociated panniculitis: Resolution with Intravenous alpha 1-antitrypsin administration and liver transplantation. Transplantation 1997, 63:480-482. Paul LC, Myliamiemi M, Muzaffer S, Benediktsson H: Nitric oxide synthase inhibition is associated with decreased survival of cardiac eliografts in the rat. Transplantation 1996, 62:1193-1195. Peraldi MN, Akposso K, Hsymann JP, Rahsut A, Marlin C, Rondeau E, Sraar JD: Long-term benefit of intravenous immunoglobulins in cadavedc kidney mtranspiantation. Transplantation 1996, 62:1670-1673. Ridings J, Weedon H, Ioannou C, Flego L, Mscardle PJ, Zols H: Purification of cord blood lymphocytes. J Immunol Methods 1996, 195:43-48. Rodeck B, Melter M, Kardorff R, Hayer PF, Ringe B, Burdelski M, Oldhafer KJ, Pichlmsp" R, Brodehl J: Liver transplantation in children with chronic end stage liver disease -Factors influencing survival after transplantation. Transplantation 1996, 62:1071-1076. Rotter BA, Oh YN: MTS/PMS calorimetric assay is unsuitable for measuring mifogenic responses in porcine Mood lymphocytss. J Immunol Methods 1996, 199:205-209. Sammett D, Dagher F, Abbi R, TomasuIs JR, Delaney V, Butt KMH: Renal transplantation in muRiple myelorna -case report and review of the literature. Transplantation 1996, 62:1577-1580. SchoJz M, Bleheta RA, Henrich D, Cinatl J, Markus BH, Boerr HW, C~natl J: Immunomodulatury properties of the metal chelators desferriosemine and diathytanetriamine penta-acatic acid in vitro. Transplantation 1996. 62:1371-1374.

Schreiner T, Prochnowcalzia H, Manceri B, Eme E. Kinder I, Wolpl A, Wieseeth M: Chlmedsm analysis after ellogenelc bone marrow binsptantstion with nonradioactive RFLP and PCR-AFLP using the same DNA. J Immunol Methods 1996, 196:93-96. Scomik JC: The flow cytometry crossmatch in second kidney grafts [Letter]. Transplantsbon 1996, 62:1698-1699. Seehofer D, Butz H, Thia~ J, Mullerhocker J, Mullerdedich J, Hammer C: Fluorescence vldeomk:mecoplc assessment of xenogenelc microclrculatlon end iml)act of antibody removal by Immunoadsorption. Transplantation 1997, 63:460-465. Shsrms VK, Bologs RM, I.i BG, Xu GP, Legman M, Hiscock W, Moursdian J, Wang J, Serur D, Rao VK, Suthanthiran M: Molecular executors of cell death differential Intrerenal expression of Fes Iigand, Fes, granzyme B, and perforin dudng acute end/or chronic rejection of human renal ellogrstts. Transplantation 1996, 62:1860-1866. Shennib H, Lee AGL, Serrick C, Giaid A: Altered nonspeclftc lymphocyte ¢ytofoxidty in bronchoelveoler levage of lung trecmpiant redpients - Can it be useful in rrmnltodng rejection or infection? Transplantation 1996, 62:1262-1267. Slovut DP, Benedetti E, Metes AJ: Babesiosls and hemophagocytic syndrome in an espianic renal transplant redpienL Transplantation 1996, 62:537-539. Smyth MJ, Sutton VR, Kershsw MH, TrapaniJA: Xanospedfic cytofoxic T lymphocytas use perfodn- end Fee-mediated lyUc pathway=. Transplantation 1996, 62:1529-1632. Tanaka M, Muraee N, Ye Q, Miyazski W, Nomoto M, Miyezawa H, Manez R, Toysms Y, Demetrie AJ, Todo S, Starzl TE: Effect of antlcompisment agent K76 COOH on hamstar-to-rst and gulnmi pig-to-rat heart xenotransplantstlon. Transplantation 1996, 62:681-688. Taniguchi S, Neethlin9 FA, Korchsgins EY, Bovin N, Ye Y, Kobayeshi T, Niakrssz M, Li S, Koran E, Oriel R, Cooper DKC: In viva Immunosdsorption of sntlpig sntibodies in baboons using a specific GSl alpha 1-3Gel column. Transplantation 1996, 62:1379-1384. Tuch BE, Petchell FM, Swierkowaki P: The Importance of low blood glucose In the development of fetal sheep psncrmitic endocrine ceils transplanted into sthymlc mice. Transplantation 1996, 62:1523-1525. Vandenbecg BF, Rossen JD, Grovermoksy M, Shsmrnas NW, Bums TL, Rezai K: Evaluation of diabetic patients for renal end pancreas transplantation - Noninvesive screening for coronary artery disease using radionuclide methods. Transplantation 1996, 62:1230-1235. Verges F, Viveepi M, Somoza N, Alcalde L, Armangol P, Merti M, Serradall L, Costs M, Fernandezliamszeres J, Sanmarti A, Pujolborrell R: Advantages of using s cell separator and mstdzamide gradients for human islet pudflcstlon. Transplantation 1996, 61:1562-1566. Yazaki M, Ikeda Sl, Takei YI, Yanagieewa N, Mstsunami H, Heshikura Y, Kswesski S, Makuuchi M, Kobayeshi K, Sahaki T: Complete neurological recovery of an adult patient with type II citrullinemia sttor living related parties liver transplantation. Transplantstion 1996, 62:1679-1681. Zaneroli ML, Venturini I, Avsllone R, Farina I=, Corai L, Baraldi C, Ardizzone G, Contenaro M, Amgo A, Beraldi M: Hepatic encephelopathy in liver transplant recipients precipitated by benzodiazepines present in transfused blood. Transplantation 1996, 62:764-767. Zhang Z, Zhu LF, Quan D, Garcia B, Ozcay N, Duff J, Stille; C, Lazarovits A, Grant D, Zhong R: Pattern of liver, kidney, heart, and intestine ellogratt rejecUon in different mouse strain combinaUons. Transplantation 1996, 62:1267-1272.

Cancer Tumor biology Related reviews: T cell defined tumor antigens (pp 684-693); Serological identification of human tumor antigens (pp 709-716)-;Abbas AK, Murphy KM, Cher A: Functional diversity of • helper lymphocytes. Nature 1996, 383:787-793. [64"'].

Cancer Tumor biology

Adida C, Ambroeini G, Rescia J, Cxotty PL, Costa J, Altieri DC: Protessa receptors in Hodgldn's disease: Expression of the factor Xa receptor, effector cell protease receptor-I, in Reed-Stamberg cells. Blood 19g6, 88:1457-1464. Agrewal B, Reddish MA, Longenacker BM: In vitro induction of MUC-1 peptide-egedfic type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immuno/1996, 157:2089-2095. Aguier RCT, Sill H, Hochheus A, Goldman JM, Cross NCP: Molecular invesSgation of secondary chronic myeloid leukemia [Letter]. Blood 1996, 88:2808-2809. Ahsen H, Neugut Al: High risk of Kaposl's sarcoma end central nervous system lymphoma in the same individuals: A finding related to acquired Immunodetidency syndrome, lot J Cancer 1996, 86:176-178. Akasaka 1", Muramatsu M, Ohno H, Miura I, Tstsumi E, Fukuhara S, Mori 1", Okuma M: Application of Iong-dlatance polymerese chain reaction to detection of junctional sequences created by chromosomal translocaffon in mature B-call neoplasms. Blood 1996, 88:985-994. Alkan S, Kercher DS: Regression of MALT lymphoma and treatment for Helicobactar pylorl - Reply [Letter]. Lancet 1990, 348:1042. Alkan S, )(archer DS, Newman MA, Cohen P: Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori [Letter]. Lancet 1996, 'L 348:268--269. Amoui M, Drsberova L, Toler P, Draber P: Direct interaction of Syk and Lyn protein tyroeine kinases in rat besophllio leukemle cells sctivsted vie type I Fc epsilon receptors. Eur J Immuno11997,27:321-326. Anderson JE, Gooley TA, Sohoch G, Anasetti C, Benainger Wl, Clift RA, Hanson JA, Sanders JE, Storb R, Appelbeum FR: Stem cell transplantation for secondary acute myelold leukemie: Evaluation of trensplantation as initial therapy or following induction chemotherapy. Blood 19g7, 89:25?8-2585. Anderason ML Medstrand P, Yin H, Biomberg J: Differential expression of human endogenous reti'ovlrel sequences similar to mouse mammary tumor virus in normal peripheral blood mononuclesr cells. AIDS Res Hum Retrov/ruses 1996, 12:833-840. Andreenaky SS, He B, Ginespie GY, Soroceanu L, Merkert J, Chou J, Roizmen B, Whitley RJ: The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sc/ USA 1996, 93:11313-11316. Angeiopoulou K, Stmtis M, Diamendia EP: Humorol immune response egsinst p53 protein in pstients with cctorectal carcinoma. Int J Cancer 1997, 70:46-51. Antoniou A, Mccormick D, Scott D, Yeoman H, Chandler P, Me,or A, Dyson J: T call tolerance and activation to a tranlgene-encoded tumor antigen. Eur J Immunol 1996, 26:1094-1102. Amujo I, Foes HD, Bittencourt A, Hummel M, Demal G, Mandonca N, Herbst H, Stein H: Expression of Epsteln-Barr virus gone products in Burkift's lymphome in Northeast Brazil. Blood 1996, 87:5279-5286. Arbor DA, Jenkins KA, Siovak ML: CD79 alpha expression in acute myefold leukemia - High frequency of expression in acute promyelocytio leukemia. Am J Pathol 1996, 149:1105-1110. Arguello F, Sterrt JA, Zhso YZ, Alexander MRA, Shoemaker RH, Cohen HJ: Two serologic markers to monitor the engrsftmont, growth, and treatment response of human laukemlas in severe combined immunodetlclent mice. Blood 1996, 87:4325-4332. Armstrong JM, Vitetta ES: The roles of eas and perfodn in lak T-cell/blspeclflc entibody-medlated killing of the murlne B-lymphoma cells, BCL(1). lot J Cancer 1996, 68:822-827. Afvenitakis L, Yaseen N, Sherma S: Latent membrane protein-1 induces cy¢lin D2 expression, pRb hyperphosphor~stion, end loss of TGF-beta 1-mediated growth inhibition in EBV-positive B oells. J Immuno119g5, 155:1047-1056. Asimakopoulos FA, Gilbert JGR, Aldred MA, Pearson TC, Green AR: Interstitial deletion constitutes the major mechanism for loss of hetarozygosify on chromosome 20¢1in pelycythemla vera. Blood 1996, 88:2690-2698. Astiergin T, Porteil JP, Londosgagliardi D, Moynet D, Blancherd S, Dalibml R, Pouliquen JF, Georgescourbot MC, Hajjer C, Salnteloie S, Guillemein B: Neutrollzing sctivity snd enSbody reactivity towerd immunogenic regions of the human T cell leukemia virus type I surface glycoprotain in sere of infected patients

with different clinical states. J Intect Dis 199?, 175:716-719. Avilacadno J, Lewin N, Tomita Y, Szeles A, Sandlund A, Mosolits S, Mellstedt H, Klein G, Klein E: B-CII cells with unusual properties. Int J Cancer 1997, 70:1-8. Bacigeiupo A, Venlint MT, Valbonesi M, Lerceri G, Cadier P, Lamperelli 1", Gualendi F, Occhini D, Bregente S, Valeriani A, Pieggio G, Pitto A, Benvenuto F, Figeri O, Destefeno G, Ceimo A, Seasarego M: Thiotepa cydophosphamide followed by granulocyte colony-stimulating factor mobilized silogonelc peripheral blood cells in adults with sdvsnced leukomla. Blood 1996, 88:353-357. Bain C, Merrouche Y, Puialeux I, Duc A, Colombo MP, Favrot M: BZ1 gone traneduction of human rensl-cail-carcinoma cell lines restores the proliferetiva response snd cytotoxlc function of ellogenelc T cells. IntJ Cancer 1996, 67:769-776. Banker DE, Groudine M, Norwood 1", Appalbaum FR: Measurement of spontaneous and therapeutic agent-induced spoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood 1997, 89:243-255, Barlogie B, Jegannath S, Vesole OH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobsoo J, Crowley J, Tricot G: Superiority of tandem sutologous transplsntaUon over standard therapy for previously untreated multiple myeloma. Blood 199?, 89:789-793. Berratt-Boyes SM: Meking the most of mucin: s novel • target for tumor immunotherspy. Cancer/mmunol Immunother 19g6, 43:142-151. [30]. Bartholomew JS, Glenville S, Serker S, Burt DJ, Stanley MA, Ruizcabeilo F, Jin CO, Gerrido F, Stern PL: Integration of high-risk human pspillomevirus DNA is linked to the down-regulstion of class I human leukocyte antigens by steroid hormones in cervical tumor coils. Cancer Res 1997, 57:937-942. Batallle R, Chappard D, Basle MF: Quentiflable excess of bone resorption in monoclonel gammopsthy is sn early symptom of malignancy: A prospective study of 87 bone biopsies. Blood 1996, 87:4762-4769. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Punen J, Yu AL: Frequent snd seledive msthylsUon of p15 and deletion of both p15 snd p16 in T-cell acute lymphoblastic leukemia. Cancer Res 199?, 57:832-836. Begent RHJ, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MR Hopestone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJW, Robson L: Ctinlcal evidence of efficient tumor targeting based on sin01e-chein Fv sntibody selected from • combinatorial library. Nat Med 1996, 2:979-964. Behr TM, Sherkey RM, Juweid MI, Dunn RM, Ying ZL, Zheng CH, Siegel JA, Gold DV, Goldenberg DM: Factors influencing the pherma¢okioetics, dosimetry, and diagnostic accuracy of rodloimmunodetectlon end radioimmunotherspy of cardnoembryonio entlgen-exprossing tumors. Cancer Res 1996, 58:1805-1816. Be,one M, lezzi G, Martinfontecha A, Rivolta I. Msnfredi AA, Protti MP, Freschi M, Dellabona P, Casorati G, Rugarli C: Rejection of • nonimmunogenic melanoma by vaccination with natural melanoma pepUdes on engineered sntigon-presenting cells. J Immuno11997, 158:783-769. Bonito A, Silva M, Griliot D, Nunez G, Fernendez]unaJL: A,ooptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bd-X(L). Blood I g96, 87:3837-3843. Bentz M, Wemer CA, Dohner H, Joos S, Berth TFE, Siebert R, Schroder M, Stilgenbauer S, Fischer K, Moiler P, Lichter P: High inddence of chromosomal imbslances and gone smplificstions in the dasaical follicular vsrlant of follicle center lymphoms. Blood 1996, 88:1437-1444. Bergen R, Neckers L: How do entisense oligndeuxynudeotides inhibit the growth of chronic myelogenous leukemia cells? [Letter]. Blood 1996, 87:4019. Berk DA, Yuan F, Leunig M, Jaln RK: Direct in vivo measurement of targeted binding in • human tumor xenograft. Proc Natl Acad Scl USA 1997, 94:1785-1790. Berke 7-, Wen 1", Klein G, Dalianis T: Polyoma tumor development in neonstally polynma-virus-infected CD4-/- and CD8-/- single knockout end CD4-/-8-/- double knockout mice. Int J Cancer 1996, 67:405-408. Beasudo A, Cherepakhin V, Johnson TA, Rassanti LZ, Feigal E, Kipps TJ: Favored use of immunoglobulin V(H)4 genes in AIDS-sssociatad B-cell lymphoma. Blood 1996, 88:252-260. Bettinandi A, Brugnoni D, Quirosrolden E, Malagoli A, Lagrutta S, Coffers A, Notarangalo LD: Missense mutations in the Fas germ resuRing in sutoimmune

745

lymphoprolifemtive syndrome: A molecular and immunological analysis. Blood 1997, 8~):g02-g09. Beyiotbarry M, Lament L, Vergier B, Demurst A, Freiteg S, Delord B, Dubus P, Valllent L. Dsisuney M, Macgmgen G, Beyiot C, Demascsrol A, Delsol G, Medio JP: Detection of t(2;5)(p23;q35) translocatlon by reverse transcdptese polymemse chain reaction and in sifu hybridization In CD30-positivo pdrnsry cutaneous lymphorna and lymphometold papuiosis. Am J Patho/1 g96, 149:483-492. Beyiotberry M, Vergier B, Medio JP: Presence of t(2;5) in primary CD30(+) cutaneous lymphoproliforaSve disorders [Letter]. Blood 1996, 88:3240-3241. Bhatia R, Mccarthy JB, Verfalllie CM: Interferon-elpha restores normal beta 1 integrln-medlated inhibition of hematopoletic progenitor proliferaUon by the marrow microenvlronment in chronic mytlogenous leukemia. Blood 1996, 87:3883-3891. Bicknall DC, Kaldamanis I~ Hampenn R, Bodmer WF, Karren P: Selection for bMa(2)-microglobulln mutaUon in mismatch repair-detective coloredal cerdnomas. Curt Bio/1990, 6:1695-1697. Bigger R.I, Rosenberg PS, Cote T: Kaposi's sarcoma and non-Hodgkln's lymphoma following the diagnosis of aids. Int J Cancer 1996, 68:754-758. Billedeau O, Vennass B, Klmlinger T, Kyle RA, Themeau TM, Greipp PR, Witzlg TE: Clonel circulating cells are common in plasma cell proliferative disorders: A comparison of monoclonel gan~nopsthy of undetermined significance, smoldering multiple myelome, and active myeloma. Blood 1996, 88:289-296. Birkeiend SA, Bendtzen K: Interleukin-10 end Epsteln-Berr virus-induced posttrensplant lymphoproliferstlve disorder [Letter]. Transplantation 1996, 61:1425-1426. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampsonjohennes A, Fattaey A, Mccormick F: An sdeuovirus mutant that replicates selectively in p53-deticlent human tumor calls. ScJence 1996, 274:373-376. Bishop JF, Young GA, Matthews JP, Bradstock K: Response: Induction endpoints in AML [Letter]. B/ood 1996, 88:754-755, Bjorkstrand B, Ljungman P, Svanason H, Hermans J, Alegre A, Appedey J, Blade J, Carlson K, Cavo M, Fen'ant A, Goldstone AH, Dalaurenzi A, Majolino I, Marcus R, Prentice HG, Remas K, Samson D, Sureds A, Verdonck LF, Volin L, Gshrton G: AIIogeuel¢ bone marrow transplantation versus lutoiogous stem cell transplantation in multiple myeloms: A retrospective case-matched study from the European group for blood end marrow transplantation. Blood 1996, 88:4711-4718. Blake J, Johnston JV, Heilstrom KE, Merquerdt H, Chen LP: Use of combinetorlal pepSde libraries to constnJof functional mimics of tumor epltopes recognized by MHC dass I-restrlcted cytolytlc T lymphocytes. J Exp Med 1996, 184:121-130. Bloom MB, PerTy-LalleyD, Robbins PF, Li Y, B-Gamil • M, Rosenberg SA, Yeng JC: Identification of tyToslnsse-rolatnd protein 2 8s a tumor rejection antigen for the B16 melanoma. J Exp Med 1997, 185:453-400. [84]. Boryalewicz LK, Fiender A, Nimako M, Man S, Wilkinson GWG, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell MEG, Rutherford E, Hicklieg JK, Inglis SC: A recombinant vsc=lnla virus encoding human psplllomavima types 16 and 18, E8 end E7 proteins as Immonotherspy for cervical cancer. Lancet 1996, 347:1523-1527. Boshoff: HHV8 end skin cancers in immunosuppressed patients (vol 347, pg 339, 1996). Lancet 1996, 348:138. Boshoff C, Talbot S, Kennedy M, Oleanj J, SchuIz 1", Chang Y: HHV8 and skin cancers in immunosuppressed pabents. Lancet 19g6, 347:338-339. Boursneil MEG, Rutherlord E, Hiclding JK, Rollinson EA, Munro AJ, Rolley N, Mclean CS, Boryalewicz LK, Vouaden K, ieglis SC: ConMmctlon end charsctertsstion of a recombinant vaccines was expressiog human papillomavlrus proteins for immunotherapy of cervical cancer. Vaccine 1996, 14:1485-1494. Brambilla L, Boneschi V, Berti E, Corbellino M, Perravicini C: HHV8 cell-associated viroemla snd dinical presentation of Mediferrsnesn Kaposi's sarcoma [Letter]. Lancet 1996, 347:1336. Br~indle D, Brasseur F, Weynants P, Boon T, Van den • EyndeB: A mutated HLA-A2 molecule recognized by eutoiogous cytotoxic T lymphocytes on s human renal cell carcinoma. J Exp Med 1996, 183:2601-2508. [106]. Brisco MJ, Hughes E, Neoh SH, Sykes PJ, Bradstook K, Enno A, Szer J, Mccaul K, Modey AA: Relationship between minimal residual disease snd outcome in

746

Cancer Tumor biology

adult acute I~pnphobiaefic leuk•mia. Blood 1996, 87:5251-5256. Brouaset R Alssati T, Coaouche N, Zenou RC, Schlsifer D, Chittai S, Delsol G: Telomarase activity in reactiv• end neoplastic lymphoid tissues: Infrequent detection of activity in Hodgkin's disease. Blood 1997, 89:26-31. Brown D, Kogen S, Lagasss E, Weissman I, Alcaley M, Pelicci PG, Atwater S, Bishop JM: A PMLRAR alpha transgen• Inmates muds• acut• promyelocytic leukemia. Proc Natl Acad Sci USA 1997, 94:2551-2556. Brown DA` Xu X, Nerenberg M: Genomic footpdnting of HTLV type I and HIV type 1 in human T cell lines. AIDS Ras Hum Retmviruses 1996, 12:829-832. Brown DM, Phipps RP: Bcl-2 •xpres•lon inhibits prostagiandin E(2)-medlated •poptosis in B cell lymphomas. J Immunol 1996, 15?:1359-1370. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppelo GJ, Wahrer DCR, Eekmen CA, Schoester M, Lankelma J, Pinedo HM, Lowenberg B, Schuurhuis GJ: Quality control of muitldrug resistanc• essays in •dult acute leukemia: Correlation between •ss•ys for P-glycoprofoln •xpression •nd activity. Blood 1996, 87:4809-4616. Bullrlch F, Veronase ML, Kiteda S, Judacder J, Caligiuri MA` Reed JC, Croce CM: Minimal region of loss at 13¢114 in B-cell chronic lymphocytic I•ukemia. Blood 1996, 88:3109-3115. Bumett .6.1(,Eden OB: The treatment of acute ioukaemla. Lancet 1997, 349:270-275. Bums J, Lobe S, Bartholomew B: Requirement for CD4(+) T cells in the gamma delta T cell proliferative mspons• to Daudl Burkltt's lymphoma. Ceil Immuno11996, 174:19-24. Burrows JM, Khanne R, Sculley TB, Alpers MP, Moss DJ, Burrows SR: Id•ntification of a naturally oocurdn9 recombinant Epstein-Bert virus isolate from New Guinea that •ncodes both typ• 1 and typ• 2 nuclear antig•n sequences. J Virol 1996, 70:4829-4833. Buschfort C, Muller MR, Seeber S, Ra~ewsky MF, Thomaie J: DNA excision repair profiles of normal snd leukemic human lymphocytes: Functional analy=ia at the single-cell level. Cancer Res 1997, 57:651-658. Csllan MFC, Stevan J, Krausa P, Wilson JDK, Moss PAH, Gillesple GM, Bell JI, Rickinson AB, Mcmicheel AJ: Large donee •xpansions of CDe(+) T calls in acute Infectious mononucleosis. Nat Med 1996, 2:906-911. Cantwail MJ, Shares S, Frledmacn T, Kipps TJ: Adenovirus vector infection of chronic lymphocytic I•ukomia B cells. Blood 1996, 88:4676-4683. Carbone A` Gaidano G, Glogh/ni A` Pastors C, Sagllo G, Tirsili U, Dallatevere R, Fslini B: BCL-$ protein expression in AIDS-related non-Hodgldn's lymphomas: Invem• rel•tionship with Epateln-Barr virus-encoded latent ~ b r a n e proteln-I expression. Am J Patho11997,150:155-165. Cardoso ~ Schultze JL, Bousslotls VA` Freeman GJ, Seamen MJ, Laszlo S, Billet A` Sallen SE, Gdbben JG, Nadlor LM: Pro-B acute lympbobiaatlc leukemia cells may induce T-cell snergy to elloantlgen. Blood 1996, 88:41-48. Cerey JO, Posekany KJ, Devente JE, Pettit GR, Ways DK: Phorbol eater-stimulated phoxphorylatfon of PU.I: Assoolatlon with leukemic cell growth inhibition. Blood 1996, 87:4316-4324. Carpino N, Wieniewski D, Strife A` Marshal( D, Kobayaahi R, StiHman B, Clerkson B: p62(dok): A constitutively tyrosina-phosphorytsted, GAP-ess(x:iated protein in chronic my~ogenous leukemia progenitor cells. Cell 1997,,88:197-204. C,arrasGo D, Rizzo CA` Dodmen K, Bravo R: The v-rol oncogene promotes malignant T-cell leukemta/lymphoma in transgenic mice, EMBO J 1996, 15:3640-3650. Castills LH, Wijmenga C, Wang Q, Stacy T, Speck HA` Eckheua M, Marinpadilla M, Collins FS, Wynshewborle A` I.iu PP: Failure of embryonic hematopoiesls and iathat hemorrhages in m u s e embryos haterozygous for • knocked-in leukemia gene CBFB-MYHll, Cell 1996, 87:687-696. Cavenagh LL, Bametson RS, Bastes A, Hsllidey GM: Deflddtlc epidermal T-cell InvoN~ment in Inductloo of CD~+) T cell-mediated immunity against an ulbavfolat radll~on-induced side tumor. Int J Cancer 1997, 70:98-105. C4wols M, Wainhobsoo S, Gessain A` Piumslle Y, Wattel E: Adult T-cell leukemia.,qymphoma on • background of clonatly expanding human T-cell leukemia virus type-l-posltlve cells. Blood 1996, 88:4646-4650. Cayuele JM, Baruchel A` Orange C, M~udaclA, Auclem MF, Daniel Mr, Schaison G, Sigaux F: TEL-AML1

fusion RNA as a n•w target to detect minimal residual disease in pediatric B-ceil precursor •cute iymphohiaatic leuk•mla. Blood 1996, 88:302-308. Cereseto A` Dlelle F, Mulloy JC, Cars A` Mlohloli P, Grassmann R, Franchini G, Klotmen ME: P53 functional Impairment •nd high p21(waf1/cipl) expression in human T-cell lymphofropP,./leukemia virus typ• I-transformed T cells. Blood 1996, 88:1551-1560. Cesarmac E, Nador RG, Aozasa K, Delsol G, Said JW, Knowlas DM: Kaposl'a sarcorna-essodated herpesvirus in non-AIDS-related lymphomas ocourdng in body cavlfes. Am J Paths/1996, 149:53-57. Chapman CJ, Zhou JX, Gregory C, Rickinson AB, Stevenson FK: V-H end V-L gen• analysis in sporadic Burkltt's lymphoma shows somatic hypermutation, Intraclonel haterogen•ify, and • role for antigen selection. Blood 1996, 88:3562-3566. Charrin C, Magaud JP, Sebhan C, Rere D, Dastugue N, Huguetrigsl F, Attai M, Sle P, Lai JL, Joust JP, Simon M, Zandeckl M, Gregoire MJ, Witz F, Wi~ B, Brin C, Moraine C, Mugneret F, Fevre B, Reynaud S, Grate'cos N, Thyss A` Ayraud N, Lafage M, Amoulet C, Sainty D, Mozziconacci MJ, Steppe AM, Bernard P, Reiffers J, Barenger L, Boesson M, Ifrah N, Vacdenskker J, Parrot C, Be: Cytogenetlc •bnormelities in adult acute lymphoblastic leukemia: Correlations with hematologic findings and outcome. A collaborative study of th• Group• Francais de Cytog•natlque Hematologique (vol 87, pg 3135, 1996). Blood 1996, 88:2818. Chen CL, Fuscoe JC, Liu O, Railing MV: Etoposide causes illegiSmat• V(D)J recombination in human lymphoid iauk•mic cells. Blood 1996, 88:2210-2218. Chen 1", Scaclan J, Sahin U, T0raci O, Gure AS, Tsang S, • Williamson S, Stockert E, Pfreundschuh M, Old LI: A testicuiar antigen aberr•ntiy expressed in human cancers detected by •utologous antibody screening. Proc Nat/ Ac~d Sci USA 1997, 94:1914-1918. [31"~]. Chen W, Qin HL, Chesebro B, Cheever MA: Identification of a gag-•ncoded cytctoxic T-lymphocyte ep|tope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher mudne leukemia virus-induced tumors. J Viro11996,70:7773-7782. Chen Y'r, Stockert E, Jungbluth A, Tsang SL, Coplan KA` Scaclen MJ, Old U: Serological •nelysls of Melan-A(MART-1), • melanocyte-spaclfic protein homogeneously expressed in human melanomas. ProC Nat/Acad Sci USA 1996, 83:5916-5919. Chen0 EHY, Nicholas J, Bellows DS, Hayward GS, Guo HG, Reitz MS, Hardwick JM: A Bcl-2 homolog encoded by Kaposi ssrcoma-associated virus, human h•rpasvirus 8, inhibits apoptosls but does not haterodlm•dz• with Bax or Bak. Proc Nat/Acad Sci USA 1997, 94:690-694. Chiang AKS, Tee Q, Srivastsva G, He FCS: N•sat NK- and T-CELL lymphomas sham th• same typ• of Epsteln-Barr virus latency •s n•sopheryngesl carcinoma and Hodgkin's disea•e. Int J Cancer 1996, 68:286-290. Chiloai M, Do91ioni C, Megslini A, In9hirsmi G, Krampera M, Nadaii G, Rahsl D, Pedron S, Benndetti A` Scardoni M, Masn E, Lastani M, Menestdne F, Pizzolo G, Scarpa A: p21/WAF1 cydln-kinas• inhibitor expression in non-Hndgkin's lymphomes: A potential marker of p53 tumor-suppmssor gen• function` Blood 1996, 88:4012-4020. Chinnasamy N, Raflerty JA` Hick,son I, Ashby J, Tinwell H, Margison GR Dexter TM, Fairbaim U: O-6-benzylguanin• potentiates th• in rive toxicity end clestogenicity of temozolomide •nd BCNU in mouse bone marrow. B/sod 1997, 89:1566-1573. Choudhury A` Gajewski JL, lleng JC, Popat U, Claxton DF, Kllohe KS, Androeff M, Champlin RE: Use of leukemic dendritic cells for the generation of antilackemic cellular cytotoxicity •gainat Phil•delphia chromosome-positive chronic myelog•nous leukemia. Blood 1997, 89:1133-1142. Chu SH, Lai MK, Chueng CK, Chen HW, Chen CS, Chiang VJ, Chou CC, Huang CC: Perforated g•strointeatinel lymphomas in kidney transplant recipients. TransplantProc 1996, 28:1478-1479. Clark M: Antibody therapy for non-Hodgkin's B-cell lymphoma proves itself. Lancet 1997, 349:34. Clemens KE, Piras G, Radonovich MF, Choi KS, Duvsll JF, Dejong J, Reader R, Brady JN: Interacbon of th• human T-cell lymphotropic virus type 1 tax transactivator with tr•necril~ee factor 11.'4.Mol Cell Bio11996, 16:4656-4664. Cohen J: Controversy: Is KS really caused by new herpesvirus? (vol 268, pg 1847, 1995). Science 1995, 269:745. Collins ND, Newbound GC, Ratner L, Lairmore MD: in vitro CD4(+) lymphocyte transformation and infection in • rabbit model with a molecular clone of human

T-cell lymphotropic virus type 1. J Viro/1996, 70:7241-7246. Cooke CB, Krenacs L, Stetlerstevenson M, Gminer TC, Rsifeld M, KJngmaDW, Alxuzzo L, Franlz C, Kavkmi M, Jaffa ES: H•patospianic T-cell lymphoma: A distinct clinicopathologlc entity of cytutoxlc gamma delfo T-Cell origin. B/sod 1996, 88:4265-4274. Corbellino M, Parravicini C, Aubin iT, Berti E: Kaposrs sarcoma •nd herpeavirus-like DNA sequences in sensory ganglia [Letter]. N Engl J Mad 1996, 334:1341 - 1342. Cormdini P, Astolfi M, Cherasco C, Ladetto M, Voena C, C~acclolo D, Piled A` Tarella C: Molecular monitodn9 of minimal residual disease In fotilcuiar •nd m•ntl• cell non-Hodgldn's I~mphomas treated with high-dos• chemother•py end pedpherel bleed progenitor cell •utograftlng. Brood 1997, 89:724-731. Correale P, Walmsley K, Nieroda C, Zarembe S, Zhu M, • • Schism J, Tseng KY: In vitro generation of human cytotoxlc T lyrnphocytes specific for pepUdes dedved from p r o m - s p e c i f i c •ntlgen. J Net/Cancer /nat 199?, 89:293-300. [95]. Corsetti Mr, Calebi F: Unesg•- end ataga-spoolfic expression of runt box polypeptides in pdmltiv• • nd definitive hematopoluis. Blood 199?, 89:2359-2368. Dahl AM, Bevedey PCL, Steuss HJ: A synthetic peptide • • d•dved from the tumor-essodated protein mdm2 can stimulate •utomactive, high avidity cytotoxlc T lymphocytes that recognize naturally processed protein. J Immunol 1996, 157:239-246. [5]. Dahlenborg K, Hultman L, Cadsson R, Jansson B: Human monoclonel antibodies spedflc for th• tumour associated Thorns•n-Fdedenrelch •ntig•n` Int J Cancer 1997, 70:63-71, Davi F, Gocke C, Smith S, Sklar J: Lymphocytic prog•nifor cell odgin •nd clonal evolution of human B-IIneag• acute lymphohiastic leukemia. Blood 1996, 88:609-621. Davi F, Maloum K, Michel A` Pritsch O, Magnac C, Mscintyre E, Sslomonnguyen F, Binet .IL, Dighiem G, Medeberai H: High fmqu•ncy of somatic mutations in th• V-H genes expressed In prolymphocytlc I•ukemia. Blood 1996, 88:3963-3961. De Smet C, De Backer O, Fsrenni I, Lurquin C, Braeasur • F, Boon T: Th• activation of human gene MAGE-1 in tumor cells Is correlated with genom•-wlde demathyiation` Pro(: Nat/Acad Sci USA 1996, 93:7149-7153. [491]. Decker LL, Klemen LD, l~odeylawson DA: DatecUon of the latent form of Epateln-Ban- virus DNA in th• peripheral blood of healthy individuals. J Viral 1996, 70:3286-3289, Decker LL, Shackar P, Khan G, Freemen RB, Dezube BJ, Liebermen J, Thodeylawson DA: Th• Kaposl sarcoma-essoolated herpesvlrus (KSHV) is prssent as •n intact latent ganome in KS tissue but replicates in the pedpherel blood mononuolesr cells of KS patients. J ~rp Mad 1996, 184:283-288. Decoteau JF, Lowsky R, Kinney MC, Kadin ME: Presence of t(2;5) in pdmary CD30(+) cutaneous lymOhoprollfem'~e disorders - Response [Le#er]. Blood 1996, 88:3241. Degruijl TD, Bontkes HJ, Waiboomers JMM, Stukart MJ, Robbesom AAJP, Venderfller BMEV, Herbrink P, Remmink AJ, Verhaijec RHM, Helmerhorst TJM, Meljer CJLM, Scheper RJ: Anatysls of IgG reactivity •galnst human Paplllomevlrus type-l$ E7 in patients with cervical Intraepithellel neopia•ia Indicates an association with ¢iesrence of viral iofacUon: Results of a prospectiv• study. Int J Cancer 1998, 68:731-738. Delcambre F, Pruvot FR, Ramon P, Noel C, Psi A` Jaillardthery S, Dupont J, Declerck N, Golmslin B, Remyj=udin M, Wurtz A` Laffite JJ: Primary bronchog•nic carcinoma in transplant recipiants, TransplantPro(: 1996, 28:2884-2885. Delsol G, Lamact I., Mariame B, Pulford K, Dastugue N, Broosset P, Rigslhuguet F, Nsnti 1", Cerrstti DR Monis SW, Mason DY: A new subtyp• of large B-call lymphoma •xpmselng the ALK Idnase •rid iaoldog the 2;5 tranelocatiee. B/sod 1997, 89:1483-1490. Desenjose S, Hamaikova E, Munoz N, Bosch FX, Hofmacnova V, Gill M, Izarzugaz~ I, Viladiu P, Terms MJ, Mores P, Munoz MT, Aacunce N, Tafur L, Shah KV, Vonka V: Serological respons• to HPV16 in ClN-Iti and cendcal-cancer i~tianta. Case-control studies in Spain •nd Colombia./ntJ Cancer 1996, 66:70-74. Desbois C, Rousset R, Bantlgnies F, Jalinot P: Exclusion of Int-6 from PML nudeer bodies by binding to th• HTLV-I tax oncoprofeln` Sc;ence 1996, 273:951-953. Destivieras S, Volarevic S, Mercep L, Ferrad S: Evidence for different mechanisms of growth inhibition of T-cell lymphoma by phorbol esters sod concanavalin IL J Biol Chem 1997, 272:2470-2476.

Cancer Tumor biology

Davits S, Boiocchi M, Sorrantino D, Carbone A, Avellini C, Dolcetti R, Marzotto A, Gloghini A, Bartoli E, Beltrami CA, Ferrsccioli G: Characterization of preiymphomatous stages of B cell lymphoproliferatlon in Sjogron's syndrome. Arthritis Rheum 1997, 40:318-331. Dicelle PF, Mariani S, Riera L, Stacchini A, Reato G, Foe R: Interleukin-8 induces the accumulaffon of B-cell chronic iymphucytlc leukemia calls by prolon9ing survival In an autocrine fashion. Blood 1996, 87:4382-4389. Dierlemm .i, Pittaluga S, Wlodarska I, Michaux L, Mecucci C, Dewolfpeeters C, Vsndenberghe H: Splenic marginal zone lymphoma - Response [Letter]. Blood 1996, 88:751-752. Dilber MS, Abedi MR, Bjorkstrand B, Christensson B, Gshrton G, Xanthopoulos KG, Smith CJE: Suidde gene therapy for plasma cell tumors. Blood 1996, 88:2192-2200. Dil]oo D, Rill D, Entwistle C, Bouranell M, Zhon9 WY, Holden W, Holladay M, Inglis S, Brenner M: A novel herpes vector for the high-efficiency trsneduction of normal lind malignant human hematopoieUc cells. Blood 1997, 89:119-127. Disis ML, Cheerer MA: Oncogenic proteins as tumor • antigens. Curt Opin Immunol 1996, 8:637-642. [63~']. Dohner H, Stll9enbauer S, James MR, Benner A, Weilguni T, Bentz M, Fischer K, Honstein W, Lichter P: 11q deletlona Identify a new subset of B-ceil chronic lymphocytic leukemia characterized by extensive nodal Involvement and inferior pro9noeis. Blood 1997, 89:2616-2522. Dolcetti R, Zancai P, Oere V, Gloghinl A, Bigoni B, Pivetta B, Davits S, Carbons A, Boiocchi M: Epstein-Barr virus strains with latent membrane protein-1 deletions: Prevalence in the Italian population and high association with human Immunodeficlency vlrus-reiatad Hod9kln's disease. Blood 1997. 89:1723-1731. Dolstre H, Fredrix H, Preijers F, Goulmy E, Figdor CG, Dewltte TM, Vendewleivsnkemenade E: Recognition of a B cell loukemis-associsted minor hlato¢ompeflbllity antigen by CTL J Immuno11997, 158:660-665. Oorsk WiT, Mechulls HKG, Hentschel M, Mills KI, Lengner J, Bumett AK: Influence of the major histocomPaUbility complex on age at onset of chronic lymphoid leukaemla. Int J Cancer 1996, 65:134-139. Drlassens MHE, Vanrijthoven F_AM,Ladviere G, Roos E: Expression of pertussis toxin adenosine dlphosphata ribosyltranefersse In a T-cell hybrldorna reduces metastatic capacity. Blood 1996, 88:3116-3123. Druker BJ, TampaS, Buchdun9er E, Ohno S, Segal GM, Fannin9 S, Zimmermann J, Lydon NB: Effects of a seiecthm lohlbltor of the Abl tyroslne klnase on the growth of Bcr-Abl positive ceils. Nat Mad 1996, 2:561-566. Dubey P, Hendrickson RC, Meredith SC, SieGel CT, • ShsbanowitzJ, Skipper JCA, Engelhard VII, Hunt DF, Schreiber H: The Immunodomloant antigen of an ultrsviolet-lnduced regressor tumor is generated by a somatic polrd mutation in the DEAD box heilcase p68. JExp Mad 1997,, 185:695-?05. [102]. Dudley ME, Roopenian DC: Loss of a unique tumor antige~ by cytotoxlc T lymphocyte immunoseloctlon from l 3-mefbylcholonthrene-lnduced mouse sarcoma rlveeis secondary unique and shared antigeus. J Exp Med 1996, 184:441-447. Dursndy A, Ledeist F, Emile .IF, Debatin K, Fischer A: Seusltlvlty of Epstein-Berr virua-induced B cait tumor to epoptosis mediated by imti-CD95/Apo-1/fes Mltibody. Eur J Immune/1997, 27:538-543. Duvoux C, Ch~'qui D, Delacroix I, Metreau .aM, Fegniez PL, Dhumssu~ D: Upper respiratory and digestive tract mallg~tanctas after liver transplantation for alcoholic clntms~. TransplantProc 1996, 28:2883. Etremov DG, Ivenovski M, Batistn FD, Po~.ato G, Burrone OR: IgM-produdng chronic lymphocytic leukemia cells undergo knmunoglobulln Isotype-swltching without acquiring somatic mutations. J Clin Invest 1996, 98:290-298. Efremov DG, ivanovski M, Slljanovskl N, Pozzsto G, Cevreska L, Fais F, Chiorszzi N, BeSets FD, Bun'one OR: ReatdctM Immumoglobutin V-H region repertoire in chrol1~c lymphocytk: leukemia patients with auteimmune hemolytic anemia. B/ood 1996, 87:3860-3876. Eismer E, Linkedsrseli M, Le J, Umiel T, Michl P, Said JW, Binderup L, Reed .IC, Koefflor HP: Synergistic ~ e of donal prctifershon, induction of differevdtatlon, and epoptosls of acute promyeiocytic leukemia ceils after combined treatment with novel 20-epi vitamin D-3 analogs and 9-cts retinoic acid. J C/in Invest 1997, 90:349-360.

Engeihard M, Brittinger G, Huhn D, Gerhartz HH, Meusers P, Sieged W, Thiel E, Wilmanns W, Aydemir U, B~erwolf S, Griaseer H, Tiemann M, Lennert K: Subdsssiflcstlon of diffuse large B-ceil lymphomas according to the Kiei classification: Distinction of centrobisstic and immunobisstic lymphomas is a significant prognostic dsk factor. Blood 1997, 89:2291-2297. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schon G, Bohlan H, Tasch H, Hansmann ML, Berth S, Schindler J, Ghetie V, Uhr J, Vitetta E: A phase-I study of an anti-CD25 ricln A-chain immunotoxin (RFT5-SMPT-dgA) in pabento with refractory Hodgkin's lymphoma. Blood 1997, 89:403-410. Erickann PF, Dassev G, Lasher RS, Philips G, Robinson M, Drsbkin HA: ETO and AML1 phosphoprotelns are expressed in CD34(+) hematopolotlc progenitors: Implications for t(8;21) loukemogenesis and monitoring residual disease. B/ood 1996, 88:1813-1823. Estanol JM, Agell N, Bachs O: Nuclear protein patterns in normal T-lymphocytss and lymphoblastoid calls. Cancer Res 199"7,67:56-61. Estey E, Komblau S, Pierce S, Kantarjian H, Beran M, Keeting M: A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [Letter]. Blood 1996, 88:?56. Estey E, Pierce S: Routine bone marrow exam dudn9 first remission of acute myeioid leukemia. Blood 1996, 87:3899-3902. Fairman J, Wang RY, Liang H, Zhan L, Saltman D, Liang JC, Nagarajan L: Translocations and deletions of 5¢113.1 in myelodyspisslo and acute myeiogenous leukemia: Evidence for a novel critical locus. Blood 1996, 88:2259-2266. Fais F, Cutmna G, Ulivi M, Roncella S, Gagliardi MC, Comagllsferrsris P, Rowe M, Bamaba V, Ferrerini M: Lymphoblastoid cells transtacted with c-myc: Downreguleiion of EBV-lytic anti9ens and impaired response of autologous CD4(+) T cells in vitro. Int J Cancer 1996, 68:810-816. Farina C, Vanderbruggen P, Boel P, Parmiani G, Sensi M: Conserved TCR usage by HLA-Cw*1601-restricted T cell clones reco9nizing melanoma antl9ens. Int Imrnunol 1996, 8:1463-t466. Felix CA, Hoeler MR, Provisor D, Salhany K, Sexsmith EA, Sister DJ, Cheun9 NKV, Winick NJ, Strauss F.A, Heyn R, Lange BJ, Malkln D: The p53 gene in pediatric therapy-related leukemia and myelodysplasis. Blood 1996, 87:4376-4381. Ferr; C, Lecivita L, Caracciolo F, Belleai G, Zignego AL: Hepatitis C virus and lymphoproliteratlve disorders [Letter]. Blood 1996, 88:4730-47.31. Feuer G, Fraser JK, Zeck JA, Lee F, Fouer R, Chen ISY: Human T-ceil leukemia virus irdaction of human hematopoieUc progenitor ceils: Maintenance of virus infection during differentiation in vitro and in vlvo. J Viral 1996, 70:4038-4044. Fichtner KP, Schirrmecher V, Griesbach A, Hull WE: Characterization of a murine lymphoma cell llne by P-31-NMR spectroscopy:. In vlvo monitoring of the local anti-tumor effects of systemic immune cell transfer. Int J Cancer 1996, 66:484-495. Rscher K, Frohllng S, Scherer SW, Brown JM, Scholl C, Stilgenbauer S, Tsui LC, I.Jchter P, Dohner H: Molecular cytogenetic delineation of deieUons and translocations involving chromosome band 7q22 in myeloid ieukemiss. Blood 1997, 89:2036-2041. Fischer T, Miller M, Bottsilverman C, I.ichtin A: Posttreusplent lymphoproliferatlve disease alter cardiac tranxplantaiton - Two unusual variants with predominantly plasmacytold features. Transplantation 1996, 62:1687-1690. Fisk B, Anderson BW, Gravitt KR, Obrian CA, Kudelka AP, Murray JL, Wharton Jr, Ioannides CG: Idenfiltcaffon of naturally proctmsed human ovarian Pel~des recognized by tumor-associated CDa(+) cytotoxic T lymphocytes. Cancer Res 1997., 57:87-93. Reischhauer K, Tanzarel~ S, Wallny I-U, Bordignon C, Trsverseri C: Multiple HLA-A alleles can present en immunodomlnant peptlde of the human metsnoma antigen Metan-A/MART-I to a p e p t l d e - ~ HLA-A'0201(+) cytotoxic T ceil fine. J Immunol 1996, 167:787-797. Rowers MED, Sullivan KM, Deeg HJ: Great-versus-host reacttons: Ard~-Ieukernta effects of donor T cells. TransplantProc 1996, 28:1184-1185. Ford AM, Pombodeoliveirs MS, Mccarthy KP, Maclean JM, Cardco KC, Vincent RF, Greavas M: Monodonei origin of concordant T-ceil meii9nancy in identical twins. Blood 1997, 89:281-285. Foes HD, Anagnostopouics I, Amujo I, Ass~ C, Darnel G, Kummer JA, Hummel M, Stein H: Anapisetic lorge-ceil lymphomas of T-ceil and null-ceil

747

phenotyPe express cytotoxic molecules. Blood 1996, 88:4005-4011. Francaschi S, Sarraino D: Kaposi's sarcoma and KSHV [Lefterl Lancer 1995, 345:1360-1361. Franken M, Estabmoks A, Csvanini L, Sherbume B, Wang F, Scsdden DT: Epstein-Berr virus-driven gene therapy for EIBV-reloted lymphomas. Nat Med 1996, 2:1379-1382. Friasan C, Herr I, Krsmmer PH, Debatin KM: Involvement of the CID95 (APO-l/Fes) recaptor/ligand system in drug-induced apoptosis in leukemia caJls. Nat Med 1996, 2:574-577. Frisan 1", Zhang CLI, Levitskaye J, Corm M, KuriHeMG, Masucci MG: Defective presentation of MHC class I-restricted cytotoxic T-call eoitopes in Buddtt's lymphoma ceils. Int J Cancer 1996, 68:251-258. Fuchs EJ, Matzinger P: Is cancer dangerous to the • immune system? Semin Immuno11996,8:271-280. [44t]. Funai N, Shimsmoto Y, Wetanabe M, Yoshida SI, Kohashi O: Marked inhibition of the intreceiluler multiplication of Leglonella pneumophila in monocytes isolated from carders of human T lymphotropic virus type I. J Leukoc Biol 1997, 61:133-140. Funai N, Shimemoto Y, Yoshide SI, Nsgai Y, Nakazato S, KohashiO: Differences In immune functions between human T-lymphntroplc virus type I carders and patients with adult T-cell leukemla/lymphome` Clin Immunol Immunopathol1996, 80:325-332. Furute K, Zahursk M, Yan9 XL, Roasda C, Goodman SN, August JT, Hamilton SR: Relationship between CD44 expression and cell prollferaUon in epithelium and stroma of colorectal neoplasms. Am J Patho11996, 149:1147-1155. Gelli M, Pioltelli P, Zehender G, Monti G, Monteverde A: HCV and lymphomagenesis [Letter]. Lancet 1996, 348:275. Gellot G, Hailer MM, Gaschet J, Moreau JF, Viv]en R, Bonneville M, Milpied N, Via H: Human HI.A-specific T-ceil clones with stable expression of a suicide 9ene: A possible tool to ddve and control a greft-versus-hoat-greft-versus-leukemis reacUon? Blood 1996, 88:1098-1103. Galloway DA: Pspillomevirue oncoproteins as vaccine candidates. Lancet 1996, 347:1498-1499. Gsmberl B, Gsidano G, Parse N, Carbons A, Roncetla S, Knowlas DM, Louis DC, Shlbsts D, Chsganti RSK, Dellafavere R: Microsateilite instability is rare in B-cell non-Hodgkin'e lymphomas. Blood 1997, 89:975-979. Gao SJ, Kingsley L, Hoover DR, Spire TJ, Rinaldo CR, Sash A, Phair J, Detels R, Parry P, Chang Y, Moore PS: Seroconveralon to antibodies against Kaposl's sarcoma-essodefed herpssvlrus-reiatad latent nuclear antigens before the development of Kaposi's sarcorrm. N Engl J Mod 1996, 335:233-241. Garciamarco JA, Celdas C, Price CM, Wiedemann LM, Ashworth A, Catoveky D: Frequent sormltic deletion of the 13¢112.3locus encompassing BRCA2 in chronic lymphocytic leukemia. Blood 1996, 88:1568-1575. Garwicz D, Iindmark A, Hallmark 1", Gisdh M, Jogi J, Gullberg U: Charectadzation of the processing and 9rlmulor targeting of human proteirmse 3 after tranefestlon to the rat RBL or the mudna 32D leukemic ceil lines. J Leukoc Bio11997, 61:113-123. Gattel V, Degan M, Gloghini A, Deiullis A, Improts S, Rossi FM, Aldinucci D, Perin V, Serrsino D, Babsre R, ZAgonel V, Gruss I'Ll, Carbons A, Pinto A: CD3O llgand is frequently expressed in human hematopoietlc malignancies of myelold and lymphoid odgln. B/ood 199?, 89:2048-2059. Gaugler B, Brouwenstijn N, Vantomme V, Szikors J-P, Van • der Spek CW, Petard J-J, Boon 1", Schrier P, Van dan Eynde BJ: A new 9erie coding for an antigen recognized by autologous cytolytJc T lymphocytas on a human renal carcinoma. Immunogenetics1996, 44:323-330. [26]. Ghetle MA, Podar EM, Gordon BE, Pantazis P, Uhr JW, V'detta ES: Combination immunotoxin trsatment and chemotherapy in SCID mice with advanced. disseminated Daudi lymphoma. Int J Cancer 1996, 68:93-96. Gidlof C, Dohlsten M, Lando P, Kailand T, Sundstrom C, TottemnanTH: A superantigeu-anUbody fusion protein for T-ceil imrnunotherapy of human B-linssge malignancia6. Blood 1997, 89:2089-209?. Gleeer SL, I.in RJ, Stewart SL, Amblnder RF, Jarrett RF, Brouaset P, PeHesenG, GuHey ML, Khan G, O9rady J, Hummel M, Preciado MV, Knecht H, Chan JKC, Claviez A: Epstein-Ban' virus-aesocisted Hodgkin's disease: Epidernioiogic characteristics in international data. Int J Cancer 1997, 70:375-382.

748

Cancer Tumor biology

Goff SP: Operating under a gag order: A block against incoming virus by the Fvl genii. Ceil 1996, 86:691-693. Goldstein DJ, Austin JHM, Zuoch N, Williams DL Stoopler MB, Michler RE, Schulman LL: Carcinoma of the lung after heart fransplantetion` Transplantation1996, 62:772-775. Gong MK, Yess J, Connolly T, Ivy SP, Ohnuma T, Cowan KH, Moscow JA: Molecular mechanism of an~folato transport-deficiency in a methofraxate-reelstent MOLT-3 human leukemia cell line. Blood 1997, 89:2494-2499. Gonnella R, Angeloni A, Caicgaro A, Fa¢inaA" Santarelli R, Gentile G, Arcose W, Martino P, Mandaili F, Frets L, Faggioni A" Ragona G: Transcdption of latent and replicative Epstein-Barr-virus genes in hone-marrow end pedpherel-blood mononuclear cells of healthy donors. Int J Cancer 1997, 70:524-529. Gorllck R, Goker E. Trippett 1", Steinherz P, Bisseyeff Y, Mazumdar M, Rintoti WF, Bertlno JR: Defective transport is a common mechanism of acquired mnthofrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced relate carder expression. Blood 1997, 89:1013-1018. Gresvos MF: Aetiology of acute leukaemia. Lancet 1997, 349:344-349. Green M, Reyes J, Jabbour N, Yunis E. Putnam P, Todo S, Rowe D: Use of qusntitstive PCR to predict onset of Epstsin-Barr viral infection and post-trensplent lymphoprollterntive disease after intestinal transplantation in children. TransplantProc 1996, 28:2759-2760. Gregoire C, Malissen B, Mazza G: Charactedzation of T ceil receptor single-chain Fv fragments secreted by myeloma cells. Eur J Immunol 1996, 26:2410-2416. Greiner TC, Gascoyne RD, Anderson ME, Kingms DW, Adomst SA" Said J, Jsfle ES: Nodular lymphocyte-predominant Hodgldn's disease associated with large-call lymphoms: Analysis of Ig gone rearrangements by V-J polymerase chain reaction. Blood 1996, 88:657-666, Greiner TC, Moynlhan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR, Welsenburger DD: p53 mutations in mantle cell lymphoma are associated with vsdant cytology and predict s poor prognosis. Blood 1996, 87:4302-4310. Grisolano )L, Wesselschmidt RL, Pelicci PG, Lay TJ: Altered myeiold development and acute leukemia in transgenic mica expressing PML-RAR alpha under control of cathepeln G regulatory sequences. Blood 199?, 89:376-387. Gruss HJ, Pinto A, Gloghini A, Wehnes E, Wright B, Boiani N, Aldinucci D, Gsttei V, Zagonel V, Smith CA, Kedin ME, Vonschilling C, Goodwin RG, Herrmann F, Carbone A: CD30 Ilgand expression in nonmalignant end Hodgldn's disease-involved lymphoid tissues. Am J Patho11996, 149:469-481. Gusn E, Wang JH, Laborde J, Nomrcss M, Bseuerie P, Hoffmsn T: T cell leukemia-essociated human notch/tranelocatlon-sssocleted notch homologue has I kappa B-like activity end physically interacts with nuclear Factor-kappa B proteins in T cells. J Exp Mad t996, 183:2025-2032. Guan MX, Zhang Re, Wu B, Henderson EE: Infection of primary CD4(+) and CDa(+) T lymphncytes by Epststn-Barr virus enhances human Irnmunodeticlency virus expression. J Virol 1996, 70:7341-7346. Guan XY, Horsman D, Zhang HE, Parse NZ, Meltzer PS, Trent JM: Localization by chromosome miorodlesactlon of a recurrent breakpoint region on chromosome 6 In human B-cell lymphoma. Blood 1996, 88:1418-1422. Hangaishi A, Ogawa S, Imamura N, Miyswski S, Miurs Y, Uike N, Shimazaki C, Emi N, Takeyama K, Hirosawa S, Kamsda N, Kobeyeshi Y, Takemoto Y, Kitani T. Toyams K, Ohtake S, Yazaki Y, Ueda R, HireSH: Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTSl/pl 5(INK4A)/CDKN2, MTS2/p15(INK4B), p53, and Rb genes in pdmary lymphoid malignancies. Blood 1996, 87:4949-4958. Hangeishi A, Ogawe S, Mitani K, Hosoya N, Chiba S, Yazski Y, Hires H: MutsUons and loss of expression of a mismatch repair gone, hMLH1, in leukemia and lymphome cell lines. Blood 1997, 89:1740-1747. Henley J, Jm'vis L, S~mmonds P, Parker A, Ludlam C: HCV and non-Hodgkin lymphome [Letter]. Lancet 1996, 347:1339. Hanson MN, Momson VA" Peterson BA, Stieglbauer KT, Kubic VL, Mccormick SR, Mcglannen RC, Manivel JC, Brunning RD, Litz CE: Post~ansplent T-cell lymphoprollferative disorders - An aggressive, late complication of solid-organ transplantation. Blood 1996. 88:3626-3633.

Hansson J, Ohlsson L, Persson R, Andersson G, Ilback NG, Litton MJ, Kailand T, Dohlsten M: Genetically engineered superantigens as tolerable entifumor agents. Proc Nat/Acsd Sci USA 1997, 94:2489-2494. Harrington WJ, Bagasra O, Sosa CE, BobroskJ LE. Bantu M, Wen XL, Cabral L, Byme GE, Pomerantz RJ, Wood C: Human herpesvirus type 8 DNA sequences in cad-free plasma and mononuclesr cells of Kaposi's sarcoma patients. J Infect Dis 1996, 174:110t-1105. Hartmann F, Renner C, Jung W, Deisting C, Juwsna M, Eichentopf B, Kloft M, Pfreundschuh M: Treatment of refractory Hodgkin's disessa with an antI-CD16/CD30 bispecific antibody. Blood 1997, 89:2042-2047. Hasegawa H, Nakano M, Arakaws M: Timing of therapy in vesculitis-essociated multiple myeloma: Comment -Reply [Letter]. Arthritis Rheum 1997, 40:396. Heyward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A" Bonnefoy JY, Cosyns M, Weinberg A: Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficlancy with hyper-lgM. J Immunol 1997, 158:977-983. Height SE, Swansbury GJ, Matures E, Treleavsn JG, Catovsky D, Dyer MJS: Analysis of donel rearrangements of the Ig heavy chain locus in acute leukemia. Blood 1996, 87:5242-5250. Heike M, Schmitt U, Hohne A" Huber C, Zumbuschenfelde KHM, Seliger B: Impaired HLA-class-I stability in a sarcoma cell line which stimulates exclusively HLA-cless-II-restricted autologous T cells. Int J Cancer 1996, 67:743-748. Henderson RA" Nimgaonkar MT. Watkins SC, Robbins PD, Ball ED, Finn OJ: Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-t). Cancer Res 1996, 56:3?63-3770. Herman J, Vanderbruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Reischhauer K, Boon T, Coulie PG: A peptide encoded by the human MAGE3 gone and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells axpreesing MAGF_.3./mmunogenetics 1996, 43:377-363. Hess AD, Bright EC, Thobum C, Vogelsang GB, Jones RJ, Kennedy MJ: Specificity of effector T lymphocytes in autologous graft-versus-host disease: Role of the major histocompatibility complex class II invedant chain peptide. Blood 1997, 89:2203-2209, Higo K, Kubo Y, Iwatani Y, One 1", Meeds M, Hiai H, Masuda 1", Kuribayashi K, Zhang FM, Lamin TY, Adachi A, Ishimoto A: Susceptibility of nude mice carrying the Fv-4 gone to fdend murine leukemia virus infection` J Viro11997, 71:750-754. Hill ME, Maclennan KA" Cunninghsm DC, Hudson BV, Burke M, Clarke P, Distefano F, Anderson L, Hudson GV, Mason D, Selby P, Linch DC: Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphome Investigation Study. Blood 1996, 88:1 O46-1051. Himes SR, Kstsikeros R, Shannon MF: Costimuleticn of cytokine gone expression in T cells by the human T leukemia/lymphotropic virus type 1 trans activator tax. J VJrol 1996, 70:4001-4008. Hochhaus A, Reiter A, Sklsdny H, Male JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NCP: A novel BCR-ABL, fusion gone (e6e2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 1996, 88:2236-2240. Horrigan SK, Westbrook CA, Kim AH, Banerjee M, Stock W, Larson RA: Polymerese chain resction-beseq diagnosis of Del(Sq) in acute myeloid leukemia and myelodysplestic syndrome identifies a minimal deletion interval. Blood 1996, 88:2665-2670. Hsu FJ, Casper CB, Czerwinski D, Kwak LW, [Jles • TM, Syrengelas A" Taidi-Laskowski B, Levy R: Tumor-specif'K: idiotype vaccines in the treatment of patients with B-cell lymphoma. Long-term results of a clinical trial. Blood 1997, 89:3129-3135. [64]. Hu XY, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukheqi B: Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996, 56:2479-2483. Huang AYC, Gulden PH, Woods AS, Thomas MC, Tong • CD, Wang W, Engelhard VH, Pastemack G, Coffer R, Hunt Det el.: The immunodominent major I'istocompatibility complex class I-restricted antigen of a routine colon tumor derives from In endogenous retrovirel gone product. Proc Nat/Acsd Sci USA 1996. 93:g730-9736. [100].

Huang YQ, Li JJ, Zhang WG, Feiner D, Friedmankian AE: Transcription of human herpesvirus-Ilke agent (HHV-8) in Kapoel's sarcoma. J CJin Invest 1996, 97:2003-2806. Hudnail SD, Berenson JR: Further evidence for in rive isotype switching in B-ceil chronic Ilm~phocytic leukemia [Letter]. B/ood 1996, 87:4481. Humphrey RW, Obrien TR, Newcomb FM, Nishihara H, Wyvill KM, Ramos GA, Seville MW, Gosdert JJ, Strsus SE. Ysrchoan R: Kapears sarcoma (KS)-essodatnd herpesvirus-like DNA sequences in peripheral blood mononudear ceils: Association with KS and persistence in patients receiving anti-herpesvlrus drugs. Blood 1996, 88:297-301. Hunt BJ, Thomas JA, Burke M, Walker H, Yacoub M, Crawford DH: Epstein-Barr virus associated Burkitt lymphoma in a heart transplant reciplenL Transplantation 1996, 62:869-872. Ikeda H, Lath6 B, Lehmann F, Van Baran N, Baurain J-F, ** De Smet C, Chambost H, Vitale M, Moretts A, Boon T, Coulie PG: Charactadzatlon of an antigen that is recognized on • melanoma showing partial HLA less by CTL expressing an NK inhibitory receptor. Immunity 1997, 6:199-208. [52]. Inoue K, Ogawa H, Sonoda Y, Kimura T, Ssksbe H, Oka Y, Miyake S, Tamaki H, eli Y, Yamsgsmi T, Tstekaws 1", Soma 1", Kishimoto T, Sugiysms H: Aberrant overoxpression of the Wllms tumor gane (WT1) in human leukemia. Blood 1997, 89:1405-1412. Inoue K, Ogawa H, Ysmagaml T, Soma T, TanSY, Tatekawa T, eli Y, Tamaki H, Kyo 1", Dohy H, Hirsoka A" Masscka 1", Kishimoto 1", Sugiyama H: Long-term follow-up of minimal residual disease In leukemia patients by monltodng WT1 (Wilms tumor gone) expression levels. Blood 1996, 88:2267-2278. Ioachim HL: Kapoel's sarcoma end KSHV [Letter]. Lancet 1995, 346:1360-1361. Isaacson PG: Splenic marginal zone lymphoma [Letter]. Blood 1996, 88:751. Ivy SP, Olshefski RS, Taylor BJ, Patel KM, Reaman GH: Correlation of P-glycoproteln expression and function in childhood acute leukemia: A children's cancer group study. Blood 1996, 88:309-318. Iwamoto KS, Mizuno 1", Ito T, Tsuyams N, Kyoizumi S, Seyama T: Geln-of-functlon p53 mutations enhance alteration of the T-ceil receptor following X-Irradiation, independently of the call cycle and cell survival. Cancer Res 1996, 56:3802-3866. Izumi KM, Kaye KM, Kieff ED: The Epsteln-Barr virus LMP1 amino add sequence that engages tumor necrosis factor receptor associated factors is critical for pdmary B lymphocyte growth transformation. Proc Nell Acad Sci USA 1997, 94:1447-1452. Izumi T, Sasaki R, Miura Y, Okamoto H: I:~lmary hepatosplenic lymphoma: Association with hepatitis C virus Infection [Letter]. Blood 1996, 87:5380-5381. Jager E, Ringhoffer M, Dienes HI=, Arand M, Ksrbsch J, • JagerD, Ilsemann C, Hageclom M, Oesch F, Knuth A: Grenulocyte-macmphage-colony-stimuiatlng factor enhances immune responses to melanoma-associated peptides in rive. Int J Cancer 1996, 67:54-62. [71]. Jager E. Ringhoffer M, Karbach J, Arand M, Oesch F, • KnuthA: Inverse reie41tionshlp of melanncyte differentiation antigen expression In melanoma tissues and CD8+ cytotoxic-T-ceil responses: evidence for immunoselection of antigen-loss variants in rive. Int J Cancer 1996, 66:470-476. [67t").

Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernandez PL, Ssnchezbeato M, Solar F' Perezlossda A" Neyach I, Mallofrs C, Piris MA, Montserrat E. Cardesa A: Expression of ratinoblestema gone product (pRb) in mantle cell lymphomes: Correlation with cyclin D1 (PRADI/CCND1) mRNA levels and proliferative activity. Am J Patho11996, 148:1591-1600. Jeang KT, Rsuscher FJ: The XVIII Symposium of the International Associel~on for Comparative Research on Leukemia and Related Diseases (IACRLRD): Leukemia and lymphoma pathogenesls and treatment molecular aspects. Cancer Res 1996, 56:4286-4292. Jensen T, G~dlistampino L, Mouriteen S, Frische K, Peters S, Meldai M, Werdelin O: T cell recognition of Tn-glycosylated peptide antigens. Eur J Immune/ 1996, 26:1342-1349. Jansen HB, Leach CT, Montalvo EA, Lin JC, Murphy SB: Absence of herpesvirus in AIDS-associated smooth-muscle tumors [Letter]. N Eng/J &fed 1996, 335:1690. Ji L Mochon E, Arcinas M, Boxer LM: CREB proteins function as positive regulators of the trenslocated bcl-2 allele in t(14;18) lymphomas. J Bio/Chem 1996 271:92687-22691.

C a n c e r T u m o r biology

Jiang X, U JP, Psskind M, Epstein PM: Inhibition of calmodulin-dependent phosphodlesterase induces epoptoels in human leukemic cells. Proc Nat/Acad Sci USA 1996, 93:11236-11241. Johanneen E, Miller CL, Groeeman SR, Kieff E: EBNA-2 end EBNA-3C extem=lveiy and mutually exclusively associate with RBPJ kappa in Epsteln-Bsrr virus-tranoformed B lymphocytes. J Virol 1996, 70:4179-4183. Johnston JV, Melacko AR, Mizuno MT, Mcgowan P, Hellstrom I, Hellstrom KE, Marquardt H, Chan LP: B7-CD28 costlmula0on unveils the hierarchy of tumor epitopes recognized by major histucompatbllity coml~ex class i-restricted CDe(+) cytofyUc T lymphocytes. J Exp Med 1996, 183:791-800. Jones GW, Thorson B: Cutaneous T-cell lymphoma (mycosis fungoldes) (Le'~tar]. Lancet 1996, 348:130-131. Jonkers J, Kerswagen HC, Acton D, Breuer M, Betas A: Activation of • novel proto-on¢ogene, Frstl, contdbutas to progression of mouse T-ceil lymphorrms. EMBO J 1997, 16:441-450. Joshus DE, Brown RD, Luo XF, Gibson J: Circulating donal lymphocytes in myetoma determined by mRNA in sltu hybddicatlon [Lsttpr]. Blood 1996, 88:1125. Jurlander J, Celigiuri MA, Ruutu T, Beer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Freilahr DA, Christiansan NP, Block AW, Knuutila S, Herzig GP, Bloomfield CD: Persistence of the AMLI/ETO fusion transcript in Patients treated with eilogenelc bone marrow transplantation for t(8;21) leukemia. Blood 1996, 88:2183-2191. Kamigeki 1", Ysrmm~oto M, Ohyansgi H, Ohya M, Kono A, Ohtani W, Narita Y, Ohkubo M, Ohmura T, Saitoh Y: Improved tumor detection by anti-CEA chimeric Feb ongomers with disulfide linkages in a pancrea0c-carclnoma-xeoogreft model. Int J Cancer 1996, 66:261-287. Kang XQ, Kawel~mi Y, Elgamil M, Wan9 RF, Sakaguchi K, Yanneili JR, Appella E, Rosenberg SA, Robbins PF: Ide~lfic4~on of • t~trosinase epitope recognized by HLA-A24-restrlcted, tumor-lnfltretn9 lyr~hocytes. J Immuno11995, 155:1343-1348. Kanno H, YssunN;IS Y, Ohsawa M, Tsniwaki M, luchi K, N=d~ N, Torilud K, Shlmoyama M, Aozass K: Expression of Epstain-Berr virus latent IofectJon genes end oncogenes in lymphoma cell lines derived from pyothorex-esloclated lymphoma. Int J Cancer 1998, 97:86-94. Kanwar VS, Witthuhn B, Campana D, Ihle JN: Lack of consttutlve aofhteflon of Janus kicasee and signal trnnlduoflon end Ictvstlon of transcription factors in Phttadeiphln chromosome-positive acute I~phoblas0c leukemia [Letter]. Blood 1996, 87:4911-4912. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K: Hodgldn and Reed-Sternberg cells In Hodgkln's disease represent the outgrowth of • dominant tumor done derived from (crippled) 9erminel center B cells. J F_xpMed 1996, 184:1495-1505. Kaufmann SH, S,~ngen PA, Gore SD, Armstrong DK, Chang YC, Rowinsky EK: Altered formation of topotecan-stnbilized topofsomerase I DNA eddu¢ta in human leukemia cens. Blood 1997, 99:2098-2104. Kawaniehi M: Expression of Epstein-Berr virus Intent membrane protein 1 protects Jurkat T cells from M)optosis induced by serum deprivation. Virology 1997, 228:244-256. Kelther MA, Seldin DC, Leder P: Tel-1 induces T cell acute lymphoblasti¢ leukemia accelerated by casein klnase II alpha. EMBO J 1998, 15:5160-8166. Kerr BM, Kiende N, Bun'ows JM, Cross S, Silins SL, Buck M, Benson EM, Couper B, Moss DJ, Sculley TB: Identification of type B-spedflc and cross-reactive cytotoxlc T-L~mphocyta r e s p o n m to Epstein-Bsrr virus. J Viroi 1996, 70:8858-8884. Kersten MJ, Evers LM, Dellemijn PLI, Vandenberg H, Porlegiee P, Hintzen RQ, Vanlier RAW, Vondemboma AAEG, Vanoers RHJ: Elevltion of cerebruspinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid meilgnendes (vol 87, pg 1985, 1996). Blood 1996, 88:2818. Khan G, Miyashita EM, Yang B, Babcock GJ, Thorleylawson DA: Is EBV persistence in vivo • model for B cell homeostasis? Immunity 1998, 5:173-I 79. Khanim F, Yeo QY, Niedobitek G, Sihota S, Rickinson AB, Young LS: Analysis of Epsteln-Berr virus gene polymorphlams in normal donors and in virus-associated tumors from different geographic locations. Blood 1996, 88:3491-3501. Khanna R, Burrows SR, Moss DJ, Silins SL: Peptide transporter (TAP-I and TAP-2)-independent endogenous prncmin9 of Epstetn-Barr virus (EBV) latent membrane protein 2A: Implications for

cytotoxlc T-lymphocyte control of EBV-essocinted malignancies. J Viro11996, 70:5357-5362. Kieff E: Epsteln-Barr virus: Increasing evidence of s link to carcinoma. N En91J ~ 1995, 333:?24-726. Kikuchi A, Nishikawa I", Ikeda Y, Yamaguchi K: Absence of human T-lymphotropic virus type I in Jepanese paUents with cutaneous T-cell lymphoma. Blood 1997, 89:1529-1532. Kikuchi A, Nishikawa T, Ysmaguchi K: Absence of human T-ceil lymphofroplc vires type I in cutaneous T-cell lyrnphoma [Letter], N Engl J Mad 1997, 336:296-297. Kim DH, Moldwin RL, Vignon C, Bohlander SK, Suto Y, Giordano L, Gupta R, Fears S, Nucifora G, Rowley JD, Smith SD: TEL-AML1 trnneloca6ons with TEL and CDKN2 inac0vstton in -,cute lymphoblastic leukemia call lines. Blood 1996, 88:788-794. Kim FJ, Beeche AA, Hunter JJ, Chin DJ, Hope TJ: Characterization of the nuclear export signal of human T-cell lymphotropic virus type 1 Rex reveals that nuclear export is mediated by posltlon-vedabla hydrophoblc interactions. Mol Cell Blo/1996, 16:5147-5155. Kingma DW, Weiss WB, Jafle ES, Kumar S, Frekko K, Raffeld M: Epstein-Bert virus latent membrane protein-I oncogene deletions: Correlations with malignancy in Epsteln-Barr virus-essoclated I~pnphoproliferefive disorders end melignant lymphomas. Blood 1996, 88:242-251. Kizaki M, Matsushita H, Takayama N, Muto A, Ueno H, Awaya N, Kawai Y, Asou H, Kamada N, Ikeda Y: Establishment end charsctedzstion of • novel acute promyelocytic leukemia ceil line (UF-1) with retinoic add-resistant features. Blood 1996, 88:1824-1833. Kluinnelemans JC, Kester MGD, Meleohorst JJ, Landegent JE, Vandecorput L, Willemze R, Falkenburg JHF: Persistent donal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia. Blood 1996, 87:3795-3802. Kluth B, Hess S, Engelmann H, Schafnitzel S, Riethmuller G, Feucht HE: Endothelial expression of CD40 in renal cell carcinoma. Cancer Res 1997, 57:891-899. Kohno 1", Yamada Y, Hate 1", Mori H, Yamamura M, Tomonaga M, Ursta Y, Goto S, Kondo T: RelntJon of oxidative stress and glutnthione synthesis to CD95(Fes/APO-1)-medlated spoptoels of adult T cell leukemia cells. J Immunol 1996, 156:4722-4728. Koide J, Takada K, Sugiura M, Sekine H, Ito T, Saito K, Mori S, Takeuchi T, Uchida S, Abe T: Spontaneous establishment of sn Epstein-Berr virus-infected flbroblest line from the synovlal tissue of a rheumatoid arthritis patient J V/tel 1997, 71:2478-2481. Kono K, Halapi E, Hisin9 C, Petersson M, Gerdin E, Vanky F, Kiessling R: Mechanisms of escape from CD8(+) T-ceil clones specific for the HER-2/neu proto-oncogena expressed in ovadan cercinomes: Related and unrelated to decreased MHC class 1 expression, lot J Cancer 1997, 70:112-119. Krenacs L, Weilmann A, Serbara L, Himmelmann AW, Bagdi E, Jaffe ES, Raffeld M: Cytotoxic cell antigen expression in anaplestc large cell lymphomas of T- end null-ceil type end Hodgkin's disease: Evidence for distinct cellular odgin. Blood 1997, 89:980-989. Krummenacher C, Diggelmann H, Achaorbea H: in vivo effects of a recombinant vaccinla virus expressing s mouse mammary tumor virus supersntgen. J Viro/ 1996, 70:3026-3031. Kubo H, Abe J, Obata F, Nakajima H, Tsunoda M, Ogawa A, Nakayama S, Beck Y, Kohsaka T, Darrow TL, Abdelwahab Z, Saida T, Takiguchi M: Dual recognition of a human cytotoxic T-ceil done for melanoma antigens. Cancer Res 1996, 58:2368-2374. Kumagai MA. Man-he A, Pui CH, Behm FG, Raimondi SC, Hancock ML, Mahmoud H, Crist WM, Carnpana D: Stroma-supported culture of childhood B-lineage acute lymphoblastc leukemia cells predicts treatment outcome. J Cfin Invest 1996, 97:755-760. Kuppers R, Hajadi M, Plank L, Rajewsky K, Hansmann ML: Molecular Ig gene analysis reveals that monocytoid B call lymphoma is a malignancy of mature B cells carrying somnticelly mutab~ V region genes and suggests that rearrengement of the kappa-deleting element (resulting in dele4Jon of the Ig kappa enhancers) abolishes somatic hypermutation in the human. Eur J Immunol 1996, 26:1794-1800. Lacabanne V, Viguiar M, Guillet JG, Chopp~n J: A wild-type p53 cytotoxic T ceil epitope is presented by mouse hepatocercinoma cells. Eur J Immuno/1996, 26:2635-2639. Lapidot 1", Grunberger 1", Vormoor J, Estrov Z, Kollet O, Bunin N, Zaizov R, Wi~ams DE, Freedman MH: Identification of human juvenile chronic myelogenous leukemia stem cells capable of

749

initiating the disease in primary and secondary SCID mice. Blood 1996, 88:2655-2664. Larcher C, Kempkes B, Kmmmer E, Prodinger WM, Pawlita M, Bornkamm GW, Distich MP: Expression of Epstein-Barr virus nudeer Mdligen-2 (EBNA2) induces CD211CR2 on B and T cell Unes lind shedding of soluble CD21. EurJ Immuno11995, 25:1713-1719. Lavignon M, Evans L: A multstafl process of leukamogeneeis in moloney mudna leukemia vires-infested mice that is modulated by refrovimi pseudotyping and btterferencL J Viro11996, 70:3852-3862. Lee SP, "riemey RJ, Thomas WA, Brooks JM, Rickinson AB: Conserved CTL Ndtopes within EBV latent membrane protein 2 - A potantal target for CTL-besed tumor therapy. J Immuno11997, 158:3325-3334. Lefrem JJ, Meyohss MC, Msnotti M, Maynard JL, Thsuvin M, Frottier J: Detection of human herpesvirus 8 DNA sequences before the appearance of Kaposrs sarcoma in human Immunodefidency virus (HIV)-pcoltve subjects with • known date of HIV seroconverslon. J Infect Dis 1996, 174:283-287. Lennette ET, Blackboum DJ, Levy JA: Antibodies to human herpesvirus type 8 In the general population end In Kapoel'e sarcoma pntlents. Lancet 1996, 348:858-861. Lens D, Deschouwer PJJC, Hernoudi RA, AI0dulrsuf M, Ferahat N, Matutee E, Crook 1", Dyer MJS, Catovsky D: p53 abnormalities in B-ceil prolymphocytic leukemia. Blood 1997, 89:2018-2023. Li RX, Ladisch S: Abrogation of shedding of Immunosuppreeslve neuroblestoma gnngllosldes. Cancer Res 1996, 56:4602-4605. I;da S, Reo PH, Nellasivern P, Hibshoosh H, Butler M, Louis DC, Dyomin V, Ohno H, Chaganti RSK, Dailafavara R: The t(9;14)(p13;¢132) chromosomal trnnslocaflon associated with lymphoplesmocytoid lymphoma involves the PAX-5 gens. Blood 1996, 88:4110-4117. l_in AY, Kingms DW, Lennstte ET, Fears TR, Whitehouse JM, Ambinder RF, Jaffa ES, Levine PH, Tucker MA: Epstein-Bert virus and familial Hodgkin's disease. Blood 1996, 88:3180-3166. Linet MS, Nyren O, Gridley G, Mellemkjeer L Mclaughlin JK, Olsen JH, Adaml HO, Frsumeni JF: Risk of cancer following splenectomy. Int J Cancer 1998, 86:611-816. I.itz CE, Vos JA, Copenhaver CM: Aberrant msthyloflon of the major breakpoint cluster region in chronic myeioid leukemia. Blood 1996, 88:2241-2249. Liu CN, Lambert JM, Teicher BA, Battler WA, Oconnor R: Cure of multldrug-reslatant human B-ooll lymphoma xenogrefta by combinations of sntI-B4-blocked rtcin end chemotherapeutic drugs. Blood 1996, 87:3892-3898. Uu PC, Leong 1", Quam L, Billsdeeu D, Kay NE, Greipp P, Ky~eRA, Okee MM, Vannees B: A¢0vetn9 mutations of N- end K-ms in multiple myeioma show different dlnical associations: Analysis of the Eastern Cooperative Oncology Group phase Ill btai. Blood 1996, 88:2699-2?06. Loftus DJ, Ceetelli C, Clay TM, Squarcina R Marincols FM, Nishimura MI, Parmiani G, Appella E, Rivoltini L: Identification of epitope mimics recognized by CTL reactive to the metanoma/meianocyte-dertved peptde MART-l((27-35)). J Exp Med 1996, 184:647-657. Lonncz AL: Cutaneous T-cell lymphoma (mycosis tungoides) - Reply [Letter]. Lancet 1996, 348:131. Lotem J, Peledkamar M, Groner Y, Sachs L: Cellular oxidative stress nnd the control of npoptosla by wild-type p53, cytotoxic compounds, and cytoklnes. Proc Nstl Acad Sci USA 1996, 93:9168-9171. Lowsky R, Deooteeu JF, Reitmair AH, Ichinchssams R, Dong WF, Xu Y, Mak TW, Kadin ME, Mindan MD: Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblasflc lymphomas end ere associated with the aberrant expression of rhombotn-2 (Lmo-2) nnd TAL-1 (SCL). Blood 1997, 89:2276-2282. Luppi M, Barozzi P, Maiorana A, Artusi 1", Trovato R, Marasca R, Savarino M, Ceccherininelli L, Torelli G: Human herpesvirus-8 DNA sequences in human immunoder¢tency virus-negstive engioimmunoblastlc lymphedenopnthy and benign lymphadenopnthy with giant germinal center hype~otaele and increased vasculedty. Blood 1996, 87:3903-3909. Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson • P, Disis ML. Cheerer MA, Sherman LA: Identification of Her-2/neu CTL epitopes using double trsnsgenic mice expressing HLA-A2.1 end human CD.8. Hum Immune/ 1997, 52:109-118. [55].

750

Cancer Tumor biology

Machii 1", Yamaguchi M, Inoue R, Tokumine Y, Kuratsune H, Nagai H, Fukuda S, Furuyama K, Yamade O, Yahata Y, Kitani T: Polycionel B-cell lymphocytosis with features resembling hairy cell leukemia Japanese vadant. Blood 1997, 89:2008-2014. Maestro R, Gloghini A, Doglioni C, Piccinin S, Vukosavljevic 1", Gasparotto D, Carbone A, Boiocchi M: Human non-Hodgldn'$ lymphomas overoxprsas a wild-type form of p53 which is a functional transcdptionel activator of the cyclin-dependent kinase inhibitor p21. Blood 1997, 89:2523-2528. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT: Tumor escape from immune recognition - Lethal recurrent melanoma in s patisnt associated with downregulation of the peptide transporter protein TAP-1 end loss of exprassion of the irnmunodominent MART-1/Melen-A antigen. J CI/n Invest 1996, 98:1633-1641. Maguersstta V, Petzer AL, Eaves AC, Eaves CJ: BCR-ABL expression in different subpopulations of functionally characterized Ph(+) CD34(+) cells from patients with chronic my•laid leukemia. Blood 1996, 88:1796-1804. Melarkannan S, Serwold 1", Nguyan V, Sherman LA, Shastri N: The mouss mammary tumor virus env 9ens is the sourcs Of a CD8(+) T-cell-stlrouiatin9 peptids prsssnted by • major histocompatioility complex class I molecule In a murins thymoma. Proc Nat/ Acad Sci USA 1996, 93:13991-13996. Mandruzzato S, Brasseur F, Andry G, Boon T, van der • . Bruggan P: A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Mad 1997, in press. [43]. Manome Y, Wen PY, Dang YH, Tanaka T, Mitchell BS, Kufe DW, Fine HA: Viral vector traneduction of the human deoxycytldlna kinaae cDNA sensitizes gleams cells to the cytotoxlc effects of cytosine erabinoside in vitro and in viva. Nat Mad 1996, 2:567-573. Manshouri T, Yang Y, I.in H, Stass SA, Glassman AB, Kesting MJ, Albitar M: Downrsgulstion of PAR alpha in mics by antis•nee transgsne leads to a oompensatory increase in RAR bets end RAR gamma and development of lymphoma. Blood 1997, 89:2507-2615. Man M, Yu M, Tong JH, Ye J, Zhu J, Huang QH, Fu G, Yu L, Zhao BY, Waxman S, Lanotte M, Wang ZY, Tan JZ, Chan S.}, Chert Z: RIG-E, a human homolo9 of the mudne Ly-6 family, Is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell Proc Nat/Acad Sci USA 1996, 93:6910-5914. Martini F, Iscchari L, Lazzarin L, Carinci P, Corallini A, Gerosa M, luzzolino P, Barbantibrodano G, Tognon M: SV40 ashy region and large T antigen in human brain tumors, pedpherel blood cells, and sperm fluids from healthy indlviduel~ Cancer Res 1996, 56:4620-4825. Melhew P, Sanger WG, Wsisenburger DD, Valentine M, Valentine V, Pick•ring D, Higgins C, Hess M, Cui XL, Sdvestavs DK, Morns SW: Detection of the t(2;3)(p23;q35) and NPM-ALK fusion In non-Hodgkln's lymphoma by two-color fluorescence in sifu hybddlzation. Blood 1997, 89:1678-1685. Mstolcsy A, C.,Meli P, Nsdor RG, I.iu YF, Knowles DM: Molecular chsrentericaSon of igA- end/or 19G-switched chronlo lymphocytic leukemia B cells. B/ood 1997, 89:1732-1739. Matoicay A, Casals P, Wamke PA, Knowies DM: Morphoiogic tmnsformedon of follicular lymphoma is associated with son~Uc mutation of ths translocated bd-2 gane. Blood 1996, 88:3937-3944, Msuch PM, Kelish i.A, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canelics GP, Tarbell NJ: Second malignancies after treatment for isparotomy staged IA-UlB Hodgkin'a disease: Long-term analysis of dsk factors and outcome. Blood 1996, 87:3625-3632. Mezzoni A, Mezzanzonca D, Jun9 GR, Wolf H, Colnaghi MI, Caneverl S: CD3-CD28 ¢ostimulation as a • means to avoiding T cell preacthmSon in bispe¢ific monoclonel antibody-hased treatment of ovsdan carcinoma. Cancer Res 1996, 56:5443-5449. Mcsweeney PA, Wells DA, Shults KE, Nash RA, Bensinger WI, Buclmer CO, Loken MR: Tumor-specific enenploldy not date(ted in CD19(+) B-lyre)hold cells from my•lama patients in a muffidimensionsl flow cytomatric analysis. Blood 1996, 88:622-632. Me9getto F, Brousset P, Selves J, Delsol G, Mariame B: Reed-Steinberg cells and "Bystander" lymphocytos in lymph nodes affected by Hodgkin's disease are infected with different sfrelns of Epsteln-Berr virus. J Viral 1997, 71:2547-2549. Male JV: The diversity of BCR-ABL fusion proteins and their relationship to isukemla phenotype` Blood 1996. 88:2375-2384.

Mentz F, Mossalayi MD, Ouaaz F, Baudet S, Issely F, Ktorza S, Semichon M, Binet JL, Medeberal H: Theophyllins synergizas with chlorsmbucil in inducln9 spoptusis of B-chronic lymphocytic leukemia cells. Blood 1996, 88:2172-2182. Mantzer SJ, Longtine J, Fingeroth J, Reilly JJ, Decamp MM, Odonnell W, Swanson SJ, Failer DV, Sugarbakar DJ: Immunoblsstic lymphoma of donor odgin in the sllo9rsff after lung fransplantetion. Transplantation 1996, 61:1720-1725. Mikovits JA, Hoffman PM, Rethwilm A, Ruscetti FW: In vitro infection of pdmary and refrovirus-infected human leukocytss by human foamy virus. J Viral 1996, 70:2774-2780. Miles DK, Freedman MH, Stephens K, Pelleviclni M, Slavers EL, Weaver M, Grunberger "I", Thompson P, Shannon KM: Patterns of hsmatopoistic lineage involvement in children with neurofibromatosis type 1 and malignant my•laid disorders, Blood 1996, 88:4314-4320. Miller G, Heston I., Grogan E, Gradoville L, Rigsby M, Sun R, Shedd D, Kushnaryov VM, Grossberg S, Chang Y: Selective switch between latsncy and lytlc replication of Kaposi's sarcoma herpesvirus and Epstein-Bert virus in dually inteded body cavity lymphoma cells. J Viral 1997, 71:314-324. Miyamoto 1", Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaks K, Mizuno S, Gondo H, Okamura T, Dohy H, Niho Y: Persistence of multipotent progenitors expressing AMLI/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996, 87:4789-4796. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hansel N, Fukushirna P, Barrett AJ: Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptlde dedved from proteinase 3 preferentially lyse human my•laid Isukemla calls. Blood 1996, 88:2450-2457. Monaco MCG, Atwood WJ, Grave, M, Tornatore CS, Major EO: JC virus infection of hematopoietic progenitor cells, pdmary B lymphocytes, and tonsillar atromal cells: Implications for viral latency. J Viral 1996, 70:7004-7012. Monini P, Rotola A, Delellis L, Corallini A, Secchiero P, Albini A, Benelli R, Parravicini C, Barbantibrodano G, Cassal E: Latent BK virus infection and Kaposi's sarcoma pathogenesia. Int J Cancer 1996, 66:717-722. Monni O, Joensuu H, Franssila K, Knuutila S: DNA copy number chan9es in diffuse large B-cell lymphoma -Comperative 9anemic hybridization study. Blood 1996, 87:5269-5278. Moorman JP, Bobak DA, Hahn CS: Insctivatlon of the small GTP binding protein Rho induces muItlnu¢leste cell formation and epoptosis in mudne T lymphoma EL4. J Immunol 1996, 156:4146-4153. Morosetti R, Grignani F, Liberators C, Pelicci PG, Schiller GJ, Kizaki M, Bertram CR, Miller CW, Koeffler HP: Infrequent elf•rations of the PAR alpha gens in acute myelogenous Isuksrnias, ratlnoic acid-resistent acute promyelocytic leukemiss, myelodysplsstic syndromes, and cell lines. Blood 1996, 87:4399-4403. Mouzaki A, Serfling E, Zublar RH: Interleukin-2 promoter activity in Epstein-Berr virus-transformed B lymphocytes is controlled by nuclear tector-chl B. Eur J Immuno11995,25:2177-2182. MuIIoy JC, Crowisy RW, FuUenJ, Leonard WJ, Franchini G: The human T-cell Ilmkemis/lymphofropic virus type 1 p12(I) protein binds the intedeuldn-2 receptor beta and 9stoma(c) chains and affects their expression on the cell surface. J Viral 1996, 70:3599-3605. Munker R, Kobayashi 1", Bstner E, Norman AW, Uskokovic M, Zhang W, Andraeff M, Koeffler HP: A new series of vitamin d analogs is highly active for cionsl inhibition, diferentiaSon, and induction of WAF1 in myeloid Isukemia. Blood 1996, 88:2201-2209. Munshi NC, Govindarajan R, Drake R, Ding LM, lyer R, Saylors R, Kombluth J, Marcus S, Chiang Y, Ennist D, Kwak L, Reynolds C, Tricot G, Barlogie B: Thymidine klnass (TK) g4me-frsnsduced human lymphocytas can be bigMy purified, remain fully function•l, and are killed efficiently with gandclovir. Blood 1997, 89:1334-1340. Murata K, Fujita M, Honda 1", Yamada Y, Tomonaga M, Shiku H: Rat pdmary T cells expressin9 HTLV-I tax gane transduced by a rsfrovirsl vector:. In vitro and in viva characterization. Int J Cancer 1996, 68:102-108. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, Chang AE: Immune response in human melanoma after transfer of an allogermtc class I major histocompatibility complex gene with DNA-Ilposoma complexes. Proc Nat/Acad Sci USA 1996. 93:16388-16393.

Nador RG, Cesarman E, Chadbum A, Dawson DB, Anssri MQ, Said J, Knowies DM: Primary effusion lymphoms: A distinct clinlcopathologlc entity associated with the Kaposl's ssmome-sssodated herpes virus. Blood 1996, 88:645--686. Nakabo Y, Pabst MJ: Lyels of leukemic cells by human macropheges: Inhibition by 4-(2-emlnoathyl)-benzenasulfunyl fluoride (AEBSF), • amine protease inhibitor. J Leukoc B/o/1996, 60:328-336. Nfdcagaws M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM: Cytofuxlc T lymphocyte responses to E$ and E7 proteins of human paplliornavlrus type 16: Relationship to cervical intraspithelisl neoplasie` J Infect Dis 1997, 175:927-931. Nakamura N, Wajjwelku W, Nishiroura H, Okubo H, Niimi N, Ando Y, Yoshikai Y: Nucisoflde sequences of any and 3'LTROrf genes of endogenous m u s e mammary tumor viruses encoding superentigsn specific for TcrV bate 2. Immunogenet/cs1996, 44:319-320. Neilson J, Harrison P, Milligan DW, Skidmore SJ, Collingham KE: Hepatitis G virus in long-term survivors of haematologlcel mellgnency [Letter]. Lancet 1996, 347:1632-1633, Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C, • KrenskyAM: Tumor-apedflc, cytotoxtc T-lymphocyte response after Idiofyps vaccination for B-cell, non-Hogldn's lymphoma. Blood 1996, 88:580-589.

[881 Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR: Posftrsnsplent lymphoprollferatlvs disease In pedistdc liver transplantation - Interplay between primary Epsteln-Berr virus infection and Immunosupprasion. Transplantation 1996, (;2:370-375. Nicholas J, Ruvolo VR, Burns WH, Sandford G, Wan XY, Ciufo D, Handrickson SB, Guo HG, Ha)ward GS, Reitz MS: Kaposi's semoma-essocisted human herpeavirus-8 encodes hornologusa of macrophags inflammatory protein-1 end Intedeukln-6. Nat Mad 1997, 3:287-292. Nishinaka Y, Ravindransth MH, Iris RF: Development of a human monodonel antibody to gangnoelds G(M2) with potential for cancer troatmenL Cancer Res 1996, 56:5666-5671. Nishiura T, Karasuno T, Yoshida H, Nakao H, Ogawa M, Horikawa Y, Yoshimurs M, Okajima Y, Kanakura Y, Kanaysma Y, Mstsuzswa Y: Functional role of cation-independent mannoea 6-phnsphsfe/Inaulln-Ilha growth factor II receptor In cell adhesion end proliferation of = human my•lama cell line OPM-2. B/ood 1996, 88:3548-3554. Noel JC: Kaposi's samaras and KSHV [Letter]. Lancet 1995, 346:1359. Nomurs A, Stemmermann GN, Chyoo PH, Tabor E: Hepatitis B end C virus serologiea among Japanese Americana with hepatocelluisr cardnoma. J Infect Dis 1996, 173:1474-1476. Norrbank KF, Dahienborg K, Cadsson R, Roos G: Telomersse activation in normal B lymphocytas end non-Hodgkln's lymphomes. Blood 1996, 88:222-229. Oberbauer R, Banyai S, Schmidt A, Karnak G, Scheithauer W, Mayer G: Serum tumor markers after renal transpisntation. Transplantatk)n1996, 62:1506-1609. Ode A, Miyakawa Y, Druker BJ, Ishids A, Ozaki K, Ohash~ H, Wakui M, Hands M, Watanabe K, Okamoto S, Ikeda Y: Crkl is constitutively tyro•ins phosphorylated in plat•lets from chronic myelogenous leukemia patients and induclbiy phoaphorylated in normal plat•eats stimulated by thrombopoiatln. Blood 1996, 88:4304-4313. Odunsi K, Terry G, He I., Bell J, Cu=ck J, Ganesan TS: SusceptlbiUty to human papillomavlrus-aasocisted cendcel intra-epithelisl neopiesis is determined by specific HLA DR-DQ elleles. Int J Cancer 1996, 67:595-602. Odik O, Spear GA: FYograssion to persistent lymphocytosls end tumor development in bovine leukemia virus (BLV)-Infocted cattJs correlates with impaired proliferation Of CD4(+) T cells in response to gag- and any-encoded BLV proteins. J V/ro11996, 70:7684-7593. Orozcotopete R, Archerdubon C, Veladezhuerta N, Harnandezpando R, OrozcoestevezH, Gahilondo F, Bordesaznar J, Alberu J: Cutaneous neoplasms and human papillornavirus in renal transplant paUents: Experience of one canter in Mexico. TransplantProc 1996, 28:3314-3316. Otem JC, Santirlana S, Fereyros G: High frequency of acute promyelocyttc leukemia among Lagnos with acute myeloid leukemia [Latter]. Blood 1996, 88:377.

Cancer Tumor biology

Ott G, Kalla J, Oft MM, Schryen B, Kstzenberger T, Muller JG, Mullerhermelink HK: Biaatold vedanta of mantle cell lymphoma: Frequent bci-1 rearrangements st the major frenslocation cluster region and tetraploid chromosome danes. B/ood 1997, 8~:1421-1429. Oudejans JJ, Jews NM, Kummer JA, Ossenkoppeie GJ, Vanheerde P, Burs JW, Kluin PM. Kluinnelemans JC, Vandiest PJ, Middeldorp JM, Meijer CJLM: Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997, 89:1376-1382. Pal( J, Feller DV: Moloney mudne leukemia virus activates NF-kappa B. J Viral 1996, 70:4167-4172. Pane F, Frigeri F, Sindons M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Sslvatore F, Rotoli B: Neutrophilic-chroolc myeiold leukemia: A distinct disease with s spedflc molecular marker (BCR/ABL with C3/A2 junction). Blood 1996, 88:2410-2414. Parsons SK, Skapek SX, Neufeld FJ, Kuhlman C, Young ML, Donnelly M, Brunzell JD, arras JD, Sellan SE, Rifai N: Aspersginase-essociatmd lipid abnormalities in children with acute lymphoblaatlc leukemia. Blood 1997, 89:1886-1895. Pateer A, Kamoto 1", Lu LM, Yarnsda Y, Hisi H: Two dominant host resistance genes to pra-B lymphoma in wild-derived inbred mouse sfreln MSM/Ms. Cancer Res 1996, 56:3716-3720. Patarcs R, Frisdlandar A, Hsrrington WJ, Cabral L, Bymes JJ, Ratchet MA: Pedphersl blood T cell subsets as prognostic indicators of chemotherapy outcome In AIDS pstien~ with large cell lymphoma - Short communication. AIDS Res Hum Retroviruses 1996, 12:645-649. Pauza ME, Doumbis SO, Pennell CA: Construction snd characterization of human CD7-spadfic single-chain Fv immunotoxins. J Immuno11997,158:3259-3269. Pear WS, Aster JC, Scott ML, Hasserjisn RR Softer B, Skier J, Baltimore D: Exclusive development of T cell neoplasms in mice transplanted with bone msrrow expressing actlvsted Notch alleles. J Exp Med 1996, 183:2283-2291. Pericle F, Epllngburnette PK, Podack ER, Wee S, Djeu JY: CD40-CD40L Interactions provide "third-psrty" coatlmuiation for T cell response sgeinst B7-1-fransfected human breast tumor cells. J Leukoc Biol 199?, 61:201-208. Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, Eaves AC: Charactedzatlon of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well es established chronic myoloid leukemia. Blood 1996, 88:2162-2171. Pinczower GD, Williams RPW, Gianello RD, Robinson HC, Preston BN, Linnane AW: C h a r a ~ o n of the tumour-essociated carbohydrate epltupe recogniaod by monodonst enebody 4D3. Int J Cancer 1996, 59:836-644. Pique C, Connan F, Levilain JP, Choppin J, Dokhelar MC: Among all haman T-cell leukemia virus type 1 proteins, tax, polymerase" and envelope proteins ere predicted es prefMontiol targets for the HLA-A2-resricted cytotoxic T-ceil response. J Virol 1996, 70:4919-4926. Piras G, Dittmer J, Radonovich MF, Brady JN: Human T-ceil leukemia virus type I tax protein transactlvstes RNA polymerese lit promoter In vitro and In viva. J Biol Chem 1998, 271:20501-20506. Pittelu~ S, Bijnans L, Tocdorovic I, Hagenbeek A, Meerwaldt JH, Samara R, Thomas J, Noordijk EM, Dowolfpeeters C: Clinical analysis of 670 cases In two rials of the European orgenlzaeon for the research end treatment of cancer lymphoma cooperative group subtyped according to the revised European-American desslflcetlon of lymphoid necplesms: A comparison with the working formulation. B/ood 1996, 87:4358-4367. Piuschke G, Vanek M, Evans A, Oittmar T, Sohmid P, Itin P, Fiisrdo FJ, Reisfeld RA: Molecular cloning of a human meianoma-essoolated chondroitin sulfate proteoglysan. Proc Nstl Acsd Sc/USA 1996, 93:9710-9715. Poleck A, Hormagel K, Pajic A, Christoph B, Baier B, Felk M, M~ttner J, Geltinger C, Bomkamm GW, Kempkes B: c-myc actlvstJon render= proliferation of Epateln-Barr virus (BV)-transformed ceils independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci USA 1996, 93:10411-10416. Polito P. Canzonieri V, cells AM, Gioghini A, Gaidano G, Carbone A: Structural abnormality of l q in an AIDS-ratatad body-¢avibybased lymphoma [Letter]. Int J Cancer 1996, 57:588-590. Porcher C, Swat W, Rockwell K, Fujiwara Y, Air FW, Orkin SH: The T cell leukemia on¢oprofein SCIJtsI-1 Is essential for development of all hematopoistlc lineages. Cell 1996, 86:47-57. Przepiorka D, Ippoliti C, Khouri I, Andedini P, Mehra R, Girelt S, Gajewski J, Fritsche H, Deisseroth AB, Cleary

K, Champlin R, Vanbesien K, Andersson B, Korbling M: AIIogeneic transplantation for sdvenced leukemia - Improved short-torm outcome with blood stem cell 9rafts snd tacrolimus. Transplantation1996, 62:1806-1810. Przybylski GK, Goldman J, Ng VL, Mcgrath MS, Hemdier BG, Schenkein DP, Monroe JG, Silberstein LE: Evidence for eady B-COIl activation preceding the development of Epsteln*Berr virus-negative acquired immunodaticiency syndrome-related lymphoma. Blood 1996, 88:4620-4629. Puisieux I, Bain C, Merrouche Y, Maischer P, Kourilsky P, Even J, Favrot M: Restriction of the T-cell repertoire in tumor-intihrsting lymphncytss from nine patients with renal-ceil caminoma. Relevance of the CDR3 length analysis for the identification of in situ cionei T-cell expansions./nt J Cancer 1996, 66:201-208. Pulford K, Lament L, Morris SW, Butler LH, Wood KM, Stmud D, Dolso= G, Mason DY: Detection of anapiastic lymphoma klnsse (ALIa snd nucieoler protein nucisophosmin (NPM)-ALK proteins in normal snd neoplastic cells with the monocional sntibody ALK1. Blood 1997, 89:1394-1404. Purvis SF, Katongolembidde E, Johnson JL, Leonard DGB, Byabazaire N, Luckey C, Schick HE, Wallis R, Elrnets CA, Giam CZ: High incidence of Kaposi's sarcoma-associated herpeevirus and Epstein-Berr virus in tumor lesions and peripheral blood mononudear cells from patients with Kaposi's sarcoms in Uganda. J Infect Dis 1997, 175:947-950. Puthier D, Bataille R, Barille S, Mellerin MP, Harousseau JL, Ponzio A, Robillard N, Wijdenes J, Amiot M: Myeloma cell growth street, apoptosis, snd intedeukin-6 receptor modulation induced by EB1089, s vitamin D-3 derivstive, alone or in sssociation with dezamethasor, e. Blood 1996, 88:4659-4666. Putnam P, Reyes J, Kocoshis S, Jabbour N, Green M, Buano J, Todo S: Gsstrointastinsl posttransplant lymphoproliferative disease in children after small intestinal transplsntetion. TransplantProc 1996, 28:2777. Guintanillamartinez L, Lomemaldonado C, art G, Gschwendtner A, Gredler E, Reyes E, Angelesangeles A, Fend F: Pdmary non-Hodgkin's lymphoma of the intestine: High prevalence of Epsteln-Berr virus in Mexican lymphomas as compsred with European cases. Blood 199"/, 89:644-651. Radford KJ, Thorns RF, Heresy P: Regulation of tumor cell motility and migration by CD63 in a human meisnoma cell line. J Immuno11997, 158:3353-3358. Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S, Gooley T, Kessler P, Kirk J, Ladne P, Thomas ED, Appelbaum FR: Detection of bcr-ebl frsnscdpts in Philadelphia chromosome-positive acute lymphoblesttc leukemia after marrow transplantation. Blood 1997, 89:2802-2609. Ramadi D, Reins S, Merola M, Scupoli MT, Poffe O, Riviera AP, Brentegani M, Fiorini E, Vella A, Vernier O, Tridents G: HTLVtype lUB infection of human thymtc epithelial cells: Viral expression correlates with the induction of NF-kappe B-binding activity in ceils activstad by cell adhesion. AIDS Res Hum Retroviruses t996, 12:1217-1225. Ravindranath MH, Bauer PM, Comillezty C, Garcia J, Morton DL: Qusntitstion of the density of cell surfsce carbohydrate antigens on cancer cells with s sensitive cell-suspension ELISA. J Immuno/ Methods 1996, 197:51-67. Reiter LS, Spertini O, Kruithol EKO: Ptasmlnogon activators play an esseofiol role in extraceiluiar-marix invasion by lymphoblastic T cells. Int J Cancer 1997, 70:481-486. Renard N, Lafagepochitaioff M, Durand I, Duvert V, Coignet L, Banchereau J, Saeland S: Demonstration of functional CD40 in B-lineage acute lymphoblestic leukemia cells in response to T-ceil CD40 legend. Blood 1996, 87:5162-5170. Rennar C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeiar JP, Pfreundschuh M: T cells from pa~ents with Hodgkin's disease have a defective T-ceil receptor zeta c h i n expression that is reversible by T-cell sUmuletion with CD3 and CD28. Blood 1996, 88:236-241. Reyes J, Green M, Buena J, Jabbour N, Naieenik M, Yunis E, Kocoshis S, Kauffman M, Tndo S: Epstein Barr virus associated posttranspiant lymphoproliteretive disease alter intestinal transplantation. Transplant Proc 1996, 28:2768-2769. Riley DJ, Nikitin AY, Lee WH: Adenovirus-mediated retinoblastoma 9ene therapy suppresses spontaneous pituitary muianotroph tumors in Rb-+/- mice. Nat Med 1996, 2:1316-1321. Ristemaki R, Joensuu H, Gronvirta K, Saline M, Jelkanen S: Odgin end function of circulating CD44 in non-Hodgkin's lymphome" J Immuno11997, 158:3000-3008,

751

Rivoltini L Loftus DJ, Barracchini K. Arienti F, Mazzocchi A, Biddieen WE, Selgeller ML Appalls E, Parmiani G, Manncola FM: Binding and presentation of pepbdes derived from melanoma antigens MART-1 and glynopmtein-100 by HLA-A2 subtypes - Implications for peptide-based Immunofherapy. J Immunol 1996, 156:3882-3891. Roche M, Umansky V, Lee KH, Hacker HJ, Banner A, Schirrmacher V: Differences between 9raft-vemus-lsukernia and gmR-versus*hoat reactivity. 1. Interaction of donor Immune T cells with tumor and/or host cells. Blood 1997, 89:2189-2202. Rojas G, Alberu J, BordasaznarJ, Quintanillamartinez L, Lomemaidonado MC, Cesarman G, Angeleeangelee A, Correarotter R: Clinical and pethologicst charactsdzatlon of posttranspiantstion lymphoprollferstive disorders in kidney transplant recipients: Single insUtution experience. Transplant Proc 1998, 28:3317-3320. Roncells S, Cutrona G, Favre A, Ulivi M, Fais F, Signorini A, Grossi CE, Chiorszzi N, Ferrarini M: Apoptosis of Burkitt's lymphoma cells induced by spedflc interaction of surface IgM with • self-antigen: Implications for lymphornagenesis in acquired irnmunodoficiency syndrome. Blood 1996, 88:599-608. R6pke M, Held J, Guldbarg P, Zeuthen J, Norgaard L, = FuggerL, Svejgurd A, Van Der Burg S, Nijman HW, Melief CJM, Cteesson MH: Spontaneous human squamous cell carcinomas ere killed by s human cytutoxic T lymphocyte clone recognizing a wild-type p53-dedved pepUde. Proc Nat/Acad Sci USA 1996, 93:14704-14707. [591Ross TM, Pettiford SM, Green PL: The tax gene of human T-ceil leukemia vires type 2 is essential for transformation of human T lymphocytes. J Viral 1996, 70:5194-5202. Rozman C, Montserrat E: Current concepts: Chronic lymphocytic leukemia. N Eng/ J Mad 1995, 333:1052-1087. Rubinfeld B, Robbins P, EI-Gamll M, Albert I, Porfiri E, • - Polakis P: Stsblllzstion of [3-¢atanln by genetic defects in melanoma cell lines. Science 1997, 275:1790-1792. [41]. Rubnitz JE, Behm FG, Cumiobfint AM, Pinheiro VRP, Carroll AJ, Raimondi SC, Shurtleff SA, Downing JR: Molecular analysis of t(11;19) breskpolnts In cblldhond acute leukernies. Blood 1996, 87:4804-4808. Rubnitz JE, Shuster JJ, Land VJ, Link MR Pullen J, Camitts BM, Pui CH, Downing JR, Behrn FG: Case-control study suggests s favorable impact of TEL rearrangement in patients with B-lineage acute lymphobiaatio leukemia treated with sntimatabollte-based therapy:. A pedlstdc oncology group study. Blood 1997, 89:1143-1146. Russell NH: Biology of acute leukaemia. Lancet 1997, 349:118-122. Russo JJ, Bohenz~ RA, Chien MC, Chen J, Yen M, Maddalena D, Parry JP, Peru~i D, Edelman IS, Chang YA, Moore PS: Nucleutide sequence of the Kaposl sarcoma-acsoolated herpesvirus (HHVe). Proc Nstl Acad Sci USA 1996, 93:14862-14867, Ruzek MC, Msthur A: Plasma cell tumors decrease CD23 mRNA expression in viva in mudne splenic B cells. Eur J Irnmunol 1995, 25:2228-2233. Sachs L: The control of hernatopolesls end leukemia: From basic biology to the clinic. Proc Nat/Acad Sci USA 1996, 93:4742-4749. Sadovnikova E, Stauss I-Ll: Peptide-speclfic ¢ytofoxlc T lymphocytss restricted by nons~f major hlstocompatlbility cornpiax class I molecules: Reagents for tumor Immunofherlpy. Proc Nstl Acad Sci USA 1996, 93:13114-13118. Ssid JW, Chien K, Takeuchi S, Taaska T, Asou H, Cho SK, Devos S, Ceasrman F., Knowlee DM, Koeffter HP: Kaposi's sarcoma-associated horpesvirus (KSHV or HHV8) in primary effusion lyrophoma: Ultrestructural demonstration of herpesvlrus in lymphoma ceils. Blood 1996, 87:4937-4943. Said JW, Tasaka 1". Takeuchi S, Asou H, Devos S, Ceseenan E, Knowiee DM, Koeffler HP: Primary effusion lymphoma in women: Report of two cases of Kaposi*s sarcoma herpes virus-asaociated effusion-based lymphoma in human immunodaticiency virus-negative women. Blood 1996, 88:3124-3128. Saito S, Kato N, H[jikata M, Gunji T, Itabashi M, Kondo M, Tanai~ K, Shimotohno K: Comparison of hypervorlable regions (HVRI end HVR2) in positive- end negative-stranded hepatitis C virus RNA in cancerous and non-cancerous liver tissue, pedpherat blood mononudear ceils snd serum from a patient wRh hepetoceiluler cardnoma. Int J Cancer 1996, 67:199-203. Samaniego F, Markham PD, Gendelman R, Gano RC, Ensoll B: Inflammatory cytokines Induce

752

C a n c e r T u m o r biology

endothelial cells to Produce and release basic flbroblest growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. J Immune/1997, 158:1887-1894. Sander CA, Simon M, Puchta U, Raffeld M, Kind P: HHV-8 In lymphopronferstive lesions in skin [Letter]. Lancet 1996, 348:475-476. Sandig V, Brand K, Herwig S, Lukes J, Bartek J, Strauss M: Adenovirelly transferred p16(INK4/CDKN2) and p53 genes cooperate to Induce apoptotic tumor cell death. Nat Mad 1997, 3:313-319. Sengfell O, Einhorn S, Sjorklund AC, Wimen KG, Okec I, Grander D: Wild-type p53-induced apoptosia in a Buddtt lymphoma cell line is inhibited by interferon gamma. Ins J Cancer 1996, 67:106-112. Sadati M, Chevret S, Chasten9 C, Biron G, Stryckmans P, Deleapesae G, Binet JL, Medeberal H, Bron D: Prognostic importance of serum soluble CD23 level tn chronic lymphocytic leukemia. Blood 1996, 88:4259-4264. Sadd R, Sate 1", Bohenzky RA, Russc JJ, Chang Y: Kaposi's sarcomo-essocieted herpesvirus encodes a functional Bd-2 homolo8ue. Nat Med 199?, 3:293-298. Sarris AH, Luthra R, Papadimittscopoulou V, Waasdorp M, Dimopoulos MA, Mcbride JA, Cabenillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC: Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23;q35) in snsplaetic large cell lymphoma, but not In other non-Hodgkin's lymphomes, Hod8kin's disease, or lymphometoid pepulosia. Blood 1996, 88:1771-1 ?79. Sauter M, Roemer K, Best B, Afting M, Schommer S, Seitz G, Hartmann M, Muelledantzsch N: Specifidty of andbndles directed against Env protein of human endogenous retroviruses in patients with germ cell tumors. Cancer Res 1996, 56:4362-4365. Sawyers CL: Molecular genetics of acute leuksemie. Lancet 1997, 349:196-200. Schlager S, Speck SH, Wolsetechlager M: Transcription of the Epsteln-Berr virus nuclear antigen 1 (EBNAI) gene o¢cum before induction of the BCR2 (Cp) EBNA germ Promoter dudng the intiiel stages of infection in B celia. J Viro11996,70:3561-3570. Schlelfer D, Krajewski S, Galoin S, Rigalhuguet F, Laurent G, Masslp P, Pris J, Delscl G, Reed JC, Brousset P: Immunodstectlon of apoptosls-raguleting proteins in lymphomas from patients with and without human Immunodeflclency virus Infection. Am J Patho11996, 149:177-185. Schnell R, Katouzi AA, Linnartz C, Schoen G, Ddllich S, Hansmann ML, Schiefer D, Berth S, Zangemelsterwiftke U, Stahel RA, Diehl V, Engert A: Potent anti-tumor effect= of an anti-CD24 ddn A-chain immunotoxin In vitro end in a disaeminsted human Burkitt's lymphoma model in SCID mica. Int J Cancer 1996, 56:526-531. Sch6nberger SP, Sercerz EE: Hameeslng self reactivity • in cancer immunotherspy. Semin Irnmunol 1996, 8:303-309. [40f]. Schulte AM, Lai SP, Kurtz A, Czubayko F, Riegel AT, Wellstein A: Human trophoblaet end chodocercinoma expression of the grcwih factor plelotrophin attributable to germ-lloa inserllon of an endogenous retrovirus. Proc Natl Acad Sci USA 1996, 93:14759-14?64. Schwarzmeier JD, Hilgarth M, Nguyen ST, Shehata M, Gruber G, Spittler A, Willheim M, Boltznitulescu G, Hocker P, Berger R: Inedequste production of hemntopolstlc growth factors in hairy cell leukemia: Up-regulation of interleukin 6 by recombinant IFN-elpha in vitro. Cancer Res 1996, 56:46?9-4685. Schweighoffer T: Tumor cells expressing a recall antigen ire powerful cancer vsocines. Eur J Immunol 1996, 26:2559-2564. Serreco D, Monteiro J, Allen SL, Kolitz J, Schulmec P, LJchtman SM, Buchbinder A, Vinciguerra VP, Chiorezzi N, Gregersen PK: Clones expansion within the CD4(+)CD57(+) and CD8(+)CD57(+) T cell subsets in chronic lymphocytic leukemia. J Immunol 1997, 158:1482-1489. Seydel J, Kramer A: Transmission and population dynamics of HTLVolinfection. Int J Cancer t996, 66:197-200. Shepherd JD, Barnett MJ, Phillips GL: High-dose cytsrabine induction for acute myeloid leukemia [Letter]. Blood 1996, 88:754. Shingadia D, Howard MR, Brink NS, Gibb D, Klein N, Tedder R, Novelli V: Kaposi's sarcoma and KSHV [Letter]. Lancet 1995, 346:1359-1360. Silvestri F, Pipen C, Barillari G, Zaja F, Fanin R, Infecti L, Russo D, Faiasca E, Botts GA, Bsccareci M: Prevalence of hepatitis C virus infection In patients with lymphopronferetive disorders. Blood 1996, 87:4296-4301. Simonian PL, Grillot DAM, Andrews DW, Leber B, Nunez G: Bax homodimerization is not required for Bax to

accelerate chemotherapy-induced cell death. J Biol Chem 1996, 271:32073-32077. Simpson GR, Schulz TF, Whitby D, Cook PM, Boshofl C, Rainbow L, Howard MR, GSC SJ, Bohen;d(y RA, Simmonds P, Lee C, Deruiter A, Hatzakis A, Tedder RS, Waller IVD, Weiss RA, Moore IS: Prevalence of Kapost'~, sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent Immunofluore~:ence antigen, Lancet 1996, 348:1133-1138. Siriann~ MC, Uccini S, Angeloni A, Faggioni A, Cottoni F, Ensoll B: Circulating spindle cells: Correlation with human herpesvtrus-8 (HHV-8) infection and Kaposi's sarcoma. Lancet 1997, 349:255. Skipper JCA, Hendrickson RC, Gulden PH, Brichard • V, Van Pal A, Chen Y, Shabanowitz J, Wlfel 1", Slingluf CUR, Boon Tet a/.: An HLA-A2-rastricted tyrosinase antigen on melanoma cells results from posttranslstlonel modification and suggests a novel pathway for processing of membrane proteins. J Exp Mad 1996, 183:527-534. [36t]. Skorski T, Nieborowskaskorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA, Celabretta B: Biastic transformation of p53-defident bone marrow cells by p210(bcr/abl) tyrosine kinase. Proc Nat/Acad Sci USA 1996, 93:13137-13142. So CW, Caldas C, Liu MM, C~en SJ, Huan9 QH, Gu U, Sham MH, Wiedemarm LM, Chan LC: BEN encodes for • member of a new family of proteins containing an Src homology 3 domain and is the third 8ene located on chromosome 19p13 that fuses to MLL in human leukemia. Proc Natl Acad Sci USA 199?, 94:2563-2568. Soslow RA, Davis RE, Warnke RA, Clear,/ML, Kamel OWe True hiatiocyttc lymphoma following therapy for lymphoblestlc neoplasms. Blood 1996, 87:5207-5212. Soweid AM, Zachary PE: Mucosa-essociatad lymphotd tissue lymphoma of the oesophagus [Letter]. Lancet 1996, 348:268. Speck RR, Couto JR, Godwin SG, Christian RB, Kiwan R, Carieci RL, Paterson JA: Inverted Fab2s (IFab2s): Engineerin8 end expression of novel, dimeric molecules, with a molecular weight of 100 000. Mol frnmuno/1996, 33:1095-t 102. Spriggs MK, Armitage RJ, Comeau MR, Strockbine L, Farrah T, Macduff B, Ulrich D, Alderson MR, Mullberg J, Cohen Jl: The extraoalluiar domain of the Epstein-Bert virus BZLF2 protein binds the HLA-DR beta chain end inhibits antigen presentation. J Viro/ 1996, 70:5557-5563. Srivastava PK: Do human cancers express shared • protective antigens? Or the necessity of remembrance of things past. Semin fmmunol 1996, 8:295-302. [4t]. Stewart SA. Feuer G, JeweSSA, Lee FV, Bonavida B, Chen ISY: HTLV-I gene expression in adult T-call leukemia cells elicits an NK cell response in vitro and correlates with cell rejection in SCID mice. Virology 1996, 226:167-175. S1ilgenbauer S, Liebisch P, James MR, Schroder M, Schlegelberger B, Fischer K, Bentz M, Lichter P, Dohner H: Molecular cytogenetic delineation of a novel critical genorntc region in chromosome hands 11q22.3-923,1 in lymphoprollfersUve disorders. Proc Nat/Acad Sci USA 1996, 93:11837-11841. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Marieni SM, Stremmel W, Krammer PH, Galls PR: Lymphocyte epopfosis induced by CD95 (APO-1/Fas) ligand-expreesing tumor cells - A mechanism of immune evasion? Nat Med 1996, 2:1361-1366. Strzadala L, Miazek A, Metuszyk J, Kisielow P: Role of thymic selection in the development of thymic lymphomas in TCR tmnsgenic mice./nt Immune/ 199?, 9:127-138. Su 7 7 Lin JA, Shen RCL Fisher PE, Goldstein NI, Fisher PB: Surfece-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the gelectin gene family. Proc Nat/Acad Sci USA 1996, 93:?252-7257, Susie T, Kubota H, Sate M, Nakamura E, Imamura M, Minato N: NKt(+) CD4(-) CD8(-) alpha beta T cells in the peritoneal cavity - Specific T cell receptor~medieted cytotoxicity and selective IFN-gamma produc~on against B cell leukemia end myeloma cells. J Immuno11996, 157:3925-3935. Sugita S, Sagawa K, Moohizuki M, Shichijo S, Itoh K: Melanocyte I/sia by cytntoxic T lymphocytes recognizing the MART~I melanoma antigen in HLA-A2 patients with Vogt-Koysnagi-Harada disease. Int Imrnunol 1996, 8:799-803. Sutherland HJ, Blair A. Zapf RW: Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996, 87:4754-4761.

Sutton RE, Littmen DR: Broad host range of human T-ca8 leukemia virus type 1 demonstrated with an Improved pseudotyplng system. J Vim/1996, 70:7322-7326. Syrengeles AD, Chen Tr, Levy R: DNA Immunization induces protective immunity against B-cMI lymphoma. Nat Mad 1996, 2:1038-1041. Syrigos KN, Konstantoulalds MM, Fysssa t, Katsilambros N, Golemati8 BC: Autoantlbodies against insulin and bets-iaklt celia In I~ncrentic sdenocarclnoma: A possible explanation for diabetes mellltus. Int J Cancer 1996, $6:624-626. Szczepek AJ, Bergsagel PL, Axelsenn L, Brown CB, Belch AR, Pilerski LM: CD34(+) cells In the blood of patients with multiple myeloma express CDt9 and IgH mRNA and have patient-speclfic IgH VDJ germ rearrangements. Blood 1997, 89:1824-1833. Tschibans K, Uchida T, Hisano S, Morioke E: Eliminating adult T-cell leukaemle cells with ultrasound. Lancet 1997, 349:325. Takeyama H, Hosoya 1", Sakurai K, Mori Y, Wetanabe M, Kisaki H, Ohno T: Production of a novel monoclonel antibody, .n'-tis, which can detect antigen of thyroid cardnoma. Cancer Res 1996, 56:1817-1822. Tallman MS, Haklmiec D, Radernaker AW, Zanz~ C, Wollins E, Ross E, Paterson LC: Relapse of hairy cell leukemia after 2-chlorodeoxysdenoelrm: Long-term follow-up of the northwestern unlvemlty experience. Blood 1996, 88:1954-1959. Tamlya S, Matsuoka M, Etoh KI, Watanabe T, Kamihim S, Yamaguchi K, Takatauk; K: Two types of defective human T-lymphotroplc virus type I proviroa in adult T-cell leukemia. B/ood 1996, 88:3065-3073, Tanaka K, Arif M, Eguchi M, Kyo 1", Dohy H, Kamada N: Frequent jumping translocettons of chromosomal segments involving the ABL oncogene alone or in combination with CD3-MLL genes in secondary leukemia*=° Blood 1997, 89:596-600. Taniguchi S, Manhi M, Ohno Y: Epsteln-Berr virus-essocisted CD3(-) large granular lymphocyte leukemia presenting with polycranlal nerve palsies [Letter]. Blood 1996, 87:4914-4915. Tanner JE, Wel MX, Altierl C, Abroad A, Taylor P, Ooka 1", Menezes J: Antibody end antibody-dependent cellular cytntoxidty responses against the BamHI a rightward open-resding frame-1 protein of Epsteln-Berr Vires (EBV) In EBV-sesoclsted disorders. J Infect Dis 1997, 175:38-46. Ten Q, Srlvutsva G, Dickens P, He FCS: Detection of Epsteln-Berr virus-Infected mucosel lymphocytas In nasal polyps. Am J Pathol 1995, 149:1111-1118. Tehranlan A, Morris DW, Min BH, Bird DJ, Cardiff RD, Barry PA: NeoplaStic transtormMIon of prostatic and urogenital epithelium by the polyorna virus middle 1 Sane. Am J Patho/1996, 149:1177-1191. ten Bosch GJA, Joosten AM, Kessler JH, Meliel CJM, • Leeksma OC: Recognition of BCR-ABL positive leukemic blasts by human CO4+ T cells elicited by pdmary in vitro immunization with a BCR-ABL breakpoint peptlde. Blood 1996, 88:3522-3527. [50]. Tenbosch GJA, Joosten AM, Kessler JH, Melief CJM, Leeksma OC: Recognition of BCR-ABL positive leukemic blasts by human CD4(+)T cells elldted by pdmary in vitro Immunization with : BCR-ABL breakpoint peptide. B/ood 1996, 88:3522-3527. Terpstra W, Ploemscher RE, Pfins A, Vanlom K. Pouwels K, Wognum AW, Wagemaker G, Lowenber9 S, Wielanga JJ: Ruorouracil selectively spares acute myeloid leukemia ceils with Iong-tswn 8rowth sblllties in immunodstlcient mice end in culture. Blood 1996, 88:1944-1950. Teshlma 1", Miyajl R, Fukuda M, Ohshima F: Bone-marrow trensplentetion for Epsteln-Berr-virus-essociated natural killer call-large granular lymphocyte leukaemia [Letter]. Lancet 1996, 347:1124. Testoni N, Martinel]i G, Ferabegoli P, Zecceria A, Amabile M, Raspadori D, Pelliconi S, Zuffa E, Carboni C, Tura S: A new method of "in-cell revame transcriptsse-polymerese chain reaction* for the detection of BCR/ABL transcript In chronic myeloid leukemia patients. Blood 1996, 87:3822-3827. Thejpal R, Vaithilingum M, Chesty R, Coovadla HM: MALT lymphoma [Letter]. Lancet 1997, 349:434-435. Theobald M, Biggs J, Hemandez J, Lustgartan J, Labadie C, Sherman LA: Tolerance to p53 by A2.l-restrlcted cytotoxic T lymphocyte,J;. J Exp Med 1997, 185:833-841. Thkman MJ, Disk.in EB, Bin SS, Ip HS, Miller JM, Simon MC: Developmental analysis and subcelluiar localization of the mudne homologue of ELL Proc Natt Acad Sci USA 199?, 94:1408-1413. Todd SC, Tsoukas CD: EBV induces proliferation of immature human thymocytes in an IL-2-mediated response. J Immunol 1996, 156:4217-4223. Toes REM, Biota RJJ, Oifringa R, Kast WM, Melief CJM: Enhanced tumor outgrowth after peptide vaccination -Functional deletion of tumor-specific

Cancer Tumor biology

CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immune~ 1996, 156:3911-3918. Toes REM, Kast WM, Blom RJ J, Bakker SC, Offringa R, Melief CJM: Efflolent tumor eradication by adoptively transferred cytotoxic T-csil clones in ellogeneic hosts. Int J Cancer 1996, 66:666-691. Tomita Y, Ohsawa M, Oiu K, Hashimoto M, Yang Wl, Kim GF~ Aozass K: Epstsin-Barr virus in lymphoproifferetive diseases in the sinG-nasal region: Close association with CD56(+) immunophenotype and polymorphic-reticulosls morphology. Int J Cancer 199?, 70:9-13. Topalian SL, Gonzales MI, Perkhurst M, IJ YF, • Southwood S, Sette A, Rosenherg SA, Robbins PF: Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR restricted tyroslnase epitopes. J ~ p Mad 1996, 183:1965-1971. [58t]. Topali A, Barista I, Calik I, Kansu E: Timing of therapy in vasculltis-essocieted multiple mysioma: Comment [Letter]. Arthritis Rheum 1997, 40:395-396. Tosi P, Gherlinzoni F, Mezza P, Visani G, Coronado O, Coetigliols P, Raise E, Maestri M, Gritti F, Chiodo F, Tufa S: 3"-Azido 3'-deoxythymidine plus methotrexata as a novel sntineoplaetio combination in the treatment of human immonodeticiency virus-releted non-Hodgldn's lymphomes. Blood 199"/, 89:419-425. T0reci ~, Sahin U, Pfreundschuh M: Serological analysis • • of human tumor antigens: molecular definition and implications. Me/Med Today 1997, 3:342-349. [27"~]. T(ireci ~), Sahin U, Schobert I, Koslowskl M, Schmiff • • H, Schild HJ, Stanner F, Seitz G, Rammensee HG, Pfreundschuh M: The SSX2 9ene, which is involved in the t(X,18) translocation of synovlal sarcomas, codes for the human tumor antigen HeM-Me/-40. Cancer Rea 1996, 56:4756-4772. [28"P]. Tssi V, Scuthwood S, Sidney J, Bakaguchi K, Kawakami Y, Appalls E, Sette A, Calls E: Identification of subdomlnant CTL epitopes of the GP100 melanoma-essoclatad tumor antigen by pdmary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 1997, 158:1796-1802. Tsang P, CeaanTtsn E, Chsdbum A, Liu YF, Knowles DM: Molecular charoctadzatlon of pdmory mediastinal B cell lymphoma. Am J Patho/1996, 148:2017-2025. Tsomidee TJ, Reilly EB, Eisen HN: Anti-melanoma cytotoxlc T lymphocytes (CTI.) recognize numerous antigenic peptides having 'selr sequences: Aufoimmune nature of the snb-melanome CTL response. Int Immunol 1997, 9:327-338. Tsukasski K, Tsushima H, Yernamura M, Hats T, Murata K, Meeds T, Atogami S, Sohda H, Momita S, Ideda S, Katamine S, Yamada Y, Kamihira S, Tomonaga M: Integration patterns of HTLV-! provirus In relation to the clinical course of ATL: Frequent clonal change st crisis from indolent disease. Blood 1997, 89:948-956. Tu YR Xu FH, Uu J, Vescio R, Beranson J, Fady C, Lichtenstein A: Upregulated expression of BCL-2 in multiple my•lores cells induced by exposure to doxorublclrk etoposide, end hydrogen peroxide. Blood 1996, 88:f 806-1812. Tupitsyn NN, Frankel MA, Rudinskaya TD, Poltoranina VS, Sholokhova EN, Lebedeva NB, Probatova NA, Zabotina TN, Shipova LY: Reactivity of anti-macrophage monoclonal antibody D l l in human leukemia and malignant lymphomo. Int J Cancer 1996, 88:t 60-163. Turner AM, Lie NL, Issarachai S, Lyman SD, Broudy VC: FLT3 receptor expression on the surface of normal and malignant human hernatopoietic cells. Blood t996, 88:3383-3390. Tyring SK, Rady P, Yen A, Hughes TK: HHV8 and skin cancers in Immunosuppressed patients: Reply. Lancet 1996, 347:339. Uchimaru K, Taniguchi T, Yoshikawa M, Asano S, Arnold A, Fujits T, Motokura T: Detection of cyclin D1 (bd-1, PRAD1) overexpreasion by a simple competitive ray•me trenscdption-polymerase chain reaction assay in t(11;14)(q13;q32)-beadng B-cell malignancies end/or mantle cell lymphoma. Blood 1997, 89:965-974. Uckun FM, Steinherz PG, Sather H, Trigg M, Arthur D, Tubergen D, Gaynon P, Rasman G: CD2 antigen expression on leukemic calls as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblaeac leukemia: A Children's Cancer Group study. Blood 1996, 88:4288-4295. Uckun FM, Waddick KG, Mahajan S, Jun X, Takata M, Bolen J, Kumsaki T: BTK as a mediator of radiation-induced spoptosls in DT-40 lymphoma B ceils. Science 1996, 273:1096-1100. Uthman A, Brn= C, Weningar W, Tschachler E: No HHV8 in non-Kaposi's sarcoma mucocutaneous lesions from immunodeficient HIV-positive patients [Letter]. Lancet 1996, 347:1700-1701.

Uyttenhove C, Godfraind C, Lath6 B, Amar-Costasac A, • RenautdJ-C, Gajewski TF, Duflour T, Wamier G, Boon T, Van den Eynde BJ: The expression of mouse gene PIA in testis does not prevent safe induction of cytolytic T cells against a PIA-encoded tumor antigen. Int J Cancer 1997, 70:349-365. [10]. Vaandrager JW, Schuuring E, Zwikstra E, Deboer CJ, Kleiverde KK, Vankrieken JHJM, Kluinnalemans HC, Vanommen GJB, Rasp AK. Kluin PM: Direct visualization of dispersed 11q13 chromosomal translocatlons in mantle cell lymphoma by muIticolor DNA fiber fluorescence in situ hybridization. Blood 1995, 88:1177-1182. Vaerman JL, Martiat P: How do ant/sense oli9odeoxynucleotides inhibit the growth of chronic myelogenous leukemia cells? Response [Letter]. Blood 1996, 87:4020. Vandenberg D, Wessman M, Murray L, Tong J, Chen B, Chen S, Simonettl D, King J, Yamasaki G, Digiusto R, Car•lie A, Frassoni F, Gorin NC, Snyder D, Sciecinskl I, Negrin R, Deisseroth A, Tsukamoto A, Gearing D, Reading C, Hoffman R: Leukemic burden in subpopuletions of CD34(+) cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic my•/old leukemia. Blood 1996, 87:4348-4367, Vandenbroek MF, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJM, Zinkemagel RM, Hengartner H: Decreased tumor surveillance in perforin-deticient mice. J Exp Mad 1996, 184:1781-1790, Vandeneynde B, Peetars O, Dabackar O, Gauglar B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995, 182:689-698. Vanderijn M, Clear'/ML, Variakojis D, Wamke RA, Chang PP, Kamel OW: Epstein-Bert virus clonaltty in lymphomas occurring in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:638-642. Vanelsas A, Vanderburg SH, Vanderminne CE, Borghl M, Mourer JS, Melief CJM, Schrier PI: Peptide-pulsed dendritic cells induce tumodcidal cytotoxtc T lymphocytes from healthy donors against stably HLA-A'0201 -binding peptldes from the Melan-A/MART-1 self antigen. Eur J Immunol 1996, 26:1683-1689. Vanhorssen PJ, Preijers FWMB, Vanoosterhout YVJM, Dewitte T: Highly potent CD22-recombinant dcin a results in complete cure of disseminated malignant B-cell xenografts in SClD mice but tails to cure solid xenogretts in nude mice. let J Cancer 1996, 68:378-383. Vanrhee F, Hochhaus A, Lie F, Melo JV, Goldman JM, Cross NCP: p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic teukamlas. Blood 1996, 87:5213-5217, Vasovic LV, DyaJl R, Clynes RA, Ravetch JV, Nikoliczugic J: Synergy between an antibody and CD8(+) cells in eliminating an established tumor. Eur J Immunol 1997, 27:374-382. Veenstra H, Jacobs P, Dowdle EB: Abnormal association between invadant chnin and HLA class II alpha and beta chains in chronic lymphocytic leukemia. Ceil Immunol 1996, 171:68-73. Velin D, Acheorbea H, Kraehanbuhl JP: The neonatal fc receptor is not required for mucossl infection by mouse mammary tumor virus. J Virol 1996, 70:7250-7254, Vanditfi A, Delpoeta G, Buccieano F, Tambudni A, Cox MC, Stas; R, Bruno A, Aronica G, Maitei L, Suppo G, Simon• MD, Forte L, Cordaro V, Pestering M, Tufilli V, Isacchi G, Masi M, Papa G, Amadori S: Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes. Blood 1997, 89:621-629. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, Mcculiough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, Mcglave PB: BCR/ABL-nega~ve primitive progenitors suitable fur transplantation can be selected from the marrow of most eady-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996, 87:4770-4779. Vescio RA, Cao J, Hong CH, Lee JC, Wu CH, Danielian MD, ~ V, Newman R, Liohtanstein AK, Barenson JR: Myelomo Ig heavy chain V region sequences reveal pnor antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol t 996, 155:2487-2497. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Chason B, Crowley J, Badogie B: Aufotransplants in multiple myeloma: What have we learned? Blood 1996, 88:838-847.

753

Vincent AM, C~wley JC, Burthem J: Integdn function in chronic lymphocytic leukende. Blood 1996, 87:4780-4788. Vogd CA, ~ MC, Buchegg~ F: Redloimmono~wspy and frantionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Ree 1997, 57:447-453. Vogel CA, Galmiche MC, Weetermann P, Sun LQ, Pal•grin A, FoUlS, Dekdoye AB, Slosman DO, Manh JP, Buchegger F: Cardnoembryonio antigen expression, antibody locallsetlen end Irnmunophotodetection of human colon cancer liver metasbmes in nude mica: A model for radioimmunotherapy. Int J Cancer 1996, 67:294-302. Vogel W, Behringer D, Scheding S, Kanz L, BnJgger W: Ex rive expansion of CD34(+) peripheral blood progenitor cells: Implications for the expansion of contaminating epithelial tumor cells. Blood 1996, 88:2707-2713. Vonbrevem MC, Hollstein MC, Cawley HM, Oebenedetti VMG, Bennett WP, Liang L, He AG, Zhu SM, Tursz T, Janln N, TriveraGE: Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Ras 1995, 55:4917-4921. Vonwasielewskl R, Warner M, Fischer R, Hanamann ML, Hubner K, Has•no/ever D, Franklin J, Sextro M, Diahl V, Georgii A: Lymphocyte-predominant Hodgkln's disease: An Immunohlatochemicel analysis of 208 reviewed Hodgkln's disease cases from the German Hodgkio Study Group. Am J Pathol 1997, 150:793-803. Waldmann TA. Ndson DL, White JD: RedlolmmonoUw~. Promising treatment of aggressive adult T-call leukemia? - Response [Letter]. Blood 1996, 87:5379-5380. Walt RP: Regression of MALT lymphoma and treatment for Hellcobacter pYlod [Letter]. Lancet 1995, 348:1041-1042. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, Wu MH, Wu WP, Wang LW, Wang CL Huang GT, Yang PM, Lee HS, Santells RM: Aflatoxin exposure and dsk of hepetocellular carcinoma in Telwsn. Int J Cancer 1996, 67:620-625. Wang Q, Stacy T, Miller JD, Lewis AF, Gu TL, Huang XM, Bushwellsr JH, Borias JC, Ah FW, Ryan G, Liu PP, Wynshewboris A, Binder M, Marinpadilla M, Sharps AH, Speck NA: The CBF beta subunit is essential for CBF alpha 2 (AML1) function in rive. Ceil 1996, 87:697-708. Wernier G, Duffour MT, Uyttenhove C, Gajewski TF, Lurquin C, Haddada H, Pemcaudet M, Boon T: Induction of a cytolytic T-cell response in mice with • recombinant edenovlrus coding for tumor antigen P815A. let J Cancer 1996, 87:303-310. Wataba M, Masuda Y, Nakajo S, Yoshida 1", Kuroiwa Y, Nakaya K: The cooperative interaction of two different signaling pathways in response to bufelin induces spopfosis in human leukemia U937 calls. J BIOl Chem 1996, 271:14067-14073, Webb PM, Yu MC, Forman D, Henderson BE, NeweU DG, Yuan JM, GaG YT, Ross RK: An apparent lack of association between Helicobectar pytorl infection and dsk of gastric cancer in Chins. let J Cancer 1996, 67:603-607. Webarmatthlssen K, Deerbergwittrarn J, Rosanwald A, Poetsch M, Grote W, Schlegelberger B: Trsnalocatlon t(2;5) is not a pdmary event in Hodgldn's disease: Simultaneous immunophenotyping and interphase cytogene~cs. Am J Patho11996, 149:463-468. Webemordt RM, Egen C, Wehinger J, Ludwig W, Gouillsuxgruart V, Mertalsmann R, Rnke J: Constitutive activation of STAT proteins in primary lymphoid and myelold leukemia calls and in Epstaln-Berr virus (EBV)-rotatad lymphoma cell lines. Blood 1996, 88:009-816, Wei WZ, Gill RF, Jones RF, Lichlyter D, Abastado JP: Induction of cytofoxic T lymphocytes to mudne mammary tumor cells with a K-d-restricted tmmunogenlc peptide./nt J Cancer 1996, 66:659-663. Weinberg RA: The cat and mouse games that genes, viruses, and cells play. Ce# 1997, 88:573-575. Weinreb M, Day PJR, Niggli F, Green EK, Nyongo AO, Othianoabinya NA, Riyat MS, Rasfat F, Mann JR: The consistent association between Epstein-Bert virus and Hodgkln's disease in children in Kenya. Blood 1996, 07:3828-3836. Weisanburger DD, Armitage JO: Mantle cell lymphoma - An entity comes of age. Blood 1996, 87:4483-4494. Weisenburger DD, Gordon BG, Vose JM, Bast MA, Chan WC, Greinet TC, Anderson JR, Sanger WG: Occurrence of the t(2;6)(p23;q35) in non-Hodgkin's lymphomo. Blood 1996, 87:3860-3868.

754

Cancer Immune response to cancer

Wen SM, Shimizu N, Yoshiyerna H, Mizugaki Y, Shinozaki F, Takeds K: Assodation of Epst=ln-Berr virus (EBV) with Sjogren's syndrome: Differontl=l EBV expression between =pitheliel cells end lymphocyt=s in lymphocylas in salivary glands. Am J Pstho11996, 149:1511-1517. Wen Y-J, Lira SH: T ceils recognize the VH • complemenfadty-detarmining region 3 of the idiotypic protein of B cell non*Hodgldn's lymphoma. Eur J Immunol 1997, 27:1043-1047, [38]. Wilks R, Hanchard B, Morgan O, Williams E, Cranston B, Smith ML, Rodgersjohnson P, Manns A: Patterns of HTLV-I infection =mong family members of patients with =duR T-call leukemla/lymphom= end HTLV-I associated myelopathy b'opical spastic persparesis` Int J Cancer 1996, 65:272-273. Willemse MJ, Schooneveld SHe, Chaln'mrs WSK, Sondermeijer PJA:Vaccination =galnat feline leukaerni= using = new feline herpesvtrus type I vector. Veccine 1996, 14:1511-1516. Wilson JB, Bell JL, Levine AJ: Expression of Epsteln-Bsrr virus nuclear sntig=n-1 induces B call nenplsel= in transg=nic mice. EMBO J 1996, 15:3117-3126. Wilson WH, Teruysfeldstein J, Feat 1", Harris C, Steinberg SM, Jaife ES, Raifeld M: Relstionship of I)53, bct-2, snd tumor proliferation to clinical drug resistance In non-Hodgkin's lymphomas` Blood 1997, 89:601-609. Winter JN, Andersen J, Veriakoii8 D, Gordon U, Fisher RI, Ok=n MM, Neiman RS, Jieng SW, Bauer KD: Progncotic impUcatlons of ploldy =rid proliferative activity In the diffuse, aggressive non-Hodgldn's lymphom=s. Blood 1996, 88:3919-3925. Wit,zig TE, Gertz MA" Lust JA, Kyle RA, Ot=licn WM, Greipp PR: Peripheral blood monoclonel plasma cells as s predictor of survival In patients with multiple myeloma. B/ood 1996, 88:1780-1787. Wlodarsks I, Aventin A, Inglssesteve J, Fldzettl D, Criel A, Cassimsn JJ, Mecucci C, Vandenberghe H, Marynen P: A new subtype of pm-B acute lymphoblastic leukaml= with t(5;12)(q31 q33;pl 2), molecuiady end cytogon=tically distinct from t(5;12) in chronic myelomonocytlc leukemia. Blood 1997, 89:1716-1722, Wloderska I, Beans M, Pesters P, Aerssans J, Mecucci C, Brock P, Marynan P, Vandanberghe H: Biallelic elterstions of both ETV6 end CDKNIB genes in s t(12;21) childhood =cute lymphobiastic leukemia case. Cancer Res 1996, 56:2655-2661. Woinsr J, Holowiecki J, Krswczykkulis M, Merkiewicz M, Wojciechowsks M, KyrczkrzemianS, Kopera M, Kluzel T, Kachel L: Antoiogous ben= marrow transplentation in adult acute lymphoblastic leukaemle. TransplantF~'oc 1996, 28:3618-3521. Wood GS, Hsrdman DL, Bonl R, Dummer R, Kim YH, Smeller BR, Takeshita M, Kikuchi M, Burg G: Lack of the t(2;5) or other mutations resulting In expression of =nsplsstic lymphom= kinas= catalyUc domain in CD30(+) primary cutaneous lymphoprollferetiv= disorders snd Hodgkln's disease. Blood 1996, 88:1765-1770. Wood GS, Schsifer JM, Boni R, Dummer R, Burg G, Takeshits M, Klkuchi M: No evidence of HTLV°I provlrel integration in lymphoprollferetiv= disorders essuclated with cutaneous T-coil lymphoma. Am J Pathol 1997, 150:667-673. Xu W, Seiter K, Feldman E, Ahmed 1", Chieo JW: The d;ffMentlaeon end maturation mediator for human myelold leukerni= cells shares homology with n=uroleukin or phnsphoglucosa Isomarase. Blood 1996, 87:4502-4506. Yameds I", Kondoh N, Mstsumoto M, Yoshida M, Maekswa A, Oikaws T: Overexpmssion of PU.1 induces growth and differentiation inhlbWon snd epoptotic call death in mudn= erythroleukemi= cells. Blood lggT, 89:1383-1393. Yamamoto A" Shimlzu E, Ogura T, Sone S: Detection of mdo-=ntibndles =gainat L-myc oncogene products in sera from lung cancer patlsnta. Int J Cancer 1996, 69:283-289. Yamessk3 T, Akiyerns Y, Fukuds M, Klmura Y, Modtake K, Kikuchi H, Ljunggran HG, Kerr= K, Klein G: Natural resistance against tumors grafted into the brain in =ssodatlon with hlstocompatibiilty-cl=ss-l-sntigen expression, let J Cancer 1996. 67:365-371. Yen Y, S=lomon 0, Mcg,;rk J, Dennlg D, Fernandez J, Jagiello C, Hid N, Collins N, Steinherz P, Omilly RJ: Growth pattern end dlnlcel correlation of subcutaneously inoculated human pdmery acute leulmmlas In sever= combined irnmunodeflclency mice. B/ood 1996, 88:3137-3146. Yano S, Nishioka Y, Izumi K, Tsuruo T, Tanaka T, Miyasaka M, Sone S: Novel metastasis model of human lung

cancer in SCID mice depleted of NK cells` Int J Cancer 1996, 67:211-217. Yao QY, Tiemey RJ, Croomcarter D, Cooper GM, Ellis CJ, Rowe M, Rickinson AB: Isolation of interfypic recomblnents Of Epsteln-Barr virus from T-call-immunocomprondsed individuals, J V/rol 1996, 70:4895-4903. Yao QY, Tiemey RJ, Croomcarter D, Dukers D, Cooper GM, Ellis CJ, Rowe M, Rickinson AB: Frequency of muRiple Epsteln-Berr virus intec'dons in T-celHmmunocompromised individuals. J Vim/ 1~6, 70:.4884-4894. Yes C, Gilbert MJ, Ridd=ll SR, Bricherd VG, Fefer A, • ThompsonJA" Boon 1", Greenberg PD: Isolation of tyroslnsse-specltic CDe+ and CD4+ T cell clones from the peripheral blood of melanoma pati=nts following in vitro stimulation with recombinant v=cclnls virus. J Immuno11996,157:4079-4086.

[ti8t]. Yokoyama A" Okabekedo J, Sakashita A, Maseki N, Kaneko Y, Hino K, Tomoyssu S, Tsuruoka N, Kasuksbe 1", Honma Y: Diffnrentistion Inhibitory factor nm23 =s s new prognostic factor in acute monocytk= leukemia. Blood 1996, 88:3555-3561. Yoshida K, Inoue T, Nojima K, Hirabsyashi Y, Sedo T: Calode rasfriction reduces the incidence of myelold leukemia Induced by a single whole-body radiation in C3H/He mice. Proo Nat/Acad Sci USA 1997, 94:2615-2619. Yuen AR, Rosenberg SA" Hoppe RT, H=lpern JD, Homing SJ: Compadson between conventional ssivsg= therspy and high-dos= therapy with sutogmfting for recurrent or refractory Hodgldn's disease. Blood 1997, 89:814-822. Zehander G, Girotto M, Demeddalena C, Francisco G, Moroni M, Gslli M: HTLV infection in ELISA-negative blood donors, A/DS Res Hum Retroviruses 1996, 12:737-740. Zeidler R, Meissner P, Eissner G, Lazis S, Hsmmerschmidt W: Rapid proliferstion of B cells from adenoids in response to Epstsin-Berr virus infection. Cancer Res 1996, 56:5610-5614. Zhsng DJ, Ts~sgbeVK, Huang C, Thorbecke GJ: ContTol of endogenous mouse mammary tumor virus superenUgen expression in SJL lymphom=s by s promoter within the env region. J Immunol 1996, 157:3510-3517. Zhang CI, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, Shaw LM, Wasik MA: Activation Of Jek/STAT proteins involved in signal tr=nsduction psthw=y mediated by receptor for Inted=ukin 2 in mslign=nt T lymphocytes dodved from cutaneous snsplastic large T-cell lymphoma end Sezsry syndrome. Proc Nat/Acad SCI USA 1996, 93:9148-9153. Zhan B, Marshall DR, Sample CE: A conserved domain of the Epstain-Barr virus nuclear =ntlg=ns 3A and 3C binds to = discrete domain of J kappa. J Virol 1996, 70:4228-4236. Zhan QY, Song XX, Wsldschmidt T, Fisher E, Krieg AM: OIIgonucleoede uptake in human hernatopoletic cells is in<=eased in leukemia end is related to celluIsr activation. Blood 1996, 88:1788-1795. Zhon9 WD, Wang H, Hemdler B, Genera D: Restricted expression of Kaposi sarcoma-associated herpesvlrus (human herpesvlrus 8) genes In Kaposi s=rcoms. Proc Natl Acad Sci USA 1996, 83:6641-6646. Zhou P, Qian LP, Kozopas KM, Craig RW: Mcl-1, a BCl-2 family member, dsi=ys the death of hernstopol=tic cells under = v=d=ty of =poptosls-indudng conditions` Blood 1997, 89:630-643. Zukerberg LR, Benedict WF, Arnold A, Dyson N, Hadow E, Harris NL: Expression of the retinobla=toma protein in low-red= B-cell lyrnphoma: Relationship to cyclin D1. B/ood 1996, 88:268-276. Zunigaa V, Alverezs L, Dillzp H: Neoplssia in renal trensplanfa~on. TransplantProc 1996, 28:3332. Zupo S, Isnardl L, Mngns M, Ma~sars R, Malevasi F, Done M, Cosulich E, Ferrarini M; CD38 expression distinguishes two groups of B-cell chronic lymphocytic lenkemies with different responses to =nti-lgM =ntibodies snd propensity to =poptosis` Blood 1996, 88:t365-1374. Zusman 1", Lisansky E, Arons E, Anavi R, Bonnerot C, Sautes C, Fridman WH, Witz IR Ran M: Contribution of th= intrecelluiar domain of mudne r-c-g=mma receptor type lIB1 to Its tumor-enhancing potantMI. IntJ Cancer 1996, 68:219-227. Zwicky Ca, Maddocks AB, Andersen N, Gribben JG: Eradication of polymeres= chain reaction dotactabl= immunoglobulin gene rearrangement in onn-Hodgldn's lymphoma I= =saodatod with decreased rolsps= after =utologous bone marrow trensplsntation. Blood 1996, 88:3314-3322.

immune response to cancer Related reviews: HLA class I specific inhibitory receptors (pp 694-701); Paraneoplastic syndromes (pp 723-729)-P Abdelwahab Z, Dar MM, Hester D, Very=eft C, Gangev=lli R, Barber J, Dsrmw TL, Seigier HF: Effect of irradiation on cytoldn= production, MHC antigen expression, end vaccine potential of Intedsuldn-2 and interferon-gamma gene-modlfled melenoma cells. Cell Immunol 1996, 171:246-254, Albi N, Rugged L, Averse F, Medgiols C, Tosti A" Tognellini R, Gmssi CE, Mertsili MF, Velsrdi A: Natural Idiler (NlO-cell function end entlleuklmic activity of s large population of CD3(+)/CDe(+) T calls expressing NK receptors for major histocompatiblilty complex clasa I after "three-loci" HLA-Incompatibl= ben= marrow transpiontation. Blood 1996, 87:3893-4000. Allan NC, Richsrds SM, Shepherd PCA: Interfaron-elphs 1 for chronic myelold leukesmls: Reply [Lafterl Lancet 1995, 346:1370. Altenschmidt U, Kahl R, Klundt E, Stocklin E, Mihstsoh M, Weindel K, Groner B: Schwimnoma cells Induce a tumor-call-specific cytoto]dc-T-cell response upon transplantation Into syngenelc rats but escape elimination through th= secretion of immunosuppresive lectern. Int J Cancer 1997, 70:542-550. Anldeau S, Scheffrshn I, Mold=los G, Brand H, Duyater J, Ksye K, Herada J, Doug=ll B, Hublnger G, Kieif E, Hen'mann F', Leutz A, GnJss HJ: Tumor necrosis factor receptor-esaocl=ted factor (TRAF)-I, TRAF-2, =nd TRAF-3 interact In rive with th= CD30 cytoplasmic domain; TRAF-2 mediates CD30-1nduced nuclear factor kappa B activation. Proc Nat/Acsd Sci USA 1996, 93:14053-14058, Antoine C, Gamier JL, Dubooat A" Bsdety J, Stevenson G, GIotz D: Successful treatment of postfrensplent lymphoproliferativ= disorder with renal graft presentation by moncolonal enebody therapy. TransplantProc 1996, 28:2825-2826. /~'sd G, Kstzenellenbogan M, Levy R, Slevin S, Ksampfer R: Unomlde" an Immunomodulator that Inhibits T(h)l cytokin= gee= =xpresslon. Int Immuno11996, 8:1603-1607. Armstrong CA: Antitumor effects of grenulocyt=macrophage colony-stimulating factor production by melanoma cetis (vol 58, pg 2191, 1996). Cancer Res 1996, 56:2879. Armstrong CA, Befalls R, Galloway TH, Murray N, Kramp JM, Song IS, Ansel JC: Antitumor effacfa of grenulocyte-mecrophag= colony-stimulating factor production by melanoma calts. Cancer Res 1896, 56:2191-2198. Armstrong JM, Vitetta ES: The roles of ess end perfodn in I=k T-cell/blspectflc antibody-mediated killing of the murlne B-lymphoma oells, BCL(1). let J Cancer 1996, 68:822-827. Bamford RN, Battlers AP, Wa)dmann TA: IL-15: The role of transiationel regulation In their expression. J Leukoc Bio11996, 59:478-480. Basker S, Clements VK, Glimcher LH, Nabavi N, Ostrandrosenberg S: Rejection of MHC class II-trensfectad tumor ceils requires induction of tumor-encoded B7-1 end/or B7-2 costlmulatory molecules. J Immunol 1996, 156:3821-3827. Basolo F, Rote L, Fontanini G, ConaJdi PG, Calve S, Felcone V, Toniolo A: Expression of and response to intedeukln 6 (IL$) in human mammary tumors. Cancer Res 1996, 56:3118-3122. Basser RL, Rasko JEJ, Clarke K, Cebon J, Green MD, Hussein S, All C, Manchacs D, Tomits D, Marly J, Fox RM, Begley CG: Thrombopoiatlc effects of pegyfatad recombinant human megakaryocyt= growth end development factor (PEG-rfluMGDF) In patients with advanced cancer. Lancet 1996, 348:1279-1281. Backer JC, Pancook JD, Gillies SD, ~ w s K, Reiefeld RA: T cell-mediated eredlcaffon of murino metesta~ melanoma induced by targeted Intadeukin 2 therapy. J E~p Med 1996, 183:2361-2366. Banker JC, Verkl N, Gillies SD, Furukaws K, Reiefeld RA: Long-lived and transferable tumor immunity in mice after targeted interiouldn-2 therapy. J Clin Invest 1996, 98:2801-2804. Benldnger WI, Buckner CD, Anasetti C, Cliff R, Storb R, Barnett 1", Chauncey 1", Shulman H, Appelbaum FR: AIIogenelc marrow trenxplantation for muWpl= myetoma: An nnalysis of risk factors on outcome. B/ood 1996, 88:2787-2793. Benldnger VVI, Buckner CO, Shannondorcy K, Rowiey S, Appelbaum FR, Benyunes M, Clift R, Martin P, Demirer

Cancer I m m u n e

T, Stodo R, Lee M, Schiller G: Transplantation of eiiogeneic CD34(+) peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996, 88:4132-4138. Berminger Wl, Cliff R, Martin P, Appelbaum FR, Demirer T, Gooley 1", Lilisby K, Rowley S, Senders J, Storb R, Buckner CO: AIIogeneic peripheral blood stem cell transplontotion in patients with advanced hematologic malignancies: A retrospective cornpadsorl with marrow transplantation. Blood 1996, 88:2794-2800. Benyosef R, Or R, Nagier A, Sisvin S: Graft-versustumour and gratt-versus-ieukaemla effect in patient with concurrent breast cancer and acute myelocytic loukaemia (Letter]. Lancet 1996, 348:1242-1243. Borg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, Thompsonsnipas L, Leech MW, Rennick D: Entarocolitis end colon cancer in intedeukin-10-doficJent mice are associated with aberrant cytokino production and CD4(+) THl-like responses. J Clin Invest 1996, 98:1010-1020. Berger LC, HawJey RG: Interferon-beta interrupts interioukin-6-dependent signaling events in myeioma calla. Blood 1997, 89:261-271. Berman RM, Suzuki T, Tahare H, Robbine PD, Narula SK, Lotze MT: Systemic administration of cellular IL-10 induces an eftoctive, specific, end long-lived immune response against established tumors in mice. J Immuno11996, 157:231-238. Bhatia R, Mccarthy JB, Verlaillie CM: Interteron-sipha restores normal beta 1 Integdn-mediatod inhibition of hematopoiatk: progenitor proliferation by the morrow micrroenvironment in chronic myeiogenous leukemia. Blood 1996, 87:3883-3891. Bisnchi R, Grohmann U, Belladonna ML, Sills S, Fallar~no F, Ayroldi E, Roretti MC, Puccetti P: IL-12 is both required and sufficient for initiating T ceil reactivity to • class I-rosbtcted tumor peptkle (P815AB) following transfer of 1=815AB-puISed dendritic ceils. J Immuno11996, 157:1589-1597, Biusoni R, C-antoni C, Faico M, Verdiani S, Bottino C, • • Vitals M, Conte R, Poggi A, Momtta A, Moretta L: The HI.A-C-specific 'actlvatory' or 'inhibitory' Natural Killer ceil receptors display highly homofogous extraceiluiar domains but differ in their transmembrane and intrecytoplesmic portions. J Med 1996, 183:646-660. [14]. Binstadt BA, Brumbaugh KM, Leibson PJ: Signal • transduction by human NK oeil MHC-recognizin9 receptoro. Immunol Ray 1997, 155:197-203. [37]. Blary M, Dolon J, Treutmann A, Cambisggi A, Olceee L, • Bieeanni R, Moretta L, Chavrier P, Moretta A, Daron M, V'wierE: R u c o n ~ Idllor-ceil inhibitory receptors for MHC dam= I molecules control mast cell mcdvation Induced via imrnunoreceptor tyroeine-based activation motifs` J Biol Chem 1997, 272:8989-8996. [36]. Borset M, Hjorthhaneen H, Boidel C, Sundan A, Wssge A: Hepatucyto growth factor and Its receptor c-mat in multiple myeioma. Blood 1996, 88:3998-4004. Brojatsch J, Naughton J, Rolls MM, Zinglor K, Youn9 JAT: CAR1, a TNFR-fldatad protein, is a cellular receptor for cytopsfh~ evkm ioukosis sarcoma viruses and mediates apoptoole. Ca//1996, 87:845-855. Burshtyn DN, Scharenberg AM, Wagtmann N, Rqngopalan S, Berrede K, Yi 1", Kinet JP, Long EO: Recruitment of tyroslno phosphatase HCP by the killer ceil inhibitory receptor. Immunity t996, 4:77°85. [33]. Cai J, Zheng 1", Lotz M, Zhang Y, Mssccd R, Gill P: Gk~:ocorkofds induce Kaponl's sarcoma ceil prollhmltiml through the regulation of transforming growth fectoPbMa. Blood 1997, 80:1491-1500. ~ m g g ; A, Varthuy C, Naquet P, Romagn6 F, Farrier P, ~, Bieesoni R, Moretts A, Moretta L, V'Mer E: NK-call acceptance of H-2 mismatch bone-marrow grafts in tmnsgent¢ mice exprmmlng HLA-Cw3 specific IdliM-¢eil inhibitory receptor (CD158b). Pmc Natl Acad Sc/USA 1997' 94:8088-8092. [62]. Cantpbeil DA, Reid M, Mcardle CS, Cooke TG, GaJlagher G: Polymomhiam at the tumour necrosis factor locus: A marker of ~m~lc predisposition to color.'tat cancer? (Reblction of vol 343, pg 293, 1994). Lancet 1996, 347:1706. ~ l l KS, Derming M, Lbpez-Botat, M, Celia M, •e ~ M: l~=eino phonphmldatlon of a human kilter Inhibitory receptor recruits protein phosphates• lC. J E.,~oMad 1996, 184:93-100. [35]. Cmwetaro M, Cantoni C, Belln 1", Bottino C, Bisssoni R, Roddguez A, Ptmz-Viller JJ, Moretta L, Moretta A, I.~oez-Botat M: The CO94 and NKG2-A C-type tactlns coveientty assemble to form a NK cell inhibitory receptor for HLA class I molecules. Eur J Immunol 1997' 27:563-567. [28]. Canoli M, Tomasson MH, Barker GF, Golub TR, Gilliland D(3: The TEL ptatatat-dorived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein

that seif-essuclofes end activates PDGF beta R ldnase-dependent signaling pathways. Proc Natl Acad Sc/USA 1996, 93:14845-14850. Caruso M, Pharnnguyen K, Kwong YL, Xu BS, Kos~i KI, Rnegold M, Woo SLC, Chen SH: Adenovirus-mediatad Interleukin-12 gene therapy for metastatic colon cerdnoma. Proc Nat/Acad Sci USA 1996, 93:11302-11306. Cavanagh LL, Heilidey GM: Dendritic epidermal T cells in uitreviolsf-irrediated skin enhance skin tumor growth by inhibiting CD4(+) T-ceil-mediated immunity. Cancer Res 1996, 56:2607-2615. Caye~z( S, Richter G, Noitz G, Dorken B, Blankanstein T: Influence of gone-modified (IL-7, IL-4, and B7) tumor call vaccines on tumor antigen presentation. J Immunol 1997' 158:2834-2841. Chakrsborty A, Chakrsborty NG, Chattopadhyay U: Prolectin response of NK cells, but not of LAK cells, IS dsfldent in patients with caminoma of oral cavity and dudng aging. Int J Cancer 1996, 66:65-69. Chauhan D, Kharbenda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW, Anderson KC: Intedeukin-6 Inhibits Fas-induced apoptosIS and stress-activated protein kinaae activation In multiple my•iotas cells. Blood 1997, 89:227-234. Chaux R Martin MS, Martin F: T-ceil co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor. Int J Cancer 1996, 66:244-246. Chen SH, Kossi K, Xu BS, Khiem PN, Content C, Fin•gold MJ, Woc SLC: Combination suicide and cytokine gone therapy for hepatic metastases of colon carcinoma: Sustained ant~umor immunity prolongs animal survival Cancer Res 1996, 56:3758-3762. Chang L, Nagabhushan M, Preticw TP, Amini SB, Pretlow TG: Expression of E-cadhadn in pdmary end nletastatic prostate cancer. Am J Patho/1996, 148:1375-1380. Chirivi RGB, Chlodoni C, Musieni P, Garofalo A, Bernssconi S, Colombo MP, Giava,=i R: IL-1 alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endotheiisl calls and their retention in the lung of nude mice. Int J Cancer 1996, 67:866-863. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Failer DV, Wright DG, Falk RH, Skinner M: Dose-intensive melphalan with blood stem call support for the treatment of AL amyloldosls: One-year tollow-up in five patients. Blood 1996, 88:2801-2806. Cook JL., Krentz CK, Routes BA: Role of p300-tamily proteins In EIA oncogene Induction of cytolytlc sueceptiblllty and tumor cell rejection. Proc Natl Acad Sci USA 1996, 93:13985-13990. Corradi J, Yang C, Darneil J, Dximau J, Damell R: A • posf-tnmsorlptional regulatory mechanism restricts expression of the persnesplestic careboller degeneration antigen cdr2 to immune privileged tissues. J Neurosci 1997, 17:1406-1415. [43t']. Coventry BJ, Weeks SC, Heckford SE, Sykes PJ, Bradley J, Skinner JM: Lack of IL-2 cytoklne expression despite IL-2 messenger RNA transcription in tumor-infiltrating I~mlphocytes In pdmary human breast carcinoma - Selective expression of esdy activation markers. J Immuno/1996, 156:3486-3492. D'Andrea A, Chang C, Phillips JH, Lanier LL: Regulation of • 1" oeil lymphokine production by killer cell inhibitory receptor recognition of self HLA class I eilsies. J Exp Mad 1996, 184:789-794. [55]. De Maria A, Ferrsris A, Guastalis M, Pills S, Cantoni C, • • Polem L, Mingari MC, Bsseetti D, Fauci AS, Moretta L: Expression of HLA-¢iaes I-spedfic Inhibitory Natural Killer cell receptors In HIV-sppolfi¢ cytolytl¢ T lymphocytes. Impairment of specific cytolytic functions. Prcc Nat/Acad Sci USA 1997, in press.

[59]. Demartis A, Bemsssola F, Saving R, Melino G, Ciliberto G: Intedeukin 6 receptor superantagonists era potent inducers of human multiple myeioma cell death. Cancer Res 1996, 56:4213-4218. Denizot Y, Fix• P, Uozon E, Preloran V: Serum Intodeukin-8 (IL-8) and IL-6 concanb'atJone in pptients with hematologic malignancies [Latterl Blood 1996, 87:4016-40 ! 7. Denottar W, Degn:x)t JW, Bemssn MR, Heintz APM, Mass R, Hordijk GJ, Hill FWG, Klein WR, Ruitanberg EJ, Ruttan VPMG: Optimal regimes for local IL-2 turnout therapy. Int J Cancer 1996, 66:400-403. Desrivierea S, Volarevic S, Marcap L, Ferrari S: Evidence for differmlt mechanisms of growth inhibition of T-coil lymphoma by phorbol esters and concanavadln A. J Biol Chern 1997, 272:2470-2476. Dicelle PF, Mariani S, Riem L, Slanchini A, Reato G, Foa R: Intorleukin-8 induces the accumulation of B-ceil chronic lymphocytic leukemia cells by prolonging

r e s p o n s e to c a n c e r

755

survival in an autocrine fashion. Blood 1996, 87:4382-4369. Dilloo D, Bacon K, Holdan W, Zhong WY, Burdach S, Zlotnik A, Brenner M: Combined chemofdne and cytoldna gone transfer enhances antltumor Inmlmlity. Nat Mad 1996, 2:1090-1096. Dinapoli MR, Cxideron CL, Lopez DM: The altered tumorlcldei capacity of macrophagec Isolated from tumor-bearing mice is related to reduced expression of the inducible nitric oxide synthese gena. J Exp Mad 1996, 183:1323-1329. Dinapoli MR, Cxideron CL, Lopez OM: Phosphatidyl sedne is involved in the reduced rate of transcription of the Inducible nitric oxide synthasa gone in macrophages from tumor-bsadng mice. J Immunol 1997, 158:1810-1817. D~hring C, Scheidegger D, Samaridis J, Calla M, Col•one • M: A human killer InhlbRory receptor specific for HLA-IL J Immuno11996, 156:3098-3101. [21l Dombret H, Chasteng C: Recombinant grenulucyte colony-stimulating factor in acute myeiogenous leukemia: Reply, N Engl J Mad 1995, 333:1156. Douglas RS, Capocasxie RJ, Lamb RJ, Nowell PC, Moore JS: Chronic lymphocytic leukemia B ceils are resistant to the apoptotlc effects of transforming growth factor-beta. Blood 1997, 89:941-947.. Dummer W, Basfian BC, Ernst N, Sche~le C, Schwlmf A, Brccker EB: Intedeukin-10 production In malignant melanoma: Preferential detection of IL-10-secrsfJng tumor ceils in metastatic lesions. Int J Cancer 1996, 66:607-610. Egie A, Villungar A, Kos M, Bock G, Gruber J, Auer B, Grail R: Modulation of Apo-1/Fes (CD95)-Induced programmed cell death In rnyeiorna celia by InterMron-eipha(2). Eur J Immunol 1996, 26:3119-3126. Ellictt S, Loranzini T, Chang D, Barziley J, Dsiorme E: Mapping of the active site of recombinant human erythropolatin. Blood 1997, 89:493-502. Farreil HE, Holly H, Lynch DM, Reming P, Shellam GR, • , ScaJzoAA, Davie-Poynter NJ: Inhibition of natural killer cells by a cytomegatovlrus MHC class I homologoue in vlvo. Nature 1997' 386:510-514. [51 ]. Feetherstone C: Chaperoning tumour antigens Into the immune system. Lancet 1996, 348:1436. Forrare N: Natural killer calls, adhesion and tumor anglogenesls. Nat Mad 1996, 2:971-972. Fiedler W, Greeven U, Ergun S, Versgo S, Kilic N, Stockschisder M, Hossfeld DK: Vascular endothelial growth factor, a possible paracrlne growth factor in human acute my•load leukemia. Blood 1997, 89:1870-1875. Fishman RHB: IL-2 expression predicts recovery in bladder cancer. Lancet 1996, 347:1542. Fogler WE, Volker K, Mccormick KL, Watanabe M, Ortaldo JR, Wlitrout RH: NK cell infiltration Into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J Immuno11996, 156:4707-4714. Fowler DH, Breglio J, Nagei G, Eckhaus MA, Gross RE: Aliospecitic CD8(+) Tcl and Tc2 populations in grsft-verous-loukernia effect and grsft-versus-host disease. J Immunol 1996, 157:4811-4821. Freedmen AS, Gribben JG, Neuberg D, Mauch P, Soiffar RJ, Anderson KC, Pandite I., Robortson MJ, Kroon M, Ritz J, Nadior LM: High-done therapy and autologous bone marrow transplanbdJon in patients follicular lymphorna during first remission. Blood 1996, 88:2780-2786. Fray AB: Role of host antigen receptor-bearing and antigen receptor-negative cells in Immune response to rat adlmocerctnoma 13762. J Immuno11996, 156:3841-3649. Fry AM, Lanier LL, Weiss A: Phosphotyrcalnes In the *- killer catl Inhibitory receptor motif of NKBI era required for negative signatllng and for association with protein tyrosine pbosphatasa IC. J Exp Meal 1996, 184:295-300. [34]. Gabrilovich DI, Chan HL, Cunningham liT, Many GM, Nadal S, Kavanaugh D, Carbone DP: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Mad 1996, 2:1096-1103. Gabrilovich DI, Chart HL, Girgis KR, Cunningham HT, Men,/GM, Nadaf S, Kavanaugh D, ~ DP: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic calls (vol 2, pg 1096, 1995). Nat Mad 1996, 2:1267. Gangopsdhyey A, Bajanova O, Kelly TM, Thomas P: Cerdnoembryonic antigen induces cytokina expression in Kupffer cells: implications for hepatic metastasis from colorecial cancer. Cancer Res 1996, 56:4805-4810. Ganju RK, Shpektor RG, Brenner DG, Shipp MA: CD10/neutral endopegUdase 24.11

756

C a n c e r I m m u n e r e s p o n s e to c a n c e r

is phosphorylated by casein kinase II and ccassociates with other phosphoprofelns including the lyn src-reiated kinese. Blood 1996, 88:4159-4165. Geissler K, Ohler L, Fodinger M, Virgolini I, Leimer M, Kabrna E, Koliars M, Skoupy S, Bohle B, Rogy M, Lechner K: Intadeukin 10 inhibits growth and granulocyte/macrophage colony-stimulsting factor production In chronic myeiomonocytic leukemia cells` J Exp Med 1996, 184:1377-1384, Gang YJ, Hellstrand K, Wennmldm A, Hansson GK: Apoptotic death of human leukemic cells induced by vascular cells expressing nitric oxide synthase in response to gamrna-lnterferon and tumor necrosis factor-alpha` Cancer Res 1996, 58:866-874. Georgiihemming P, Wiklund FU, Ljunggren O, Nilsson K: Insulin-like growth factor I is a growth and survival factor in human multiple myeioma cell lines. Blood 1996, 88:2250-2258, Gervois N, GuUlouxY, Oiez E, Jotersau F: Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med 1996, 183:2403-2407, Gianni M, Terso M, ForSno I, LicldzJ M, Viggiano V, Bsrbui T, Rambaldi A, Garattini E: Statl Is induced and activated by eil-trsns retinoic acid In acute promyeiocyflc leukemia cells. Blood 199"7, 89:1001-1012. Goedegebuure PS, Douville CC, Doherty JM, I_inehan DC, Lee KY, Ganguly EK, Ebedein TJ: Simultaneous production of T helper-l-like cytokines and cytolytic activity by tumor-spocific T cells in ovarian and breast cancer. Ceil Immuno11997,175:150-156. Goldstein J, Graziano RF, Sundarapandiyan K, Somasundaram C, Deo YM: Cytolytlc end cytostatic properties of an anti-human Fc gamma RI (CD64) x epidermal growth factor bispeciflc fusion protein. J Immuno11997, 158:872-879. Gonda TJ, Dandrea RJ: Activating mutations in cytokine receptors: Implications for receptor function and role in disease, Blood 1997, 89:S55-369. Gorelik L, Bardagan Y, Mokyr MB: Insight into the mochanlsm(s) through which TNF promotes the generation of T ceil-mediated antitumor cytotoxicity by tumor bearer splenic calls. J Immunol 1996, 156:4298-4S08. Gosslar U, Jonas P, Luz A, Lifka A, Naor D, Hamann A, Holzmann B: Predominant roll of alpha 4-lotegdns for distinct steps of Lymphoma metastasis. Proc Nat/Acad Sci USA 1996, 93:4821-4826. Graus F, Dalmau J, Rene R, Tore M, Malats N, Verschuuren • . JJ, Cardanal F, Vinoias N, del Mum J, Vadell Cet el.: AntI-Hu antibodies in patients with smell-cell lung cancer: Association with complete response to therapy end improved survival. J C/in Onco11997, 15:2866-2872. [54t]. Gu ZJ, Costes V, Lu ZY, Zhang XG, Pitard V, Moreau JF, Bataille R, Wijdenes J, Rossi JF, Klein B: Intedeukin-1O is a growth factor for human myolome cells by induction of an oncostatin M autocHne loop. Blood t 996, 88:3972-3986. Guarini A, Riera L, Clgnetti A, Montacchini L, Massaia M, Foe R: Transfer of the interlsukin-2 gene into human cancer cells Induces specific antltumor re¢ognkion and restores the expression of co3/r-ceil receptor associated signal transduction molecules. Blood 1997, 89:212-218. Guo WX,/mtakly 1", Cadotte M, Kachra 7-, Kunkel L, Masood R, Gill P: Expression and cytokine regulation of glucocorftcold receptors in Kaposi's sarcoma. Am J Patho11996,148:1999-2008. Guo YJ, Che XY, Shen F, Xie TP, Ma J, Wang XN, Wu SG, Anthony DD, Wu MC: Effentivo tumor vaccines generated by in vitro modification of tumor ceils with cytokines and bispecitic monoclonal antibodies. Nat Mad 1997, 3:451-455. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bomand 1", Fontana A, Lienard D, Cerottini JC, Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. ScJence 1996, 274:1363-1366. Hakim I, Levy S, Levy R: A nine-amino add pep~de from IL-1 beta augments antltumor immune responses induced by protein and DNA vaccines` J Immunol 1996, 157:5503-5511. Hanania EG, Giles RE, Kavanagh J, Ellerson D, Zu Z, Wang 1", Su Y, Kudelka A. Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Chang S, Heater J, Ostrove JM, Bird RE, Chang A, KorbSng M, Seong D, Cote R, Holzmayer1", Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Bast R, Andmeff M, Cha~.plin R, Delsseroth AB: Results of MDR-1 vector modification trial indicate that granulocyte/macrophaga colony-forming unit cells do no1 contdbute to posttrenspiant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sc/ USA 1996, 93:15346-t 5351.

Handelfemandez ME, Chang XF, Herbert LM, Lopez DM: Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impeirod IFN-gamma production in mammary tumor-bearing mice. J Immunol 1997, 158:280-286. Harada M, Matsunsga K, Oguchl Y, liiima H, Tamada K, Abe K, Takenoyama M, ito O, Kimura G, Nomoto K: Oral edminlstraiton of PSK can improve the impaired anti-tumor CD4(+) T-ceil response in gut-associated lymphoid tissue (GALl') of specific-pathogen-free mice./nt J Cancer 1997, 70:362-372. Haranghera N, Krautghamer R, Lapidot 1", Paled A, Dominguez MG, Stanley ER: Increased circulating colony-stimulating factor-1 (CSF-1) in SJI./J mice with rsdiation-induced acute myoloid leukemia (AML) is associated with autocrine regulation of AML cells by CSF-1. Blood 1997, 89:2537-2545. Harrington W.I, Cabral L, C.ai JP, Chanasue S, Wood C: Azothymidine and intarforon-alpha are active in AIDS-associetod small non-cleaved cell lymphoma but not large-ceil lymphoma [Letter]. Lancet 1996, 348:83S, Harvill ET, Fleming JM, Morrison SL: In vivo properties of an IgG3-1L-2 fusion protein - A general strategy for Immune potentiation. J Immuno/t 996, 157:3165-3170. Hasford J, Baccarani M, Hehlmann R, Ansari H, Tura S, Zuffa E: Interferon-alpha and hydroxyurea in eady chronic myeioid leukemia: A comparative analysis of the Italian and German chronic myeioid leukemia trials with interferon-alpha [Letter]. Blood 1996, 87:5384-5391. Hassuneh MR, Nagarkatti PS, Nagarkat5 M: Evidence for the participation of Intedeukin-2 (IL-2) and IL-4 in the regulation of autonomous growth and tumorigenesis of transformed cells of lymphoid odgin. Blood 199?, 89:610-620. Heaney C, Kolibaba K, Bhat A, Ode T, Ohno S, Fanning S, Druker BJ: Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood 1997, 89:297-306. Hilbert DM, Migone TS, Kopf M, Leonard WJ, Rudikoff S: Distinct tumodgenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway. Immunity 1996, 5:81-89. Hishii M, Andrews D, Boyle LA, Wong JT, Pandolfi F, Vandenelsen PJ, Kumick JT: In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc Nat/Acad Sci USA 1997, 94:1378-1383. Ho}tschke 1", Lohler J, Kanno Y, Fehr 1", Giese N, Rosenbauer F, Lou J, Knobeloch KP, Gabriele L, Waring JF, Bachmann MF, Zinkernagel RM, Morse HC, Ozato K, Horak h Immunodeflciency and chronic myelogenous leukemia-like syndrome in mica with a targeted mutation of the ICSBP 9ene, Cell 1996, 87:307-317. Horvatharcidlacono JA, Mostowsld HS, Bloom ET: IL-12 administered in vlvo to young and aged mice. Discrepancy between the effects on tumor growth in vlvo and cytofoxic T lymphocyte generation ax vivo: Dependence on IFN-gsmma. Int Immuno/t 996, 8:661-673. Hu PS, Hornick JL, Glaaky MS, Yun AY, Milkie MN, Khawli LA, Anderson PM, Epstein AL:A chimedc Lym-1/intorleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake, Cancer Res 1996, 56:4998-5004. Huang M, Shsrms S, MeG JT, Dubinett SM: Non-small cell lung cancer-derived soluble mediators and prostaglsndln E(2) enhance peripheral blood lymphucyte IL-10 transcription and protein production. J Immunol 1996, 157:5512-5520. Ikeda H, Lethe B, Lehmann F, Van Baron N, Baurain JF, • e De Smet C, Chambost H, Vitale M, Momtts A, Boon T, Coulie PG: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997, 6:199-206. [58]. Ikushima S, Inukai T, Inaba T, Nimer SD, Cleveland JL, Look AT: Pivotal role for the NRL3/EABP4 transcription factor in intedeukin 3-mediated survival of pro-B lymphocytas` Proc Nat/Acad Sci USA 1997, 94:2609-2614. Im SY, Ko HM, Ko YS, Kim JW, Lee HK, Ha TY, Lee HB, Oh SJ, Bai S, Chung KC, Lee YB, Kang HS, Chun SB: Augmentation of tumor metastasis by platolet-activaUng factor. Cancer Res 1996, 56:2662-2665. Isono T, Nagano Y, Seto A: Expression of the interferon-gamma and Intedoukin-lO genes in rabbit HTLV-I-transformed T-ceti lines. Immunogenetics 1996, 44:306-308. Issa JPJ,VettinG PM, Boehm CD, Newsham IF, Baylin SB: Switch from monoalleiic to biallelic human IGF2 promoter methylation dudn9 aging and

carcinogenesis. Proc Natl Acad Sci USA 1996, 93:11757-11762. Iversen PO, Hart PH, Bonder CS, Lobez AF: Intedeukin (IL)-10, but not IL-4 or IL-13, inhibits cytoldne production and growth In juvenile myolomonocy~ leukemia calls, Cancer Res 1997, 57:476-480. Iversan PO, Rodwell RL, Pitcher L, Taylor KM, Lopez AF: Inhibition of proliferation and Induction of apoptosls In juvenile myolomonocy8c leukemic cells by the granulocyte-menrophage colnoy-stlmulsting factor analogue E21R. B/God 1996, 88:2634-2639. Iwats N, Mursyama T, Matsumori Y, Ito M, Nagats A, Taniguchi T, Chiham K, Matsuo Y, Minowada J, Matsui T: Autocdna loop through cholocystoklnin-B/pstfln receptors involved In growth of human leukemia cells. Blood 1996, 88:2683-2689. Izuhara K, Feldman RA, Greet P, Harsda N: Intsdeukin-4 induces associaiton of the c-fes proto-onoogene product with phosphatidylinositol-3 kinase. B/God 1996, 88:3910-3918. Jadus MR, Irwin MCN, Irwin MR, Horanaky RD, Sekhon S, Pepper KA, Kohn DB, Wepsic HT: Maorophages can recognize and kill tumor cells besdng the membrane Isoform of rnacrophage colony-stimulating factor. Blood 1996, 87:5232-5241. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager O, Ilsemann C, Hagedom M, Oesch F, Knuth A: Grsnulocyte-macrophage-colony-stlmulsting factor enhances immune responses to meianome-eeaodated peptldes In vivo. Int J Cancer 1996, 67:54-62. Jucker M, Schiffer CA, Feldman RAmA tyrosinephosphorylatad protein of 140 kD is ¢onlUtutlveiy associated with the phosphotyroslne binding domain of Shc and the SH3 domains of Grb2 in acute myelold leukemia calls. Blood 1997, 89:2024-2035. Kalechman Y, Srednl B: Differential effect of the immunomodulstor AS101 on B7-1 and B7-2 costimulstory molecules • Role in the antltumorsl effects of AS101. J Immuno11996,157:589-597. Kanegane H, Wang F, Tosato G: Virus-ceil interactions in a natural killer-like cell line from a patient with lymphoblestic lymphoms` Blood 1996, 88:4667-4675. Kanno H, Naka N, Yasunaga Y, luchl K, Yamauchi S, Hashimoto M, Aozasa K: Production of the immunosuppresslve cytokine intedeukin-10 by Epstein-Borr-virus-exprassing pyofhorsx-sssociatad lymphorns: Possible role in the development of overt I~'nphoma In Immunocompetont hosts. Am J Patho11997,150:349-357. Karpoff HM, Dangelica M, Blair S, Brownies MD, Federoif H, Fong YM: PrevertSon of hepatic tumor metastases in rats with herpes viral vaccines and gamma-intorferon. J C/in Invest 1997, 99:799-804. Katsanis E, Xu ZY, Panoskeitsismortari A, Weiedorf DJ, Widmer MB, Blasar BR: IL-15 administration following syngeneic bone marrow transplantation prolongs survival of iymphoma besdng mice. Transplantation 1996, 62:872-875. Kaye KM, Devergne O, Harada JN, Izumi KM, Yaiamanchili R, Kieff E, Mosialos G: Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B actlvaSon by latent InfecSon membrane protein 1, the Epatein-Berr virus transforming protein. Proc Nat/Acad Sci USA 1996, 93:11085-11090. Kim J, Modlin RL, Moy RL, Dubinett SM, Mchugh 1", Nickoloff BJ, Uyemura K: IL-10 production In cutaneous basal and squemous ceil carcinomas - A mechanism for evading the local T cell immune response. J Immuno11995,155:2240-2247. KitsukJ H, Katano M, Ikubo A, Morisaki T,/mann K, Tanaka M, Torisu M: Induction of inflammatory cytokines in effusion cavity by OK-432 injoction therapy for patients with malignant effusion: Role of Interferon-gamma in enhancement of surface expression of ICAM-I on tumor ceils In vivo. Clin Immunol Immunopathol 1996, 78:283-290. Knaus PI, Lindemann D, Decoteau JF, Pedman R, Yankelev H, Hille M, Kadin ME, Lndish HF: Dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymohoma. Mo/Cell B/ol 1996, 16:3480-3489. Kobayashi D, Watanabe N, Yamauchi N, Tsuji N, Sato T, Niltsu Y: Endogenous tumor necrosis factor as a predictor of doxorubicin sensitivity in leukemic pabenta. Blood t 997, 89:2472-2479, Kono K, Salazaronfray F, Petersson M, Hansson J, Masucci G, Wasserman K, NakazawaT, Anderson P, Kiessling R: Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transduclog zeta molecules and inhibits tumor-soecific T

C a n c e r I m m u n e r e s p o n s e to c a n c e r

call- end natural killer cell-re°dieted cytoto)dcdy. Eur J Immunol 1996, 26:1308-1313. Konur A, Kreutz M, Knuchel R, Krsuse SW, Andre°sen R: Thrse-dimenalonel co-culture of human monocytes end mao'ophages with tumor ceils: Analysis of mecrophage dlffenmtlation and activation. Int J Cancer 1996, 66:645-652. Kooi S, Zhang HZ, Patenis R, Edwards C;L Platsoucas CD, Freedman RS: HLA daes I expression on human ovarian carcinoma ceils correlates with T-Cell infiltration in vlvo and T-Cell expanalon in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996, 174:116-128. Lazetic S, C~an9 C, Houchins JR Lanier LL, Philips JH: ** Human natural killer cell receptors Involved in MHC class I recognition ere disulphide-linked haterodimero of CD94 end NKG2 subunits. J Immunol 1996, 157:4741-4745. [29]. Lebeau MM, Espinoaa R, Davis EM, Eisenbart JD, I.arson iRA, Green ED: Cytogenetlc end molecular delineation of • region of chromosome 7 commonly deleted In malignant myalo|d diseases. Blood 1996, 88:1930-1935. Lebelbiney S, Laguerrs B, Quintincolonna F, Conjeaud H, MRga,ldn M, Miloux B, Pecceu F, Caput D, Farters R Fred°lid D: Expedmental g i n ° therapy of cancer using tumor cells engineered to secrete intedeuldn-13. Eur J Immunol 1995, 25:2340-2348. Leboussekerdiles MC, Chevlilard S, Cherpentier A, Romquln N, Clay D, Smadjajoffe F, Prslorso V, Dupriez B, Demory JL, Jumin C, Martyr° MC: Differential expression of transforming growth factor-hate, basic fitiroblest growth factor, end their receptors in CD34(+) hematopoietlc progenitor ceils from patients with myaloflbrosis end myaloid rnetaplasia. B/ood 1996, 88:4534-4546. Lemoli RM, Fortune A, Tafuri A, Fogli M, Amabile M, Grande A, Ricciardi MR, Petrucci MT, Bonsi L, Bagnara GP, Visani G, Martin°lie G, Ferrari S, Turs S: Interleukin-9 stimulates the proliferation of human myaloid leukemic cells. Blood 1996, 87:3852-3859. Levraud JP, Duffour MT, Cordier L, Perricaudet M, I-laddada H, Kourilsky P: IL-2 gone delivery within an established murlne tumor causes its regression wtihout proliferation of preexisting entitumor-spe¢ific CTL J Immuno11997, 158:3335-3343. Lippman SM, Lotan R, Schleuniger U: Retlnold-lnterforon therapy of solid tumors. Int J Cancer 199?, 70:481-483. Lonmer IAJ, Kepplerhalkemeyer A, Beers RA, Pegram CN, Bigner DD, Putan h Recombinant Immunotoxins specific for • mutant epidermal growth factor receptor: TMgetleg with I single chain antibody verletile domain isolated by phage display. Proc Nat/ Acad Sci USA 1996, 93:14815-14820. Maeurar MJ, Martin D, Walter W, Liu KH, Zitvogel L Haluaczcak K, Rabinowich H, Duquesnoy R, Storkus W, Lotze MT: Human intestinal V delta 1(+) T lymphocytos recognize tumor calls of epithelial origin. J Exp Mod 1996, 183:1681-1696. Mandelboim O, Davis DM, Reybum HT, V)des-Gomez M, • Shau EG, Pazmsoy L, Strominger Jl: Enhancement of daes II-mstd¢tnd T cell responses by coel~mulatory NK receptors for ,'lass I MHC proteins. Science 1996, 274:2097-2100. [601. Mapara MY, Korner U, Hildebrandt M, Bargou R, Krshl D, Reicherdt P, Dorken B: Monltodng of tumor cell purging after highly efficierd immunornagnatic selection of CD34 cells from leuhapheresis products In breast cancer pattants: Comparison of Immunocytod'Nlmlc-I tumor call staining end m e r e ° tranecdptase-polymerese chain reaction. B/ood 1997, 89:337-344. Maauda F_.Maeda H: Changes In calluler components of spleen end lymph node cells end the effector calls responsible for math A tumor eradication induced by zlnostatin stimalemer. Cancer Res 1996, 55:1868-1873. Mazzocchi A, Storkus WJ, Trsversari C, Tarsini P, Maeurer MJ, Rivolti~ L Vegetti C, Belle F, Anichini A, Permiani G, C,~telii C: Multiple malancma-aesodated e ~ recognized by HLA-A3-restrtcted CTLa and shared by malenomes but not malenocytes. J Immunol 1996, 157:3030-3038. Mccormick D, Stauss PU, Thorpe C, Tray°re P, Dyson PJ: Major hlsto¢ompatibility complex end T cell receptor Interantion of the P91A turn(-) peptide. Eur J Immuno11996,26:2895-2902. Mclaughlin JP, Schlom J, Kantor JA, Gremer JW: Improved immunuthwlpy of a recombinant carciooombrynnic antigen vac¢inle vaccine when given in combinabon with interleuidn-2. Cancer Res 1996, 56:2361-2367. Meldar RJ, Koenig GC. Witwer BP, Safabakhsh N, Munn LL Jain RK: During angiogenesis, vascular ondofhallel growth factor end basic fibrobiast

growth factor regulate natural killer cell adhesion to tumor endothalium. Nat Mad 1996, 2:992-997. Marritt WD, Taylor BJ, Dermineesian V, Reaman GH: Coexpresalon of GD(3) ganglioside with CD45RO In resting and acthratod human T lymphocytes. Cell Immunol 1996, 173:131-148. Mingari MC, Ponte M, Cantoni C, Vital° C, Schiave~ F, • Barton° S, Bellomo R, Trsdori C,appai A, Biassoni R: HLA-ctass I-specific inhibitory receptors In human cytbiytic T lymphocytes: molecular cherantedzation, distribution in lymphoid tissues and co-exprassion by Individual T cells./nt Immuno11997,9:485-491. [591. Mingari MC, Schisvetti F, Pont° M, V'dale M, Maggi E, *• Romagnani S, Demarsst J, Pantaleo G, Fauci AS, Moretta L: Human CD8 + T lymphocyte subsets that oxpraes HLA-clees I specific inhibitory receptors represent oligodonally or monoclonally expanded cell populations. Proc Nat/Acad Sci USA 1996, 93:12433-12438. [571. Mingari MC, Vitele C, Cantoni C, Bellomo R, Ponte *• M, Schiavetti F, Bertone S, Moretta A, Moretts L: Intedeukin-15-induced maturation of human Natural Killer calls from early thymic precursors. Selective expression of CD94/NKG2A as the only HLA-cless I specific inhlbitory receptor. Eur J Immuno/1997, 27:13?4-1380. [301. Moiler MJ, Kammerer R, Grunert F, Vonkleist S: Blllery gly¢oprotaln (BGP) expression on T cells end on a natural-killer-coil sub-population. Int J Cancer 1996, 65:740-745. Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee F_J, Poweli B, Godfrey S, Robert F, Schifler CA: Granulocyte-colony stimuleUng factor (fllgrestim) accelerates granulocyte recovery after Intensivo postremission chemotherapy for acute myalold leukemia with azlridlnyl benzoquinone end mitoxantrone: Cancer and leukemia group B study 9022. B/ood 1997, 89:780-788. Mon K, Fujimotoouchi K, Ishikawa 1", Seki9uchi F, Ishitsuka H, Tanaka Y: Murlne Intedeukln-I 2 prevents the development of cancer cache)de In a routine model. /nt J Cancer 1996, 67:849-855. Mori N, Gill PS, Mougdil 1", Murakerni S, Eto S, Prager D: Intedeukin-1O gone expression in adult T-cell leukemia. Blood 1996, 88:1035-1045. Motomura M, Lang B, Johnston I, Pldace J, Vincent A, =e Newson-DavisJ: Incidence of serum anti-P/Q-type and anti-N-type calcium channel autcentibodies in the Lambert-Eaton myaMhonic syndrome. J Neurol Sci 1997, 147:35-42. [20t IMunck JN, Deecaudin D, Koscislny S: Recombinant granulocyte colony-stimulating factor in ecuto myalogenous leukende. N Engl J Meal 1995, 333:1 t55-1156. Munz C, Holmes N, King A, Loke WY, Colonna M, Schild • H, Rammeneee HG: Human histocompatibillty leukocy~ antigen (HLA-G) rnoiocules inhibit NKAT3 expressing natural killer cells. J E.xpMed 1997, 185:385-391. [45]. Murata 1", Obiri NI, Puri RK: Human ovedan-cercinoma cell lines express 11.-4end IL-13 receptors: Comparison between 11.-4-and IL-13-induced signal trensductlon. Int J Cancer 1997, 70:230-240. Murata T, Purl RK: Comparison of IL-13-and IL-4-induced signaling in EBV-immortailzed human B cells. Ceil Immuno11997, 175:33-40. Myer V, Xinhao F, Steitz J: Identification of HuR as a *, protein implicated in AUUUA-medleted mRNA decay. EMBO J 1997, 18:2130-2139. [35";']. Naftzger C, Takechi Y, Kohda H, Hare I, Vijeyasarsdhi S, Houghton AN: Immune response to • differentiation antigen induced by altered antigen: A study of tumor rejection end autoimmunity. Proc Nat/Acad Sci USA 1996, 93:14809-14814. Nakajima K, YamanakaY, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka 1", I=ukada T, Hibi M, Hirano T: A contral role for star3 in IL-6-induced regulation of growth end differentiation in M1 leukemia calls. EMBO J 1996, 15:3651-3658. Nasonburchsoal K, Gandini D, Botto M, AIIopenna J, Seele JRC, Cross NCP, Goldman JM, Dmitrovsky E, Pandolfi PP: Interferon augments PML end PML/RAR alpha expression in normal myeioid and acute promyetocytic cells end cooperates with all-bans retinoic acid to induce maturation of a retinoid-rasistant promyalocyUc call line. B/ood 1996, 88:3926-3936. Nelson EL, 13 XB, Hsu FJ, Kwak LW, Levy R, Cisyberger C, Krensky AM: Tumor-spedfi¢, cytotoxic T-I~mlphocyta response after idiotype vacdnation for B-cell, non-Hodgkin's lymphomL B/ood 1996, 88:580-589. Ng MHL Chung YF, Lo KW, Wickham NWR, Lee JCK, Huang DP: Frequent hypermathylation of plE and p15 genes in mulUple myeloma. Blood 1997, 89:2500-2506.

757

Nguyan PL: Expression of CD95 antigen end Bcl-2 protein in non-Hodgkin's lymphomes end Hodgkin's disease (vo1148, pg 847, 1996), Am J Patho11996, 149:346. Niehana GA, Cherwitz DL, Stale/NA, Keepp DJ, Daimasso AP: Human cardnornes variably express the complement inhibitory proteins CD46 (membrane cofantor protein), CO5§ (decay-accelerating factor), and CD59 (protactin), Am J Patho/1996, 149:129-142. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobeyuhi K, Otani S: Randornlsnd trial of effects of Interferon-alpha on incidence of hepatocallular cerdnoma In chronic active hepatitis C with drrhosis. Lancet 1995, 346:1051-1055. Nishioka K, Sumids 1", Hasonuma T: Human T lymphotroplc virus typlPI in erthrof~dhy end eutolmmune disorders. Arthrib's Rheum 1996, 39:1410-1418. Noguchi Y, Jungl~uth A, Richards EC. Old U: Effect of Interleukin 12 on tumor induction by 3-melhyicholenthrone. Proc Nat/Acad Sci USA 1996, 93:11798-11801. Oconnell J, Osulllvan GC, Collins JK, Shanshan F: The Fes counterattack: Fes-medleted T cell killing by colon cancer cells expressing Fas legend. J Exp Mad 1996, 184:1075-1082. Odell W: Metabolic syndromes of cancer. Semin Once/ • 1997,24:299-317. [17i'1. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe 1", lizuka N, HazamaS, Hirszawa K, Hayashi H, Tangoku A, Heros° K, Ishihara 1", Suzuki T: Relationship between serum levels of interleukin 6, vedous disease Parameters, and malnutrition In patients with esophageal S¢lUamouscall carcinoma. Cancer Res 1996, 56:2776-2780. Ok.ads K, Nannmark U, Vujanovic NL, Watkins S, Basse P, Herbermen RB, Whitaside TL: Elimination of established liver metastases by human Intedeukin 2-activated natural killer cells after Iocoreglonal or systemic adoptive. Cancer Res 1996, 56:1599-1608. Olcese L, Lang P, Vbly F, Camblaggi A, Marguet D, *• Bl~ryM, Hippen KL, Biaasoni R, Moretta A, Morstta Let el.: Human and mouse Natural Killer cell Inhibitory receptors recruit the PTPlC end PTP1D protein tyrosine phosphatases. J Immuno/1996, 156:4531-4534. [221. Osuilivan GC, Corbett AR, Shanahan F, Crdlina JK: Regional Irnmunosuppression in esophageal squamous cancer -Evidence from functlonel studies with matched lymph nodes. J Immuno11996, 157:4717-4720. Otsuji M, Kimurs Y, Aoe 1", Okamoto Y, Salto T: Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-call receptor complex end entlgen-specifk: T-call responses. Proc Nat/Acad Sci USA 1996, 93:13119-13124. Oudejans JJ, Jiwa NM, Kummer JA, Horstman A, Vos W, Beak JPA, Kluin PM, Vandervalk P, Welboomera JMM, Meijer CJLM: Analysis of major histocompatlblilty complex class I expression on Reed-Steinberg calls in relation to the cytuto)dc T-call response in Epstein-Bert virus-positive end -negative Hodgkin's disease. Blood 1996, 87:3844-3851. Pad~hurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y: Improved induction of melenoma-reacUve CTL with peptides from the melanoma antigen gpl00 modified at HLA-A'0201-binding residues. J Immuno/1996, 157:2539-2548. Pazmany L, Mandelbo;m O, Val6s-Gbmez M, Davis DM, • ReybumHT, Strominger JL: Protection from Natural killer cells-mediated lysis by HLA-G expression on target cells. Science 1996, 274:792-795. [44]. Pellatdeceunynck C, Amiot M, Robillard N, Wijdenes J, Batailie R: CDlle-CD18 and CO102 interactions mediate human myaloma cell growth arrest tnduced by CD40 stimulation. Cancer Res 1996, 56:1909-1916. Panda D, Biassoni R, Cantoni C, Verdiani S, Falco M, • Di Donato C, Accame L, Bottino C, Moretta A, Moretta L: The natural killer call receptur specific for HLA-A aliotypes: • novel member of the p58/p70 family of Inldbituw receptors which is characterized by three ig-IIko domains and is expressed as • 140 kD disulphide-linked dimer. J Exp Mad 1996, 184:305-518. [201. Panda D, Sivori S, Accame L Pareti L Felco M, • GersghtyD, Le Bouteillar P, Moretta L, Moretta A: HLA-G recognition by human natural killer calls. Involvement of CD94 both as inhibitory and as adivedrlg receptor complex. Eur J Immuno/1997, 27:1875-1880. [43].

758

Cancer Immune response to cancer

Perez-Viller JJ, Melero I, Nsverro F, Carretem M, Bellon • 1", Llano M, Colonns M, Geraghty DE, Lbpez-Botet M: The CD94/NKG2A inhibitory receptor complex is involved in the Natural Killer cell-mediated recognition of ceils expressing HLA-G1. J Immunol 1997, in press. [42]. Pericle F, Kbkan RA, Eplingbumette PK, Blenchard DK, Djeu JY: Direct killing of lnterleukin-2-trsnstected tumor ceils by human neutrophils. Int J Cancer 1996, 66:36?-373. Phillips JH, Chang C, Mattson J, Gumperz JE, Psrham P, *• Lanier I1:CD94 and a novel associated protein (94AP) form of s NK cell receptor involved in the recognition of HLA-A, HLA-B, and HLA-C sllotypes. Imrnuni~, 1996, 5:163-172. [27]. Pierson BA, Miller JS: CD56(+bdght) end CD56(+dim) natural killer cells in paUents with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenlc natural killer calls, and exhibit decreased proliferation on a per call basis. Blood 1996, 88:2279-2287. Pimo A, Aldinucci D, Gloghini A, Zegonel V, Degan M, Improts S, Juzbssic S, Todssco M, Perin V, Gattei V, Hoffmann F, Gruss HJ, Carbons A: Human eosinophil= express functJonei CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996, 88:3299-3305. Prell RA, Kerkvliet NI: Involvement of altered B7 expression In dioxin immunotoxictty - B7 tranafenffon restores the CTL but not the eiloantlbody response to the P815 mastocytoma. J/mmunol 1997, 158:2696-2703. Price TH, Chstts GS, Dale DC: Effect of recombinant 9renulocyte colony-stimulating factor on neotrophll kinetics In normal young and elderly humans. Blood 1996, 88:335-340. Pulaski BA, Yah KY, Shsstri N, Msitby KM, Penney DP, Lord EM, Frellnger JG: Intedeukin 3 enhances cytotoxic T lymphocyte development and class I major hlstocompetibtlity complex =re-presentation" of exogenous antigen by tumor-Infiltrating antigen-presenting cells. Proc Nat/Acad Sci USA 1996, 93:3669-3674. Pun RK, Leland P, Obirl NI, Husain SR, Mule J, Pastan I, Krsitman RJ: An improved drcuiarly permuted intedeukin 4-toxin is highly cytotoxlc to human renal cell carcinoma cells. Ca//Immunol 1996, 171:60-86. Rabinowich H, Suminsmi Y, Reichert TE" Crowleynowick P, Bell M, Edwsrds R, Whitesrde TL: Expression of cytokine genes or proteins and signaling molecules in lymphocytea eesociatIKI with human ovarian carcinoma. Int J Cancer 1996, 68:276-284, Rsjspaksa R, Ginzton N, Rott LS, Greenberg PL: Altered oncoprotein expression end apoptosle in myeiodylpleatic syndrome marrow calls. Blood 1996, 88:4275-428?. Rakhmilevich AL, TurnerJ, Ford MJ, Mccabe D, Sun WH, Sondel PM, Grots K, Yen9 NS: Gone gun-mediated skin transtecSon with Intedeukln 12 gone results in regression of established pdmsry end metastatic mudne tumors. Proc Nat/Acad Sci USA 1996, 93:6291-6296. Rsmschendra S, Metcalf RA, Fmdrickson T, Mar5 GE, Reveche E: Requirement for inoreased IL-10 in the development of B-1 lymphoproliferative dlseaso in a mudne model of CLL J C/in Invest 1996, 98:1786-1793. Rao JB, Chambedain RS, Bro~te V, Carroll MW, Irvine KR, Moss B, Rosanberg SA, Restifo NP: IL-12 is en effenffve adjuvant to recombinant vencinia virus-haNd tumor vaccines - Enhancement by simultaneous B7-1 exprecslon. J Immuno11996, 156:335?-3365. Reieser D, Pinerd O, Jeannln JF: 11.-13restores an in vitro specific cytoly6c response of spleen ceils from tumur-beorlng rats. J Leukoc Biol 1996, 59:?28-?32. Reybum HT, Msndelboirn O, Vales-Gomez M, Davis OM, PazmaniL, Strominger JL: The (:less I MHC bomologue of human cytomegalovlrus inhibits attack by natural killer ceils. Nature 1997, 386:514-516. [50]. Robert B, Msch JP, Manl JC, Yehou M, FOl5S, Artus JC, Pelegrin A: Cytokino targeting in tumors using a bispecific antibody directed against carclnoembryonic antigen end tumor necrosis factor alpha. Cancer Res 1996, 56:4?68-4765. Rodolfo M, Zilocchi C, Melani C, Cappetti B, Arloli I, I~mmiani G, Colombo MP: ImmunoU~rspy of experimental metastases by vaccination with interfeutdn gemPtransduced adenocercinoma ceils sharing tumor-assodated antigens - Comparison between IL-12 and 11.-2gone-transduced tumor cell viccines. J Immuno/1996, t 57:5536-5542.

Rosales C, Juliano R: Integdn signaling to NF-kappa B in monocytic leukemia ceils Is blocked by ac~vated oncogenes. Cancer Res 1996, 56:2302-2305. Rossto A, Zarnbon A, Macino B, Mandruzzato S, Bronte V, Milan G, Zanovello P, Collevo D: Anti-L-seiectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in pedphorei lymph nodes draining the tumor area. Int J Cancer 19g6, 65:847-851. Rosendahl A, Hansson J, Sundstedt A, Kalland T, Dohlsten M: Immune response during tumor therapy with antibody-suporantigen fusion proteins./nt J Cancer 1996, 68:109-113. Ruzek MC, Obrien DP, Mathur A: Decreased production of IL-2 and IFN-gamma by stimulated splenncytes from mice besdng plasma ceil tumors is associated with alteration of DNA-blnding factom. Int/mmunol 1996, 8:1 g71-1982. Saevedra HI, Wang TH, Hoyt PR, Popp D, Yang WK, Stambrook PJ: Intedeukin-3 increases the incidence of 5-azacytidino-lnducad thymic lymphomas in pBOR-II-3 mice. Cell/mmuno11996, 173:116-123. Sasvedre HI, Wang TH, Hoyt PR, Popp D, Yang WK, Sternbmok PJ: Intedeukin-3 increases the incidence of 5-azacytldlne-induced thymi¢ lymphomas in pBOR*ll-3 mice (vol 173, pg 116, 1996). Ceil Immuno/1996, 174:210-211. Sadovnikova E, Stauss HJ: Peptide-specific cytotoxic T lymphncyten restricted by nonseif major histocompatibility complex class I molecules: Reagents for tumor Immunofherspy. Proc Nat/Acad Sci USA 1996, 93:13114-13118. Seato H, Kurose I, Ebinuma H, Fokumura D, Higuchi H, Atsuksws K, Tede S, Kimura H, Yonei Y, Masuds 1", Miurs S, lehii H: Kupffer cait-mediated cytotoxicity against hepatoma cells occurs through production of nitric oxide end adhesion via ICAM-1/CD18. Int Immunol 19g6, 8:1166-1172. Sslgaller ML, Marincols FM, Corrnler JN, Rosenberg SA: Immunization against epltopes in the human melanoma antigen gplO0 following patient immuniza6on with synthetic peptides. Cancer Res 1996, 55:4749-4767' Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD: Subcutaneous vacdnation with Irradiated, cytokine-prodtming tumor cells stimulateS CD8(+) call-mediated Immunity against tumors located In the =lmmunologically privileged" central nervous system. Proc Nat/Acad Sci USA 1996, 83:10399-10404. Sstomi N, Haranaka R, Hsranaka K: Purification, cherectedzatlon end anti-tumor activity of a new cytokine, hiatiocyte-secroted-factor (HSF). Int J Cancer 1996, 56:209-213. Sswads K, leko M, Notoys A, Terumi 1", Koizumi K, Kiteyama S, Nishio H, Fukada Y, Yasukouchi 1", Yamaguchi M, Kstoh S, Koike T: Role of cytoldnes in leukemic type growth of myeiodysplastic CD34(+) cells. Blood 1996, 88:319-327, Sexton ML, Loogo DL, Wetzel HE, Tnbble H, Alvord WG, Kwsk LW, Leonard AS, UIImann CD, Curti BD, Ochca AC: Adoptive transfer of anti-CD3-activeted CD4(+) T cells plus cyclophosphamlde and liposome-encapsuleted Intedeokin-2 cure mudne MC-38 and 3LL tumors and establish tumor-spedflc Immunity. Blood 1997, 89:2629-2536. Schattner EJ, Mascerenhas J, Bishop J, Yoo DH, Chsdburn A, Crow MK, Freldmen SM: CD34(+) T-ceil Induction of fes-mediated apoptosls In Burldtt's lymphorna B cells. Blood 1996, 88:1375-1382. Schiffer CA: Hernatopoletic growth factors as adjuncts to the treatment of acute mysloId leukemia. Blood 1996, 88:3675-3685. Schirrnbeck R, Bohm W, Reimann J: ONA vnccina6on pdmas MHC class I-reMdofed, simian virus 40 large tumor antigen-specific CTL In H-2(d) mice that reject syngeneic tumors. J Immunol 1996, 157:3550-3558. Schluger LK, Bodenhelmer H: Tackling IIvor cancer with interferon. Lancet 1996, 346:t 049-1050. Schmits R, Kundig TM, Baker DM, Shurnaker G, Simerd JJL, Duncan G, Wakeham A, Shahinian A, Vanderheidan A, Bachmann MF, Ohashi PS, Mak TV~/,Hickstein DD: LFA-l-defldent mice show normal CTL responses to virus but fall to reject Immunogenlc tumor. J Exp Mad 1996, 183:1415-1426. Schneider H, Chsovapong W, Metthews DJ, Karkeria C, Cess RT, Zhan HI, Boyle M, Lorenzini 1", Elliott SG, Giebei LB: Homodimedzatlon of erythropoietin receptor by a bivalent monodonei antibody triggers ceil proliferation end differentiation of erythroid precursors. Blood 1997, 89:473-482. Schwarzmeier JD, Hilgerth M, Nguyen ST, Shehata M, Gruber G, Spittler A, Willheim M, Boltwtitulescu G, Hocker P, Berger R: Inadequate production of hematopoietic growth factors in hairy cell leukemia:

Up-regulation of intedeukin 6 by recombinant IFN-elpha in vitro. Cancer Res 1996, 56:4679-4685. Seino KI, Keysgski N, Okumum K, Yagits H: Alltitumor effect of locally produced CD95 Ilpnd. Nat Med 1997, 3:165-170. Sek; N, Hoshino 1", Kikuchi M, Heyashi A, Itoh K: HLA-A Iocus-restrloted and tumor-spenlfic CTI.s in tumor-loflltretlng lymphncytes of patients with non*smell cell lung cancer. Cell Immunol 1997, 175:101-110. Selled C, Ssto T, Delvecchio L, Lucieno L, Barrett AJ, Roto5 B, Young NS, Msciejewaki JP: Involvenlent of Fas-mediated epoptosia in the inhibitor/effects of interferon-alpha in chronic myeiogenous leukemia. Blood 1997, 89:967-964. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP: The lymphoprollferetlvo disease of granular lymphncytss: Updated critede for diagnosis. Blood 199?,, 89:256-260. Shen Y, Fujimoto S: A tumor-spedfic Th2 clone InlUeting tumor rejection via pdrnad CD8(+) cytotoxlc T-lymphocyte ac6vetlon in mice. Cancer Rss 1996, 56:5005-5011. Sivori S, Vitale M, Bottino C, Mercenaro E" Sanseverino L, • e Paro~iniS, Moretta L, Moretts A: CD94 function,= as a natural killer cell Inhibitory receptor for different HLA-claes-I eileies. Identification of the Inhibitory form of CD94 by the use of novel monoclonal antibodies. Eur J Immunol 1996, 26:248?-2492. [26]. Sivori S, Vhsie M, Morelll L, Sanaseverlno L, Augugliaro R, • - Bottlno C, Moretta L, Moretts A: 1=46,a novel Natural Killer cell-spedfic surface molecule which mediates cell ncUvation. J Exp Meal 1997, in press, [51]. Skipper JCA, Kittlesen DJ, Hendrickson RC, Deacon DD, Herthun NL, Wagner SN, Hunt DF, Engelherd VH, SSngluff CL: Shaved epitoPes for HLA-A3-restricted melanoma-reactive human CTL include s naturally processed epltope from Pmei-17/gp100, J Immuno/ 1996, 157:5027-5033. Sporeno E" Ssvino R, Ciepponi L, Paonesss G, Cabibbo A, Lahm A, Pulkki K, Sun RX, Tonietti C, Klein B, Ciliberto G: Human Intedlukin*6 receptor supor-entegonizts with high potency and wide spectrum on multiple myeioma cells. Blood 1996, 87:4510-4619. Stetlerstevenson M, Mansoor A, Lim M, Fukushima P, Kehrl J, Marti G, Ptassynski K, Wang J, Stetlerstevanson WG: Expression of matrix metallopmteinasec and tissue Inhlbitors of meteiloprotelnasea In reactive and neoplastic lymphoid ceils. Blood 1997, 89:1708-1715. Stevenson FT, Turck J, Locksley RM, Lovett DH: The N-terminei proplece of Intedeuklo 1 alpha is s transforming nuclear oncoprotein. Proc Natl Acad Sci USA 1997, 94:506-513. Stockmeyer B, Vsierius 1", Repp R, Heijnen IAFM, Buhring HJ, Deo YM, Ksidan JR, Gramstzki M, Vandewinkel JGJ: Precllnlcal studies with Fc gamma R blspedflo antibodies end grenulocyte colony-eilmulatlng fnctor-prlmed neutrophlls as elfactor ceils against HER-2/neu overexpreselng breast cancer. Cancer Res 1997, 57:696-701. Suganume M, Okabe S, Sueoks E' lids N, Komori A, Kim SJ, Fojiki H: New prncess of cancer prevention mediated through Inhibition of tumor neoroala factor alpha expression. Cancer Res 1996, 56:3711-3715. Sung MW, Johnson .IT, Vandongan G, Whiteside TL: Protective effeds of Interforon-gamma on squamous-ceil cardnornl of head and neck targets in antlbody-depandent cellular cytotoxiclty mediated by human natural killer cells. Int J Cancer 1996, 65:393-399. Takamori M, Iwssa K, Komai K: Antibodies to synthetic • peptldes of the eiphe-1A subunlt of the voltege-gated caldum channel in Lambort*EMon myssthenlc syndrome. Neurology 199"/, 48:1261-1266. [21 t']. Takeda K, Seki SJ, Ogasawers K, Anzai R, Hsshimoto W, Sugiurs K. Takshashi M, Sstoh M, KumsgaJ K: Uver NKI.I(+) CD4(+) alpha beta T ceils enffvated by IL-12 as • major effector in Inhibition of experimental tumor metastasis. J Immuno11996, 156:3366-33?3. Tan J, Newton CA, Djeu JY, Gutsch DE, Chang AE" Yang NS, Klein TW, Yu H: Injection of complementary DNA encoding intedeukin-12 Inhibits tumor establishment at a distant site In a mudne renal carcinoma model. Cancer Res 1996, 56:3399-3403. Teacher BA, C,han YN, Am G, Emi Y, Kakeji Y, Muhers Y, Keyes S, Northey D: Iotorection of intedeukin-11 with cytotoxic therapies in vitro against CEM ceils and tn vivo against EMT-6 mudne mammary carcinoma./ntJ Cancer 1996, 67:664-6?6. Thlbsult C, Nelson H, Chapovsl AI: Tumor-infiltrating lymphocytas can be activated in situ by using in

Cancer Immunotherapy

vivo activents plus F(ab')(2) bispacific antibodies. Int J Cancer 1996, 67:232-237. Tilkin AF, Lub~n R, Soussi T, Lazar V, Janin N, Malhieu MC, Lefrere I, Cadu C, Roy M, Ksyibanda M, Benel D, Guillet JG, BressecdepaJllerets B: Pdmery proliferative T cell response to wild-type p53 protein in patients with breast cence¢. Eur J Immunol 1996, 25:1766-1769. Toes REM, Offringa R, Biota RJJ, Melief CJM, Kast WM: Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Nst/ Acad Sci USA 1996, 93:7855-7860. Toh U, Yamane H, Fujita H, Toh Y, Fujii 1", Kubo K, Yamada A" Shichijo S, Itoh K: A monodonal antibody KIS-1 recognizing a new membrane anfigen on human equamous-ceil carcinoma. Int J Cancer 1996, 66:600-606. Toms S, Airoldi M, Palumbo R, Raffo P, Bummia C: Combination of alpha-interferon 2a (eipha-IFN 2a) and 13-ds-refinoic acid (13cRA) In recurrent, pre-troeted squamous-ceil carcinoma of heed and neck (SCCHN). Int J Cancer 1997, 70:491-493. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA: IL-12 Induces T helper 1-directed antRumor response. J Immunol 1997, 158:3359-3365. Tzioulss AG, Boumba DS, Skopouli FN, Moutsopoulos HM: Mixed monoclonal cryogiohulinemie and monodonal rheumatoid factor cross-reactive idlotypes es predictive factors for the development of lymphoma in pdmary Sjogren's syndrome. Arthritis Rheum 1996, 39:767-772. Uchida H, Zhang J, Nimer SD: AML1A end AMLIB can trensactlvete the human IL-3 promoter. J Immunol 1997, 158:2251-225S. Ullch TR, Deicastillo J, Senaldi G, Kinstler O, Yin SM, Ksufman B, Tarpley J, Choi E, Kidey 1", Hunt P, Sheridan WP: Systemic hematologic effects of PEG-rHuMGDF-Induced megakeryocyte hyperpiasia In mice. Blood 1996, 87:5006-5015. Ureshlms M, ORate A" Chauhan D, Vidri~es MB, Teoh G, Hoshi Y, Schlossman RL, Decal)rlo JA" Anderson KC: |ntedeuldn-6 promotes multiple myeiome cell growth via phoephoryiation of retinobiastoma protein. Blood 1996, 88:2219-2227. Veliante NM, I ienert K, Shilling HG, Smite BJ, Parham P: • Killer ceil receptors: keeping pace with MHC class I evolution. Immunol Rev 1997, 156:155-164. [10]. Vandenbroek MF, Kagi D, Ossandorp F, Toes R, Vamvekss S, Lutz WK, Meliaf CJM, Zinkernsgel RM, Hengartner H: Decreased tumor surveillance in perfodn-dntident mice. J Exp Med 1996, 184:1781-1 ?90. Van.snick J, Houssiau F, Proost P, VandemmeJ, Ranauld JC: 1-309/T cell activation gene-3 chemokine protects mudne T cell lymphomas egeinst dexarnethasone-induced epoptosia. J Immunol 1996, 157:2570-2576. Vanzesnan HCT, Koopmans RP, Aarden LA" Rensink HJAM, Stouthard JML Warnaar SO, Lokhorst HM, Vanoers MHJ: Endogenous Intodsuldn 6 production in multiple myeiome patients treated with chimeric monodonni entl-lL6 antibodies Indicates the existence of • polltJve feed-hack loop. J Clin Invest 1996, 98:1441 - t 448. Vusilopoulousellin R, Thialvoldt D, Markowitz AB: Effects of interlsukin-4 administration on endocrine function and lipid profile of patients with malignant diseases [Letter]. B/ood 1996, 87:4022-4023. Veelken H, Meckensan A" Lahn M, Kohler G, Becket O, Frenke B, Brennschsidt U, Kulmburg P, Rosenthal FM, Keller H, Hesse J, Schultzeseemann W, Farthmann EH, Mertsismann R, Lindemann A: A phase-I dlntcnt study of autologous tumor ceils plus intadeutdn-2-gene-trensfacted allogeneic fibmbiests as a vaccine in patients with cancer. Int J Cancer 199'/, 70:269-277. Viale O, Vanderbmggen P, Meuer E, Kunzrnann R, Kohler H, Mertelsmann R, Boon T. Rsch P: Recognition by human V gamma 9/V delta 2 T ceils of melanoma ceils upon fusion with Daudi celia. Immunoganetics 1996, 45:2?-34. Vincent AM, Burthem J, Brew R, Cawley JC: Endothelial interactions of hairy cells: The importance of alpha 4 beta 1 In the tmusust tissue distribution of the disorder. B/ood 1996, 88:3945-3962. V'~sie M, Sivod S, Pende D, Augugliaro R, Di Donato C, • AmorosoA" Malns~ M, Boffino C, Morette L, Moretts A: Ph~cei and fund~nal independency of pT0 and p58 NK cell receptors for HLA-dass L Their role In the definition of different groups of eileresctive NK cell dorms. Proc Nat/Acad Sci USA 1996, 93:1453-1457. [18]. Voonmnger N, Touitou R, Garcia E. Delanluse ILl, Rousset F, Joab I, Fewot MC, Bay JY: kltedsukin (IL)-10 and IL-ti ere produced in vlvo by non-Hodgkin's lymphoma ceils end act as cooperative growth factors. Cancer Res 1996, 56:5499-5506.

Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H: Intensified antitumor immunity by a cancer vaccine that produces grsnulocyta-macrophage coinny-sUmutatlng factor plus intedeukln 4. Cancer Res 1996, 56:1828-1833. Wang CY, Mayo MW, Bsidwin AS: TNF- and cancer therapy-induced epoptosis: Potentietion by inhibition of NF-kappa B. Science 1996, 274:784-787. Wang JX, Kobayashi M, Sakurada K, Imarnura M, Moriuchi 1", Hosokawa M: Possible roles of en adult T-ceil leukemia (ATL)-dedved factor/thloredozin In the drug resistance of ATL to addemycin. Blood 199?, 89:2480-2487. Wang Q, Stanley J, Kudoh S, Myles J, Kolanko V, Yi TL, Tubbs R, Bukowski R, Rnke J: T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphoryletion peffem even though T cell receptor/CD3-assodeted kin•see ere presenL J Immuno/1995, 155:1382-1392. Wang RF, Appella E, Kawakami Y, Kang XQ, Rosenber9 SA: Identification of TRP-2 es • human tumor antigon recognized by cytotozic T lymphocytss. J Exp Med 1996, 184:2207-2216. Weijtens MEM, Will•rosen RA, Velerio D, Stem K, Bolhuls RLH: Single chain Ig/gamma gene-redirected human T lymphocytas produce cytokines, specifically lyse tumor ceils, end recycle lytic capacity. J Immuno11996,157:836-843. Weimar IS, Dejong D, Muller F_J,Nskamure T, Vangorp JMHH, Degast GC, Gerritsen WR: Hepetocyta growth factor/scatter fador promotes adhesion of lymphoma cells to extraceiluler matrix molecules via alpha(4)bsta(1) and eipha(5)beta(1) integdns. Blood 1997, 89:990-1000. Weissinger EM, Byrd LG, Henderson DW, Mushlnski JF: Overexpression of v-abl uniquely cooperates with c-my¢ dysregulstion in induction of plasma cell tumors, bypassing the need for T-lymphocytic help and overcoming T-lymphooytic intederence`/nt J Cancer 1996, 67:142-147. Welte K, Gabrilove J, Bronchud MH, Piatzer E, Morstyn G: Rlgrestim (r-metHuG-CSF): The first 10 years. Blood 1996, 88:1907-1929. Westendorf JJ, Jelinek DF: Growth regulatory pathways in my•iotas: Evidence for autocdne oncostatin M expression. J/mmunol 1996, 157:3081-3088. Williams N: Immunology - Tumor cells fight back to beat immune system. Science 1996, 274:1302. Williams SS, Chen FA" Kids H, Yokota S, Miya K, Kato M, Barcos MR Wang HQ, Alosco 1", Umemoto 1", Croy BA" Repasky EA" Banked RB: Engraftment of human tumor-inflRreting lymphocytes end the production of anti-tumor antibodies in SCID mice. J Immunol 1996, 156:1908-1915. Yarbro J, Bornstein R, Mastrangelo M: Persneoplestic • syndromes. Semin Onco11997,24:265-385, [1 l']. Yee C, Gilbert MJ, Riddell SR, Brichard VG, Feior A, Thompson JA" Boon 1", Greenberg PD: Isolation of tyrosinese-spocitic CD8(+) end CD4(+) T ceil clones from the pedpherel blood of mstenoma patients following in vitro stimulation wtth recombinant vecdnia virus. J/mmunol 1996, 157:4079-4086. Yim JH, Wu SJ, Casey MJ, Norton JA" Doherty GM: IFN regulatory factor-t gene transfer into en aggressive, nonlmmunogenic sarcoma suppresses the malignant phonotype and enhances immunogenicity in syngeneic mice. J Immuno11997,158:1284-1292. Younes: A pilot study of high-dose intedeukln-3 treatment of relapses follicular small cleeved-csil lymphoma: Hematologic, immunologic, and dinicel results (vol 87, pg 1698, 1996). Blood 1996, 87:4922. Young MRI, Wright MA, Lozano Y, Mstthews JP, Ban•field J, Prechel MM: Mechanisms of immune suppression in patients with head and neck cancer:. Influence on tho immune infiltrate of the cancer. Int J Cancer 1996, 67:333-338. Young MRI, Wright MA" Matthews JP, Malik I, Preche~ M: Suppression of T cell proliferation by tumor-iodoced grenulucyte-macrophage progenitor cells producing transforming growth factor-bsta and nitrk: oxide. J Immuno11996, 156:1916-1922. Yu WG, Yamamoto N, Takanaka H, Mu J, Tai XG, Zou JP, Ogawa M, Tsutsui 1", Wljesuriya R, Yoshida R, Herrmann S, Fujiwara H, I-iamaokaT: Molscuiar mechanisms underlying IFN-gamma-mediatod tumor growth Inhibition Induced dudng tumor immunotherepy with dL-12. Int Immuno11996, 8:855-865. Zambello R, Facco M, Trentin L, Sancetts R, Tassinari C, Penn A" Milani A, Pizzolo G, Rodeghiem F, Agostini C, Meazza R, Ferfini S, Semenzato G: Intadeutdn-15 riggers the protiforetlon and cytotoxicity of granular lymphocytes in patients with lymphoprollforeUve disease of granular lymphocytae` Blood 1997, 89:201-211.

759

Zeimet AG, Natoli C, Herold M, Fuchs D, Windbichler G, Daxenbichler G, lacobe~i S, Dapunt O, Marth C: Circulating immunoetimuiofory protein 90K end soluble intedsukin-2-raceptor in human ovarian cancer. Int J Cancer 1996, 68:34-38. Zerrahn J, Utermohlen O, Wamecke G, Deppart W, Lehmanngmbe F: Protective immunity in BALB/c mice against the simian virus 40-induced mKSA tumor resulting from injection of recombinant large T antigen - Requirement of CDB(+) T lymphooytes. J Immuno11996, 156:3919-3924. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, Rong H, Chen J, Wang XY, Catlno JJ, King h Intedeukln-10 inhibits tumor metastasis through an NK ceil-dependent mechanism. J Exp Med 1996, 184:579-584. Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Mseurer MJ, Campbell RL, Davis CG, Tahare H, Schreiber RD, Lotze MT: Intadeuldn-12 and BZ1 co-stimulation cooperate in the induction of effective entltumor immunity end therapy of establlehed tumors. Eur J Immuno/1996, 26:1335-1341. Ziwogel L, Tahsra H, Robbins PO, Storkus WJ, Clarke MR, Naleanik MA" Lotze MT: Cancer immunotherapy of established tumors with IL-12 - Effective delivery by genetically engineered fibroblests. J Immunol 1995, 155:1393-1403, Immunotherapy Related reviews: P r o s p e c t s for a d o p t i v e T cell therapy ( p p 7 0 2 - ? 0 8 ) ; A n t i b o d y - b a s e d i m m u n o l o g i c a l therapies (pp 7 1 7 - 7 2 2 ) ' ~ Alexander M-MA, Leggatt GR, Berzofsky JA: Selective • expansion of high- or low-avidity ¢ytotozic T lymphocytes end efficacy for adoptive immunotherapy. Proc Nat/Acad Sci USA 1996, 93:4102-4107. [39]. Alexander MMA" Leggstt GR, Sarin A, Berzctsky JA: Role • of antigen, CO8, and ¢ytofoxic T lymphocyte (CTL) avidity in high dose enfigen Induction of epoptosis of effector CTL J Exp Med 1996, 184:485-492. [38]. Anichini A, Morterini R, Maccalli C, Squarcins P, • Reischheuer K, Mascheroni L, Parmiani G: Cytotoxic T cells directed to tumor antigens not expressed on normal rnelanocytes dominate HLA-A2.1-restrlcted immune repertoire to melanoma. J Immuno/1996, 156:208-217. [31]. Barinnga M: Cancer research - Designing therapies that target tumor blood vessels. Science 1997,, 275:482-484. Baseiga J, Tripathy D, Mendelanhn J, Bsughman S, se Benz CC, Dantis L, Sklsrin NT, Seidman AS, Hudia CA, Moore Jet aS.:Phase II study of weekly intravenous recombinant humaniaed anti-p185 HER2 monocionsi antibody in patients with her2/neu-overexpreesing metastatic breast cancer. J C/in Once/1996, 14:737-744. [34";']. Batovs A" Oiccianni MB, Nobori 1", Vu 1", Yu J, Bridgeman L, Yu AL: Frequent deletion in the mnthyithlnadenosine phosphoryiose gene in T-ceil acute lymphoblastic ioukemle: Strategies for enzyme-targeted therapy. Blood 1996, 88:3083-3090. Becket JC, Varki N, Gillies SD, Furukaws K, Reisfeld RA: An antibody-intedeuldn 2 fusion protein OVercomes tumor heterogeneity by inducUon of a cellular immune response. Proc Nat/Acad Sc/USA 1996, 93:7826-7831. Benyehuda D, Knchevsky S, Caspl O, Rund D, Polliack A" Abdiovich D, Zelig O, Yahalom V, Paitiel O, Or R, Peretz 1", Benneriah S, Yehuds O, Rschmilewitz EA: Microsateilite instability end p53 mutations in therapy-related leukemia suggest mutator phenotype` Blood 1996, 88:4296-4303. Beran M, Kantarjian H, Obrian S, Kdler C, Albitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreeff M, Keating M, Estey E: Topotecan, • topoisomerese I inhibitor, is active in the treatment of myeiodysplastic syndrome and chronic myelomonocyfic kmkemia. Blood 1996, 88:2473-2479. Bergsagel PL, Chesl M, Nerdini E, Brants LA" Kirby SL, Kuehl WM: Promiscuous treneiocaitons into immunoglobulin heavy chain switch regions in multiple my•lores. Proc Nat/Acad Sci USA 1996, 93:13931-13936. Bigler RD, Boa•Ill CM, Foley B, Vonderheid EC: Failure of enU-T-cell racapfor V beta antibodies to consistently identify • malignant T-cen done in Sezary syndrome. Am J Pathol 1996, 149:1477-1483. Blakey DC, Burke PJ, Davies DH, Dowell RI, Fast SJ, Eckersley KP, Rtton JE, Mcdaid J, Melton RG,

760

Cancer Immunotherapy

Niculeecuduvaz IA, Pindar PE, Sharma SK, Wright AF, Springer CJ: ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenogrldts. Cancer Res 1996, 56:3287-3292. Bloom MB, Pony L-D, Robbins PF, I.i Y, G-M el, Rosenber0 *, SA, Yang JC: Identification of tyroslnese-reiated protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Mad 1997, 185:453-459. [36]. Blumenthal RD, Stein R, Sharkey RM, Goldenberg DM, Ong GL, Klein KM, Mattes MJ: Antibody penetration of tumor GS-7 xenogratts in nude mice: A model for mucinous adenocarcinoma of the colon. Cancer Res 1996, 56:3508-3518. Began B: Pedphorei T ceil tolerance as a tumor escape mechanism: Deletion of CD4(+) T cells specific for • monoclonei Immunoglobulin idiotype secreted by a plasmscytoma. Eur J Immuno11996, 26:2671-2679. Bonini C, Ferrari G, Verzeletti PS, Zappone E, ,= Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Treverssn (3, Bordignon C: HSV-tk gene tmnater into donor lymphucytas for control of eilogeneic groft-veraus-leukemle. Science 1997, 276:1719-1724. [59]. Cai XH, Gamn A: A melanoma-specific V-H antibody doned from a fusion phage library of a vaccinated melanoma patlenL Proc Natl Acsd SCI USA 1996, 93:6280-6285, Cadcetelle C, Oottl G, Mangoni L, Regazzi E, Garau D, Boneti A, Almici C, Sammerelli G, Sevoldo B, Rizzo MT, Rizzoli V: Selection of myeioid progenitors lacking BCP./ABL mRNA In chronic myeiogenous leukemia patients after in vitro treatment with the tyrosina kinase inhibitor genistein. Blood 1996, 88:3091-3100. Cessno A, Visonneeu S, Jeglum KA, Owen J, Wilkinson K, Career K, Reeee L, Santoli D: Phase I clinical Idal with a human major hlatocompatibillty complex nonrestricted cytotoxic T-ceil line (TALL-104) in dogs with advanced tumors. Cancer Res 1996, 56:3021-3029. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimure M, Moss B, Rossnberg SA, Restifo NP: Costimulatlon enhances the active Immunofherepy effect of recombinant enticancer vaccines. Cancer Res 1996, 56:2832-2836. Chepoval AI, Nelson H, Thibault C: Anti-CD3 X anti-tumor F(eb')(2) blfunctionei antibody activates and rofargats tumor-lntilb'atlng lymphocytes. J Immune/ 1995, 155:1296-1303. Chen YT, Stockert E, Jungbtuth A, Tssng S, Coplen KA, Scanlan MJ, Old U: Serological analysis of Melan-A(MART-1), a meienocyta-specifi¢ protein homogeneously expressed in human melanomas. Proc Nstl Acad Sci USA 1996, 83:5915-5919. [30]. Connett JM, Anderson CJ, Guc LW, Schwarz SW, Zinn KR, Rogers BE, Siegel BA, Philpott GW, Welch MJ: Radlolmmunotheropy with a Cu-64-labeied monuclonal antibody: A comparison with Cu-67. Proc Natl Acad Sci USA 1996, 93:6814-6818. DIdgleish A: Anti-idlofype vaccines tackle colorectsl cancer. Lancet 1996, 347:1682. Demanat C, Bdssinck J, Dejonge J, Thielemans K: BlepecWic antlbody-medlatad immunofherepy of the BCL(1) lymphoma: Increased efficacy with multiple injections end CD28-induced costlmulation. Blood 1996, 87:4390-4398. Du MQ, Xu C~, Dlas TC, Pang I-IZ, Wotherspoon AC, Issacson PG, Pan IX: Intestinal dissemination of gastric mucoss-esso¢iated lymphoid tissue lymphoma. B/ood 1996, 88:4445-4451. Elasser D, Valerius T, Repp R, Weiner GJ, Dee Y, Kalden JR, Vandswinkel JGJ, Stevenson GT, Glennle MJ, Grerneizki M: HLA dess II as potential target antigen on malignant B cells for therapy with blspedtic antibodies in combination with grsnulocyto colony-stimulating factor. Blood 1996, 87:3803-3812. Ellis JH, Barber KA, Tuft A, Hale C, Lewis AP, Glennle MJ, Stevenson GT, Crowe JS: Engineered entl-CD38 monuclonal antibodies for immunotherspy of muitlplo myeiome. J Immunol 1995, 155:925-937. Ely P, Wallace PK, Given AL, Grazleno RF, Guyre PM, Fanger IvaN: Blspedflc-levnerk Interferon gamma-palmed mecrephage-mecllated phagucyfosls of malignant non-Hodgkin's lymphome. B/ood 1996, 87:3813-3821. Enright H, Davies SM, Defer T, Shu X, Weisclod D, Miller W, Ramsay NKC, Arthur D, Vedaillle C, Miller J, Kersey J, Mcglave P. Relapse after non-T-ceil-deplofed eilogeneic bone marrow transplantabon for chronic myeiogonous leukemia: Eady transplentatfon use of an unrelated donor, end chronic graft-versus-host disease ere protective. Blood 1996, 88:714-720. Fals F, Sellers B, Ghiotto F, Yen XJ, Done M, Allen SL, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman

R Schuster M, Vinciguerra VP, Ral KT, Stevenson FK, Gregersen PK, Ferrarini M, Chioraz;d N: Examples of in vlvo isotypo class switching in IgM(+) chronic lymphocytic leukemia B ceils. J Clin Invest 1996, 98:1659-1666. Featherstone C: Whole-ceil vaccines in phase I trial for cancer therapy. Lancet 1996, 348:186. Feetherstooe C: Bispecific antibodies: The new magic bullets. Lancet 1996, 348:536. Featherstone C: Blspecific antibodies: The new magic hullats (vol 348, pg 536, 1996]. Lancet 1996, 348:902. Fisch P, Kohler G, Gerbe A, Herbst B, Wider D, Kohler H, Schaefer HE, Mertelsmann R, Brugger W, Kanz L: GeneraUon of snUgen-prexentlng ceils for soluble protein antigens ex rive from peripheral hlood CD34(+) hematopoletic progenitor cells in cancer patients. Eur J Immune/1996, 26:595-600. Fujii H, Inobe M, Kimurs F, Murats J, Murskami M, Onishi Y, Azuma I, Uede T, Saiki I: Vecclnstion of tumor cells tranatected with the B7-1 (CD8O) gone induces the anti-metastatic effect and tumor immunity in mice. Int J Cancer 1996, 66:219-224. Goey SH, Lamers CHJ, Stoter G, Bolhuis RLH: Modulation of immune perarnetars tn patients with metastatic renal-ceil cancer receiving combination immunotherepy (IL-2, IFN alpha and autologous. Int J Cancer 1996, 65:152-160. Gordon MS, Mccasldllstevens WJ, Bettiato LA, Loewy J, Loeech D, Breeden E, Hoffman R, Beach KJ, Kuca B, Kaye J, Sledge GW: Phase I trial of recombinant human interleukln-11 (Neumege rhlL-t I growth factor) in women with breast cancer receiving chemotherapy. B/ood 1996, 87:3615-3624. Greenfield EA, Howard E, Parsdis T, Nguyen K, Benazzo F, Mclean P, Hollsberg P, Davis G, Hailer DA, Sharps AH, Freeman GJ, Kuchmo VK: B7.2 expressed by T cells does not induce CD28-medleted costlmulatory activity but retains CTLA4 binding - Implications for induction of antltumor immunity to T cell tumors. J Immunol 1997, 158:2025-2034. Gunji Y, Tagawa M, Matsubara H, Takenega K, Shimeda H, Kondo F, Suzuki 1", Nakajima K, Aoki T, Asano 1", Ochisi 1", Isono K, Kageyems H, Nakamura Y, Sakiyarne S: Mudne colon carcinoma cells engineered to produce human interleukin-2 induce tumor-speclfic anti-tumor response. Int J Cancer 1996, 66:135-139. Hanna R, Ong GL, Mattes MJ: Processing of enSpodlas bound to B-ceil lymphomas and other hematological maUgnancles. Cancer Res 1996, 56:3062-3068. Hege KM, Cooke KS, Finer MH, Zsebo KM, Roberts MR: Systemic T call-independent tumor immunity after trensplantaUon of universal receptor-modified bone marrow into SCID mice. J Exp Mad 1996, 184:2261-2269, Hekele A, Dall P, Moritz D, Weis W, Groner B, Herrlich P, Ponta H: Growth retsrdaUon of tumors by edopave transfer of cytotoxlc T lymphocytes reprogrammed by CD44v6-speclflc ecFv:zeta-chlmare` Int J Cancer 1996, 68:232-238. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ: Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 1996, 56:3763-3770. Henelop HE, Ng CYC, I_i C, Smith CA, Loffin SK, Krence • , RA, Brenner MK, Rooney CM: Long-term restoration of Immunity egeinat Epstein-Berr virus infection by sdoptive transfer of gene-modltied virus-spedfic T lymphucytex. Nat Mad 1996, 2:551-555. [571Hsiehma ST, Shi T, Reader J, Ring DB: In vitro tumor 9rowth inhibition by bispecific antibodies to human transforrin receptor and tumor-associated antigens is augmented by the iron chelator doferoxamine. Clin Immunol Imrnunopathol1996, 80:185-193. Hu X¥, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherjl B: Enhancement of cytolyUc T lynlphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptlde loaded entigerl presenting ceil-based vaccine. Cancer Res 1996, 55:2479-2483. Huang XM, Moleme G, King S, Watldne L, Edgington TS, Thorpe PE: Tumor Intarction in mice by antibody-directed targeting of Ussue factor to tumor vanculature. Science 1997, 275:547-550. Js9er E, Ringholter M, Altmannsberger M, Arand • M, Kerbsch J, Jager D, Oesch F, Knuth A: ImmunoseiecUon in v/re: indel~mdent loss of MHC class I end metsnocyte dlfferenSation antigen ox.orueion in metaatattc melanoma. Int J Cancer 1997, 71:142-147. [29]. Johnson TA, Rsssenti LZ, Kipps TJ: Ig V(H)I genes expressed in B cell chronic lymphocyUc leukemia exhibit distinctive molecular features. J Irnmunol 1997, 158:235-246.

Kaminski MS, Zeeedny KR, Francis IR, Farmer MC, Ross • - CW, Milik AW, Estes J, Tuck M, Regan D, Rsher S eta/: Iodine-131-aofi-B1 radictmmunofherepy for B-ceil lymphoma. J Clin Onco11996, 14:1974-1981. [4tl Kang XQ, Robbins PF, Fitzgerald EB, Wang RF, Roeenberg SA, Kawakarni Y: Induction of melanoma reactive T ceils by stimulator cells expressing melanoma epifope-major hiatocompatlhility complex class I fusion proteins. Cancer Re~ 1997, 57:202-206. Katsyoee Y, Kudo T, Suzuki M, Shinoda M, Saijyo S, Sakur=; N, Saeld H, r-ukuhera K, Imai K, Meteuno S: MUCl-speclfic targeting Immunothorspy with bispectfic antibodies: Inh~ition of xenogrofted human bile duct carcinoma growth. Cancer Res 1996, 56:4205-4212. Kiteuki H, Ketene M, Ikubo A, Morissld T, Anann K, Tanaka M, Todsu M: Induction of inflammatory cytoldnes in effusion cavity by OK-432 injection therapy for patients with malignant effusion: Role of interferon-gamma in onh=ncwnant of surface expression of ICAM-1 on tumor cells In vlvo. C/in Immunol Immunopsthol1996, 78:283-290. Kolb HJ: AJlogeneic cell therapy: The treabnent of choice for all hematologic malignancies relapsing post BMT - Response [Letter]. Blood 1996, 87:4012-4013. Kwek LW, Young HA, Pennington RW, Weeks SD: Vecclnstion with ayngoneic, lymphoma-derived immunoglobulln Idlofype combined with grsnulocyte/mecrophage colony-sSmulating factor pdmee mice for a protective T-ceil response, Proc Nag Acad Sci USA 1996, 93:10972-10977. Latemple DC, Hanion TR, Anareki F, Gelili U: Synthesis of eipha-gelectosyt epitopes by recombinant alpha 1,3geiactosyltrensferase for opsonlsstlon of human tumor cell vaccines by antJ-gelacfose, Cancer Res 1996, 56:3069-3074. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Ricklnann • AB: Consented CTL el)Ropes within EBV latent membrane protein 2: • potential target for CTL-besed tumor therapy. J Immunol 1997, 158:3325-3334. [55]. Levitsky HI, Montgomery J, Ahmadzadeh M, Stsveleyocerroll K, Guernieri F, Longo DL, Kwsk LW: Immunization with granulocyte-macrophage colony-stimulating lector-transduced, but not BT-l-transduced, lymphoml cells primes Idlotype-spectflc T ceill and generates potent systemic lntitumor Immunity. J Immuno11996, 158:3858-3865. Lin L, Dsogherty B, Schlom J, Pestks S: Construction of phosphorylatable mono,-.Jonal antibody to I tumor-essoctated antigen. Cancer Res 1996, 56:4280-4254. I.indhofer H, Menzel H, Gunther W, Hultner L, Thierfalder S: BlapecJfic antibodies target operationally tumor-specific antigens In two leukemia relapse models. Blood 1996, 88:4651-4658. Usovsky M, Estmv 7-, Zhang X, Consoli U, Sanchazwil,ams G, SneNV, Mucker R, Goodicre A, Ssvchenko V, Andmeif M: Fit3 Ilgand stimulate a prolRoratJon end Inhibits apoptusis of acute myelold leukemia ceils: Regulation of Bcl-2 and Bax. Blood 1996, 88:3987-3997. I.iu CN, Tadeyoni BM, Bourret LA, Mattocks KM, Den" SM, Widdison WC, Kedersha NL, Atinlello PD, Goldmachar VS, Lambert JM, Baffler WA, Cherl RVJ: Eredlcaaon of largo colon tumor xenogrofta by targeted dedvery of maytanslnoids. Proc Natl Aced Sci USA 1996, 83:8618-8623. Loftus DJ, Castelll C, Clay "rM, Squercine P, Marincois • FM, Nishimura MI, Parmisni G, Appalls E, Rivolfini L: Identification of epRope mimics recognized by CTL reactive to the mellnoma/meianocyta-dorlved peptlde MART-l(27-38). J Exp Mad 1996, 184:647-857. [17]. Meeds Y, Miyatake J, Sono H, Sumimoto Y, Marauds I, Hoduchi F, Tatsumi Y, Irim~ri K, Honuchi A: New therapeuUc effects of retinoid for adult T-ceil leukemia [Letter]. Blood 1996, 88:4726-4727. Msrtinfonteche A, Cevallo F, Bellone M, Heltsi S, le-,; G, Tomsgh~ P, Nabevi N, Fond G, Dehbone P, Cssorsfi G: Hlataogeneous of B7-1 end B7-2 In the induction of both protective and therapeutic antltumur immonity against different mouse tumors. Eur J Immunol 1996, 26:1851-1859. Matsomure I, Kanakura Y, Kate T. Ikeds H, Horikswa V, Ishikaws J, K;teyamsH, Nish;ura T. Tomlysme Y, Miyazald H, Matsusswa Y: The biologic properties of re¢ornblmmt human thrombopolatin in the proliferation and rnegakoryocytlc differentiation of acute myeioblaatk: leukemia cells. Blood 1996, 88:3074-3082. Mawoudis D, Read E, Cottledox M, Cou,~l D, Molldrem #, Carter C, Yu M, Dunbar C, Barrett J: CD34(+) cell dose predicts survlvei, posttransplent morbidity, and rate of hematologic recovery after eilogeneic

Cancer Miscellaneous

marrow transplants for hematologic malignancies. Blood 1996, 88:3223-3229. Mayordomo JI, Loftua OJ, Sakamoto H, Dec•sere CM, Appesamy PM, Lotze MT, St(xkua WJ, Appella E, Deleo AB: Therapy of mudna tumors with p53 wild-type end mutant sequence peptlde-hased vaccines. J Exp Mad 1996, 183:1357-1365. Mcleughlin JP, Schlom J, Kantor JA, Greiner JW: Imlxoved Immunnthorapy of • recombinant cerdnoembryonic antigen vacclnia vaccine when given in combination with intedeukin-2. Cancer Res 1996, 56:2361-2367. Mclean GR, Quadma EV, Rothanberg SP, Morgan AC, Schrader JW, Ziltaner HJ: Antibodies to transcobbiemin II block in vitro proliferation of leukemic cells. B/ood 1997, 89:235-242. Mehts J: The first clinical use of donor leukocyte infusions for the treatment of leukemis relapsing after ellogenbic bone marrow transplantation [Letter]. Blood 1996, 87:4010. Morecki S, Pugatach T, Levi S, Moshel Y, Slevin S: Tumor-cell vaccination induces tumor dormancy in • modno model of B-cell leukemia/lymphoma (BCL(1)). Int J Cancer 1996, 65:204-208. Morits T, Ikeda K, Douzono M, Yamede M, Kimura F, Kswakami K. Sesaki K. Motoyoshi K, Taksham J, Irino S: Tumor vaccination with macrophaga colony-atlmulsting tactor-produclng Lewis lung carcinoma in mice. Blood 1996, 88:955-961. Ohno K, Ycehizawe H, Tack•de H, Takede 1", Yamaguchi Y, Ichikawa K, Maruyarna Y, Suzuki Y, Suzuki E, Arakawe M: Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytoidne gone-modified tumor-pdrned lymph node cells. J Immunol 1996, 156:3875-3881. Old LJ: Immunotherapy for cancer. Sci Am 1996, • • Sapt:136-143. [2?]. Orban PC, Schmder JW: Antibodies to an eutosemuletory growth factor (IL-2) or its receptor induce death of iaukemogenic cells. J Immunol 1996, 156:3334-3341. Ottone~lo L, Moron• P, Dapino P, Dailegri F: Monoclonal Lyre-1 antibody-dependent lysis of S-lymphobieatbid tumor targets by human complement and cytokina-exposed mononuclear and neutrophllic polymorphonucleer leukocytes. Blood 1996, 87:5171-51 ?8. Psi LH, Wittss R, Sester A" Willin9hsm MC, Pastan • h Treatment of advenced solid tumors with immunotosin LMB-I: an antibody linked to Pseudomonas exotoxin. Nat Med 1996, 2:350-353. [27?]. Pancake BA" Wassst EH, Zuckerfranklin D: Demonstration of entlbodias to human T-¢bil lymphofropic virus-I tax in patients with the cutaneous T-csil lymphome. mycosis tungoidas, who are seronngative for antibodies to the structural proteins of the virus. Blood 1996, 88:3004-3009. Pecher G, Rnn OJ: Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucln by vaccination with MUC-1 cDNA-trensfected Epateln-Berr virus Immortalized eutolo9ous B cells. Proc Natl Acad Sci USA 1996, 93:1699-1704. Pedley RB, Boden JA, Boden R, Boxer GM, F:tynn AA, Keep PA" Begant RHJ: Abler;on of coloractal xenografts with combined radlolmmunothorapy end tumor blood flow-modifying agents. Cancer Res 1996, 56:3293-3300. Pang D, Fan 7_, Lu Y, Deblesle T, Scher H, Mendelsohn J: Anti-epidermbi growth factor receptor monoctonbi antibody 225 up-regulates p2?(KIPI) and induces G(1) err•at in prostatic cancer cell line DU145. Cancer Res 1996, 88:3666-3669. Panna C, Dean PA" Nelson H: Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan end bispeclfic antibody. Int J Cancer 1996, 85:377-382. Pekin S, Chakraborty M, Bhattacharyechetterjee M, Zeytin H, Foon KA" Chatterjas SK: Induction of antitumor immunity by en anti-ldlotype antibody mimicking cordnoembryontc antigen. Cancer Res 1997, §7:728-734. Pomponi F, Ceriati R, Zancsi P, Depaoli R Rico S, Tedeschi RM, Pivetts B, De~ts S, Bclocchi M, Dolcettl R: Ratlnolda irreversibly inhibit in vitro growth of F.bstbin-Barr virus-Immortalized B lymphocytea. B/ood 1996, 88:3147-3159. Press OW, Shah D, Howsiiclerk J, Ea~ J, Appelbaum FR, Metthews D, King DJ, Haines AMR, Hamann P, Hinman L, Shochat D, Bemstein ID: Comparative metabolism and retention of Iodine-125, yttrium-90, and Indium-Ill rldtolmmuno¢onjugatas by cancer cells. Cancer Res 1996, 58:2123-2129. Relsfeld RA, Gitlies SD, Mendeleohn J, Varki NM, Backer JC: Involvement of B lymphocytas in the growth kihlbltton of human pulmonary melanoma mltaatlmac In athymic nu/nu mice by

in entibody-lymphotoxin fusion protein. Cancer Res 1996, 56:1707-1712. Reiat CJ, Garg I=Y..Naton KL Bigner DD, Zaiutsky MR: Radioiodination of interoelising monocloosl antibodies using N-succlnimidyl 5-iodo-3-pyrldlnecadooxytste. Cancer Res 1996, 56:4970-4977. Rheinnecker M, Hardt C, Ileg LL, Kufer P, Gruber R, Hoess A" Lupaa A, Rottanbsrger C, Pluckthun A" Pack P: Multivelent antibody fragments with high functional affinity for a tumor-esaodsted cad)ohydrate antigen. J Immunol 1996, 157:2989-2997. Robertson KD, Msons A" Swinnen U, Zong JC, Gulley ML, Ambinder RF: CpG mathylstion of the major Epstein-Bert virus latency promoter in Burkltt's lymphoma and Hodgkin's disease. Blood 1996, 88:3129-3136. Rosaneuer A, Rsolson JV, Ner~ C, Eydoux P, Deblasio A" Miller WH: Alterations in expression, binding to ligand end DNA. end trenscdptionbi activity of rearranged end wild-type retinoid receptors in retlnoid-rasistant acute promybincySc leukemia cell lines. Blood 1996, 88:2671-2682. Sahots SS, Leo R, Hamblin TJ, Stevenson FK: Mysioma V-L and V-H gone sequences reveal • complementary impdnt of antigen selec~on in tumor cells. Blood 1997, 89:219-226. Sansonno D, Devita S, Comacchiulo V, Carbone A" Boiocchi M, Dammacco F: Detection end distribution of hepatitis C virus-roosted proteins in lymph nodes of patients with type it mixed cryoglobulinemie and neoplestlc or non-neuplestlc lymphoproliteretion. Blood 1996, 88:4633-4645. Schmidt W, Steinlein P, Buachle M, Schweighoffer T, Herbst E, Mechtler K, Kirlappos H, Birnstiel ML: Translosding of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines. Proc Natl Acad Sci USA 1996, 93:9759-9763, Scott AM, Cebon JS: Clinical promise of tumor • immunolo9y. Lancet 1997, 349(supp111):19-22. [3?]. Siegfried JM, Weissfeld LA, Singhkaw P, We'jam RJ, Testa JR, Landreneau RJ: Assodatton of immunomoctive hepatocyta growth factor with poor survival in rssentable non-smell cell lung cancer. Cancer Res 1997, 57:433-439. Sing AP, Ambinder RF, Hong DJ, Jansen M, Batten • W, Peteradod E, Greanberg PD: Isolation of Epsteln-Berr virus (EBV)-speclfic cytotoxlc T lymphocytas that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgldn's disease. Blood 1997, 89:1978-1986. [54]. Slavln S, Naparstek E, Nagler A" Kapelushnik Y, Ackerstein A" Or R: Nlogeneic cell therapy: The treatment of choice for ell hematologic malignancies relapsing post BMT [Letter]. Blood 1996, 87:4011-4012. Stone MJ, Ssuaville EA" Fay JW, Headlee D, Collins RH, Fig9 WD, Stetlerstevanson M, Jain V, Jaffa ES, Solomon D, Lush RM, Senderowlcz A" Ghefie V, Schindler J, Uhr JW, Vitetta ES: A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996, 88:1188-1197. Sun SQ, Cai ZI., Langlededemoyan P, Kosaka H, Brunrnark A, Jackson MR, Paterson PA, Sprant .1: Dual function of Drosophila cells as APCs for naive CD8(+) T cells: Implications for tumor immunotherapy. Immuni~ 1996, 4:555-.564. Taguchi H: Redioimmunotherapy: Promising treatment of a99rasslve adult T-cell leukemia? [Letter]. Blood 1996, 87:5379. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine • S, Schlom J, Anderson J, Wisecarver J, Colcher D: High-dose therapy using the iodine-131-labeled monoctonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J C/in Oncol 1997, t 5:1518-1528. [22~']. Tepler I, Elias L, Smith JW, Hussein M, Rosen G, Chang AYC, Moore JO, Gordon MS, Kuca S, Beach KJ, Loewy JW, Garnick MB, Kaye JA: A randomized placebo-controlled trial of recombinant human intedeukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. B/ood 1996, 87:3607-3614. Toes REM, Biota RJJ, Vandervoorl E, Oflringa R, Melief CJM, Kast WM: Protective antltumor immunity induced by immunization with comptately eNogenelc tiJmor cells. Cancer Res 1996, 56:3782-3787. Topsiian SL Gonzales MI, ~ s t M, U YF, -• Southwood S, Sette A, Rosanberg SA, Robbins PF: Metanorna-spedfic COil + T cells recognize nonmutated HLA-DR-restrlctad tyreslnase epitopes. J Exp Mad 1996, 183:1965-1971. [51]. Tsai V, Southwood S, Skiney J, Sakaguchi K, Kawakami • * Y, Appalls E, Sette A, Celis E: IdentificaUon

761

of subdominant CTL epitopes of the GP100 melanoma-ossociated tumor antigen by pcbnery/n v/tro immunization with peptide-pulsad ¢kmddtlc cells. J Immuno11997,158:1796-1802. [22], Weick JK, Kopecky KJ, Appsibacm FR, Head DR, Kingsbury LL, Bslcerzak SP, Bickers JN, Hynea HE, W~bom JL, Simon SR, Graver M: A randomized InvestigaUon of high-dose versus standard-dose cytollml embinoside with daunorublcln in patients with previously untreated acute mysloid leukemia: A Southwest Oncology Group study. B/ood 1996, 88:2841-2851. We~t S, Scott AM, D;vgi CR, Kernany NE, Rnn RD, e• Deghighmn F, St Gerrnain J, Richards EC, Larson SM, Old I1: Phase I/if study of Iodine-125-iabeled monoclonsi antibody A33 In patients with edvenced colon cancer. J Clin Onco/1996, 14:1573-1562. [241]. White CA, Halpem SE, Parker BA, Miller RA, Hupf HB, Shawler DL Collins HA, Royaton I: Rediolmmonofherepy of relapsed B-cell lymphorna with yttrium 90 enti-idiotypa monoclonal antibodies. Blood 1996, 87:3640-3649. Widmer L, Pichert G, Joat LM, Stahsi RA: Fate of contaminating t(14;18)(+) lymphoma cells dudng ax vivo expansion of CD34-selected hernatopolatic progenitor calls. Blood 1996, 88:3166-3175. Yatebe Y, Oka K, Assi J, Mori N: Poor corraletlon between clones immunoglobulin 9ena rearrangement end Immunoglobulin gone transcription in Hodgldn's disease. Am J Patho11996, 149:1351-1361. Yea C, Gilbert MJ, Riddell SR, Brichard VG, Feler A, • ThompsonJA, Boon T, Greenberg I:~: Isolation of tyrosinase-speclfic CD8 + and CD4 + T cell donss fTom the peripheral blood of melanoma patients following in vibo stimulation with recombinant vacclnla virus. J Immuno11996,157:4079-4086. [18]. Yelton OE, Rosok MJ, Czuz G, Cosand WL, Bajoreth J, Henetrom I, Hellstrom KE, Huse WD, Glaser SM: Affinity maturation of the BR98 anti-carcinoma antibody by oodon-based mutagenesls. J Imrnunol 1995, 155:1994-2004. Yoshida M, Rybak RJ, Choi Y, Greanberg SJ, Bercos M, Kaweta A, Matsuno F, Tsai H, Soon BK: Development of • severe combined immunodatlciancy (SClD) mouse model consisting of highly disseminated human B-CSIl leukemia/lymphoma, cure of the tumors by systemic admlnlstretlon of immunotoxin, end devsiopment/eppllcatlon of • clonotype-specltic polymerase chain reaction-based essay. Cancer Res 1997, 57:678-685. Zhsog SL, Graeber LA, Helling F, Regupethi G, Adluri S, lloyd KO, Livingston PO: Augmenting the immunogeniclty of synthetic MUCt paptlda vaccines In mice. Cancer Re• 1996, 55:3315-3319. Zhu H, Molder RJ, Baxter LT, Jain RK: Physlologlcally based kinetic model of effector cell biodistributlon in mammals: Implications for adoptive immunotherapy. Cancer Res 1996, 56:3771-3781.

Miscellaneous Albina JE, Martin BA" Henry WL, Louis CA, Reichner JS: S cell lymphoma-2 transtected P815 cells resist reactive nitrogen intermediate-mediated macrophage-dependent cytotoxlclty. J Immuno/ 1996, 157:279-283. Alpan RS, Zhang M, Pardee AB: Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast osncer cell line. Cancer Res 1996, 56:4358-4361. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, lennettoni MD, Whyte TI, Strleter RM: Interferon-gamma-inducible protein 10 (IP-t0) is an anglostatk: factor tl.4it inhibits human non-small call lung cancor (NSCl.C) tumodgenesis and spontaneous metastases. J Exp Mad 1996, 184:981-992. ArvanitakJs L, Meari EA, Nador RG, Said JW, Asch AS, Knowles DM, Ceserman E: Establishment and characterization of •pdmary effusion (body cavity-based) lymphoma cell line (BC-3) herbodng Kaposrs sarcoma-associated horpesvirus (KSHV/HHV-8) in the absence of Epsteln-Barr virus. Blood 1996, 88:2648-2654. Aachen J, Lonnq~at B, Ringden O, Kumlien G, Gahrton G: Graft-vereus-myelome effect [Letter]. Lancet 1996, 348:346. Bakker ABH, Vsodedou*g SH, Huijbens RJF, D~ijfhoutJW, Msilef CJM, Adams G.I, I=igdor CG: Analogues of CTL epltop4m with improved MHC ctess-I binding capacity ~ anti-melanoma CTL recognizing the wild-type epltope. Int J Cancer 1997, 70:302-309. Baral E, Negy E, Kangas L, Bercz; I: AnS-estrogens enhance the therapeutic effect of lymphokine-

762

Cancer Miscellaneous

activated killer cells on the 1=815rnurine mastocytoma. Int J Cancer 1996, 67:580-585. Bargou RC, Leng C, Kreppmann D, Emmerich F, Mapara MY, Bommert K, Royer HD, Scheidereit C, Dorken B: High-level nuclear NK-I~ppa B and Od-2 is a common feature of cuRured Hodgkin/Reed-Stamborg cells. Blood 1996, 87:4340-4347, Bargou RC, Wagener C, Bommed K, Arnold W, Daniel PT, Mapare MY, Grinstein E, Royar HD, Dorken B: Bloddng of Iren~dptton factor F..2WDP by dominsnt-nagative mutants In • normal breast epithelial ceil line efficiently inhibits epoptosis end induces tumor growth In SCID mice. J Exp Med 1g96, 183:1205-1213, Beckwith M, Jorgensen G, Longs DL: The protein product of the proto-oncogene c-ebl forms • complex with phosphatldyllnosltol 3-kinmm 1085end CD19 in entl-lgM-stimuistad human B-lymphome cells. Blood lg96, 88:3502-3507. Bhatie S, Ramsay NKC, Steinbuch M, Dusenbery KE, Shapiro RS, Weiedorf DJ, Robison LL, Miller JS, Naglia JP: Malignant neoplasms following bone marrow transplantation. B/sod 1996, 87:3633-3639. Bologneai A, Tazzari PL, Olivieri F, Polite L, Feline B, Stirpe F: Induction of epoptolls by ribosome-inactivating proteins and related Immunotoxins. Int J Cancer 1996, ti8:349-355, Botzler C, Kolb I-U, iscels RD, Multhoff G: Noncytutoxic eikyl-lysophosphollpid treatment increases sensitivity of leukemic K562 cells to lysis by natural killer (NIO ceils (vol 65, pg 633, 1996). Int J Cancer 1996, 66:713, Brouwenstijn N, Gaugler B, Kruea KM, Vanderspek CW, Mulder A, Osanto S, Vandeneynde BJ, Schrier I=1: Renal-cell cercinoma-xpaclflc lysis by cytotoxic T-lymphocyte donas isolated from pedphersl blood lymphocytes and fumor-lnfiltratthg lymphocytas. Int J Cancer 19g6, 68:177-182. Caignard A, Guillard M, Geudin C, Escudier S, Triebel F, Dietrich PY: In sRu demonstration of renei-ceti-cercinome-speolflc T-cell clones. Int J Cancer 1996, (;6:564-570. Charles RJ, Sabo KM, Kidd PG, Abkowitz JL: The pathophysiology of pure red cell eplesis: Implications for therapy. Blood 1g96, 87:4831-4838. Chan GCL Zhu J, She XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shan ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Neoe T, Chen SJ, Wang ZY, Chen Z: In vitro studies on cellular end molecular mechanisms of arsenic trioxide (As203) In the treatment Of acute promyeiocySc leukemia: As203 induces NB4 ceil apoptosls with downrsguletion of bct-2 expression end modulaSon of PML-RAR eipha/PML proteins. Blood 1996, 88:1052-1061. Chesi M, Bargaegel PL, Brants LA, Smith CM, Gerhard DS, Kuehl WM: Dysreguiotlon of cyctin D1 by tranelncatlon Into an IgH gamma switch region In two multiple myeloma ceil lines. Blood 1996, 88:674-681. Condomlli GL, Facchiano F, Valtieri M, Proietti E, Vitelli L, Lulli V, Huebner K, Peechle C, Croce CM: T-ceil-dirncted TAL-1 expressloo induces T-cell malignancies in transganic mice. Cancer Res 1996, 56:5113-5119. Cutrone G, Done M, Pastorino S, Ulivi M, Burgio VL, Zupo S, Roncelis S, Farrarinl M: The propensity to epoptceis of cantrocytes end cenfroblests correlates with elevated levels of Intracelluisr myc protein. Eur J Immunol 1997' 27:234-238, Decosta LT, Jan J, He TC, Chan TA` Kinzler KW, Vogelstein B: Converting cancer genes into killer genes. Proc Natl Aced Sci USA 1996, 93:4192-4196. Dame, RB: Onconeoral antigens end the pareneoplestic neurctogic disorders: At the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA 1996, 93:4529-4536. David K, Oiled MW, Juhl H, VoNmertC, Erttmann R, Vogel CW, Bredehorst R: Growth arrest of solid human neurobisstoma xenogratts in nude rats by natural IgM from healthy humans. Nat Mad 1996, 2:686-689. Dent AL, Yewdell J, Puviondutilleul F, Koken MHM, Dethe H, Staudt LM: LYSP100-mociated nuclear domains (LANDs): Description of • new class of subnuclesr structures end their relationship to PML nuclear bodies. B/sod 1996, 88:1423-1436. Devys A` Thedrez P, Gautherot E, Faiwechauvet A, Salmaurel C, Rouvier E, Auget JL, Barbet J, Chatel JF: Comparative targeting of human colon-cardnoma muificell spheroids using one- and two-step (bispeclflc antibody) techniques. Int J Cancer 1996, 57.:883-891. Dohi T, Yuyama Y, Natori Y, Smith PL, Lowe JB, Oshime M: Dntedion of N-acatylgalactocaminyifrenstereee

mRNA which determines expression of Sd(a) blood group carbohydrate structure in human gastrointestinal mucose and cenceh Int J Cancer 1 g96, 67.:626-631. Donawho CK, Muller HK, Bucana CD, Kripke ML: Enhanced growth of mudne melanoma in ultrsvtolet-lrradiated skin is esancisted with local inhibition of immune effector mechanisms. J Immunol 1996, 157:781 -?86. Dugas N, Mossalayi MD, Calends A` Leotard A` Becherel P, Mentz F, Oueaz F, Arock M, Debre P, Demand J, Dugas B: Role of nitdc oxide In the anti-tumoral effect of retlnoic acid end 1,25-dihydmxyvltamln D-3 on human promonacyti¢ leukemic cells. Blood 1996, 88:3528-3534. Eitzman DT, Krauss JC, Shee TL, Cue JS, Ginsburg D: Lack of plesminogen actuator inhibitor-1 effect in a transgenic mouse model of metastaticmeisnoma. Blood 1996, 87:4718-4722. Fischbach W, Tacke W, Grelnar A` Mulicrherrnelink HK: Regression of Immunoproliferattve small intestinal disease after eradication of Hellcobactor pylod. Lancet 1997, 349:31-32. Forrester K, Arabs S, Lupold SE, Kapust RB, Spilku'e EA, Weinberg WC, Felleybosco E, Wang XW, Gellar DA` Tzeng E, Billiar TR, Harris CC: Nitric oxide-Induced p53 accumulation end regulation of inducible nitd¢ oxide synthase expresaion by wild-type p53. Proc Nat/Acad Sci USA 1996, 93:2442-2447. Frank AJ, Proctor SJ, Tilby MJ: Detection and quantification of Melphaisn-ONA edducts at the single cell level in hematopoleUc tumor cells. Blood 1996, 88:977-984. Freeman SM, Ramesh R, Marmgi AJ: Immune system in suicide-gene therapy. Lancet 1997, 349:2-3. Fujimoto J, Shiota M, Iwaham T, Seki N, Setoh H, MoreS, Yamamoto T: Characterization of the transforming activity of p80, a hyperphosphoryleted protein in a Ki-1 lymphoma (:ell line with chromosomal translocation t(2;5). Prcc Nat/Aced Sci USA I g96, 93:4181-4186. Geley S, Hartmann BL, Hela M, Sttesserwozak EMC, Kapelari K, Kofler R: Resistance to gluco¢ortiocid-lnduced apoptosis In human T-cell acute lymphobisstic leukemia CEM-C1 ceils is due to insufficient 91ucocorticold receptor expression. Cancer Re:; lg96, 56:5033-5038. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SYL, Watanabe M, Gong JL, Hayes DF, Kufe DW, Nadler LM: Breast cancer-associated antigen, DF3/MUC1, induces apoptosls of activated human T cells. Nat Mad 1996, 2:1367-1370. Gompels UA` Kasoic FC: HHV-8 serology and Kaposrs sarcoma [Letter]. Lancet 1996, 348:1687-1588. Griflioen AW, Daman CA, Blijhem GH, Groenewegen G: Tumor angiogeneels is accompanied by • decreased inflammatory response of tumor-essodatad endotheiium. Blood 1996, 88:667-673. Grimm S, Lader P: An apoptosis-lnducin9 isoform of Neu differentiation factor (NDF) identified using a novel screen for dominant, epoptesis-inductng gases. J Exp Mad 1997' 185:1137-1142. Hannun YA: Apoptesis and the dilemma of cancer chemotherapy. Blood 19g7, 89:1845-1853. Hadebachor C, Boukamp P: Teiomemse activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin korattnncytes. Proc Nat/Acad Sc/USA 1996, 93:6476-6481. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Rifler G, Cohen L, Welt S, Old LI, Nice EC, Burgess AW: The human A33 antigen ts a transmembrane glycoproteln and a novel member of the immunogiobulln suparfamily. Proc Nat/Acad Sci USA 1997, 94:469-474. He CY, Otterud B, Legate RD, Varvil 1", Saxena R, Dehart DB, Kohler SE, Aster JC, Dowton SB, Li ~ Leppert M, Gilliland DG: Unkage of • familial platelnt disorder with a propensity to develop myeioid malignancies to human chromosome 21q22.1-22.2. Blood 1996, 87:5218-5224. Homing SJ, Chao NJ, Negitn RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG: High-dose therapy and autoiogous hernatopoleUc progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997, 89:801-613. Irani K, Xla Y, Zweier JL, Sollott SJ, Der CJ, Fearoo ER, Sundaresan M, Finkel 1", Goldschmidtclermont PJ: Mitogenic signaling mediated by oxidants in res-trensformed fibroblasts. Science 19g7, 275:1649-1652.

leaacson PG, Ashtonkey M: Phenotype of Hodgkin end Reed-Steinberg ceils. Lancet 1995, 347:481. Jackow CM, Cather JC, Heeme V, Asano AT, Muaser JM, Duvic M: Association of erylhrodermic cutaneous T-ceil lymphorns, supman8geo-posltlve Staphylococcus sureus, end ollgoctonei T-ceil receptor V beta gene expansion. Blood 1997, 89:32-40. Jamom C, Denned G, Lee AS: Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction In flbrnsercoma B/C10ME. Pmc Nat/Acad Sci USA lg96, 93:7690-7694, Juretic A, Jurgenagobel J, Schaffer C, Noppan C, Wiflimann TE, Kocher 1", Zuber M, Harder F, Heberer M, Spagnoll GC: Cytotoxic T-lymphocyta responses against mutated p21 res paptldes: An analysis of specific T-ceil-receptor gene usage, Int J Cancer 1996, 68:471-478. Kishimoto 1", Ishikura H, Kimure C, Takehuhi T, Kate H, Yoshiki T: Phenotypes correlating to metastatic properties of pancreas edeflocamlnoma in vtvo: The importance of surface elelyl Lewis(e) antigen. Int J Cancer 1996, 69:290-294. Kitayama H, Tsujimura1", Matsumure I, Odtani K, Ikeda H, Ishikawa J, Okabe M, Suzuki M, YamarnumK, Matauzawa Y, Kitamura Y, Kanakum Y: Neoplastic transformaUon of normal hematopolati¢ cells by constitutively ectiveUng mutations of c-klt receptor tymelne kinese, Blood 1996, 88:995-1004. Klaamaa K, Held M, Wadstmm 1", Upping A` Kurtenkov O: IgG immune response to Heiicobeotar pylod antigens In paUents with gastric cancer as defined by F.USA end immunoblotting. Int J Cancer t995, 67:1-5. Klampfer L, Zhang J, Zelenet= AS, Uchide H, Nimer SD: The AML1/ETO fusion protein activates transcription of BCL-2. Proc Nat/Aced SCI USA 1996, 93:14059-14064. Konur A, Krauee SW, Rehli M, Kreutz M, Andreesen R: Human monocytes induce • carcinoma cell line to secrete high ernounta of nitdc oxide, J Immune/ 1996, 157:2109-2116. Krause DS, Fackier MJ, Civin CJ: CD34: StnJctore, biology, end cileical utilify (vol 87, pg 1, 1996). Blood 1996, 88:2373. Labarrlere N, Diez F_.,Pandolfino MC, Viret C, Guilloux Y, Leguiner S, Fonteneeu JF, Drone B, Jotareac F: Opamat T cell activation by melanoma ceils depends on • minimal level of antigen trenscdption. J Immuno11997,158:1238-1245. Laky K, Lefranccie L, Puddington L: Age-dependent intestinal lymphoproliferative disorder due to stem cell factor receptor deficiency - Parameters in small end large intestine, J Immuno11997,158:1417-1427. Landowski TH, Gleseenguzmlm MC, Dstion WS: Selection for drug resistance results In resistance to Fes-medisted apoptosls. Blood lg97, 89:1864-1861. Lee SW: H-cedpadn, a novel cedhedn with growth inhibitory functions and diminished expression in human breast rancor. Nat Mad 1996, 2:776-782, Li MF, Muller J, Xu F, Hearing VJ, Goralik E: Inhibition of melanoma-associated enhgen expression and ncofropic refrovirus production in B16BL6 melanoma ceils transfected with major histncompatJbilify complex class I genes. Cancer Rea lg96, 56:4464-4474. LJu SQ, Shiraiwa H, Kawai K, Hayeehi H, Akaza H, Kim BS, Ski A` Nishida M, Kubo T, Heehizaki K, SaJjo K, Ohno T: Tumor-specific eutologous cytutoxic T lymphocytes from tissue sections [Letter]. Nat Mad 1996, 2:1283. Luboldt HJ, Kubens BS, Rubben H, Gmsswilde H: Sele,.'~lve loss of human leukocyte antigen class I allele expression in advanced renal cell cardnome` Cancer Res 19g6, 56:826-830. Macmanus M, Lambom K, Khan W, Vargheee A` Greef L, Knox S: Radiothorepy-essoclatad neutropenla end thrombocytopenia: Analysis of risk factors end development of a predictive model. Blood 1997, 89:2303-2310. Mahmoud MS, Huang NH, Nobuyoshi M, Lisukov IA` Tanaka H, Kawano MM: ARMed expression of Pax-5 gene in human myeioma cells. Blood 1996, 87:4311-4315. Martiniello R, Burton RC, Smart YC: Ly-6C(+) natural T (NT) cells mediate immune surveillance against NK-sensitive end NK-resistant transplantable tumours In certain strains of mice./nt J Cancer 1996, 86:632-63?. Menoret A` Patty Y, Burg C, Lepandu J: Co-segregation of tumor immunogeolclty with expression of Inducible but nut consiffutlve hsp70 in rat colon carcinomas. J Immuno11995,155:740-747. Morelli D, Menard S, Colna9hi MI, Belsari A: Oral administration of anti-doxorubictn monocionei antibody prevents chemotherapy-induced

Cancer Miscellaneous

gestrolntaatirml toxicity in mice. Cancer Res 1996, 56:2082-2085. Muller JR, Jones GM, Janz S, Potter M: Migration of cells with Imrnunoginbulln/c-myc recombinations in lymphoid tissues of mice. Blood 1997, 89:291-296. Nag•t• S: Fee IIg•nd •nd immune evasion. Nat Mad 1996, 2:1306-1307. Nemani M, Linerescruz G, Bruzzonigiovanelli H, Roperch JP, Tuynder M, Bougueleret L Cherif D, Mndhioub M, Pasturaud P, Aivaro V, DersarlQssan H, Cazes L Lap•slier D, Legall I, Israeli D, Dausset J, Sigaux F, Chumakov I, •ran M, Calvo F, Am•on RB, Cohen D, Telerman A: Activation of the human homologue of the Drosophila sine gone in •poptosis and tumor suppression. Proc Nat/Acad Sci USA 1996, 93:9039-9042. Ogcehi M, Takashima A, Taylor RS: Mechanisms regulating tel•meres• activity in mudne T cells. J Immunol 1997,, 158:622-628. Ohwnda A, Rafts S, Moore MAS, Crystal RG: In vivo aden•virus vector-mediated transfer of the human thrombopoiadn cDNA maintains platelat levels during radiation- and chemofherapy-induced bone marrow suppression. Blood 1996, 88:7?6-?84. Ollert MW, David K, Schmitt C, Hauenschild A, Bredehorst R, Erttmann R, Vogel CW: Normal hum•n serum contains • natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Nat/Acad Sci USA 1996, 93:4495-4503. Ong ST, Koeppan H, Larson RA, •lop•de Oh Successful treatment of •nglolmmunobl•stic lymphsdenopathy with dysprotelnarni• with fludarabine [Letter]. Blood 1996, 88:2354-2355. Ozdemlr E, Kakahi Y, Nakamura E, Kin•shits H, Terachi T, Ok•de Y, Yoshida O: HLA-DRBt °0101 •nd *0405 as protective alleles in Japanese patients with renal cell cardnoma. Cancer Re• 1997, 57:742-746, Pabst 1", Schweiler J, Bell•too MJ, Oestreicher M, Muhlematter D, T,chelli A, Tobler A, Fay MF: Frequent ciorml loss of haterozygoslty but scarcity of mlorosatellita instability at chromosomal breakpoint cluster regions in adult iaukemiae. Blood 1996, 88:1025-1034. Paequalini R, Bourdoulous S, Koivunen E, Woods VL, Ruoslehti E: A polymeric form of flbroneolin has entimatastatlc effects against multiple tumor types. Nat Mad 1996, 2:1197-1203, Pawann R, Catovaky D, Schulz TF: Lack of evidence of HHV-8 in mature T-cell lymph•proliferative disorders [Letter]. Lancet 1996, 348:1450-1451. Pen{} SL, Robert ME, Heyday AC, Craft J: A tumor-suppressor function for Fee (CD95) revealed In T cell-deficient mice. J FJrpMed 1996, 184:1149-1184, Patty KU: HIV infection and neopiasia [Letter]. Lancet 1996, 348:1317` liras MA, Ssiis T, Nsltana AV, Span• L, Aceti A: HIV infection •nd neopiasia [Letter]. Lancet 1996, 348:1316-1317. Pdtchludjones K, Hawkins MM: Biology of WIIms' tumour. Lancet t 997, 349:663-664. Reslson JV, Nervi C, Rosenauer A, Banedetti L Monczak Y, Pearson M, Pelicci PG, Miller WH: The PML/RAR alpha oncoprofeln is • direct molecular target of reUnoic I d d in Icufe promyelocytic leukemia calls. B/ood t 996, 88:2826-2832. Raynsud SD, Beans M, Grcegeorge J, Rodgers K, Reid CDL, Dainton M, Dyer M, Fuzibet JG, Gratecos N, Taillan B, Ayraud N, M=uynan P: Ruorascence in situ hybddlcation analysis of t(3;12)(q26;p13): A ra¢urriog chromosomal abnormality involving the TEL glme (ETV6) in rnyolodysples~c syndromes. Blood 1996, 88:682-689. Reiter Y, Wright AF, Tonge DW, Pastan I: Recombinant singia-choln end disulfide-stabilized I=v-lmmunotoxins that cause complete regression of • human colon cancer xenogratt in nude mlc~ Int J Cancer 1996, 57:113-123. Rensingehl A, Fmi K, Fiuly R, Matiba B, Merlani SM, Wener M, Aebischer P, Krammer PH, Font•ha A: Local Fes/APO-1 (CD95) llgand-madlatad tumor cell killing in vivo. EurJ Immuno11995,25:2253-2258. Rhosdes KL Hethedngton CJ, Rowfey JD, Hieberl SW, Nucifora G, Tanan DG, Zhang DE: Synergistic up-raguiation of the myelold-xpeclflo promoter for the react•phage colony-st~uiating factor receptor by AMLI •rid the t(8;21) fusion protein may contribute to leukarnogenesle. Proc Nat/Acad Sci USA 1996, 93:11895-11900.

Roth J, Dittmer D, Res D, Tertaglia J, Paolstti E, Levine AJ: p53 as • target for cancer vaccines: Recombinent canerypox virus vectors expressing p53 protect mica against lethal tumor cell challenge. Proc Nat/ Aced Sc/ USA 1996, 93:478t-4786. Rubio CA: Tumor cells induce •poptosis in lymphucytas [Letter]. Nat Mad 1997, 3:253-254. Sanchez Y, Lovell M, Merin MC, Wong PE, Wolff•rib•tier ME, Mcdonnell TJ, Killmy AM: Tumor suppression and apoptosis of human prostate carcinoma mediated by • genetic lucus within human chromosome 10pter-ql 1. Proc Nat/Acad Sc/ USA 1996, 93:2551-2556. Sanjeevi CB, Hjelmstrom P, Heilmans G, Wiklund F, Lenner P, Angstrom T, Dillner J, Lemmark A: Different HLA-DR-DQ haplotyPes ere associated with cervical intraeplthelial neopiasiz •mong human papillomaviros type-16 set•positive and set•negative Swedish women. Int J Cancer 1996, 68:409-414. Santonirugiu E, Preisegger KH, Kiss A, Audolfsson 1", Shiota G, Schmidt EV, Tho~geirason SS: Inhibition of neoplastic development in the liver by hepatocyte growth factor in • transgentc mouse model. Proc Nat/Acad Sci USA 1996, 93:9577-9582. Sastragarau X, Loste MN, Vincentsalomon A, Fsvra M, Mouret E, Delarochefordiere A, Durand JC, Tartour E, Lepage V, Charron D: Decreased frequency of HLA-DRBl*13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. Int J Cancer 1996, 69:159-164. Schultz TF, Boahoff C, Weiss RA: HIV infection end neopiasla - Reply [Letter]. Lancet 1996, 348:1318. Saliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampa R, Momburg F, Huber C: Analysis of the major hlatocompatibility complex class I antigen presentation machinery In normal and malignant renal cells: Evidence for doficiencies associated with transtormaUon and progression. Cancer Res 1996, 55:1756-1760. ShaJinsky DR, Bischoff ED, Lamph WW, Zhang L, Boehm MF, Davies PJA, Nadzan AM, Heyman RA: A novel retinolc acid receptor-selective retinoid, ALRT1550, has potent •ntltumor activity against human oral square•us carcinoma xenografts in nude mice. Cancer Res 1997, 57:162-168. Shimizu M, Yam•mot• A, Nakano H, Mstsuzawa A: Augmentation of entitumor immunity with bacterial superantlgen, staphylococcal enter•toxin B-bound tumor cells. Cancer Res 1996, 56:3731-3736. Shim•hi A, Marcus H, Canaan A, Ergas D, David M, Berrebi A, Reianer Y: A model for human B-chronlo lymphocytic leukemia in hum•n/mouse radiation chimers: Evidence for tumor-madiated suppression of antibody production in low-stage disease. Blood 1997, 89:2210-2218. Singal DP, Ye M, Qiu XH: Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma call lines./nt J Cancer 1996, 68:629-636. Sob•lie PVV,Montone KT, Satyamoorthy K, Nesbit M, Hedyn M: Carcinogenesis in human skin grafted to SClD mice. Cancer Res 1996, 56:757-764. Stauder R, Vandriel M, Schwarzler C, Thalar J, Lokhorat HM, Krauser ED, Bloom AC, Gunthert U, Eisterar W: Different CD44 splidng patterns define prognostic subgroups in multiple my•some` Blood 1996, 88:3101-3108. Stilganbauer S, Liebisch P, James MR, Schrodar M, Schlegelberger B, Fischer K, Bentz M, LJchter P, Dohner H: Molecular cytogenefic delineation of • novel critical genomic region in chromosome hands 1lq22.3-q23.1 in lymphoprollfer•tive disorders (vol 93, pg 11837, 1996). Proc Nat/Aced Sci USA 1996, 93:14992. Stoffel M, Lebesu MM, Espinoss R, Bohlander SF, Lap•slier D, Cohen D, Xiang KS, Cox NJ, Fajana SS, Bell GI: A yeast artificial chromosome-based map of the region of chromosome 20 containing the diabetes-susceptibility genii, MODY1, and • myelold leukemia related genii. Proc Nat/Acad Sci USA t 996, 93:3937-3941. Sutton L, Chest•rig C, Ribaud P, Jooet JP, Kuentz M, AttaJ M, Reiffers J, Tigaud JM, Rio B, Dauriac C, Legros M, Dreyfus F, Lloura B, Trousserd X, Milpied N, Witz F, Odcl P, Cahn JY, Michallot M, Gluckman E, Ifrah N, sic• JL Vilmer E, Leblor¢l V: Factors influencing outcome in de nov• myek;Klyspiastic syndromes treated by ellogeneic bone marrow transplantation:

763

A long-term study of 71 paUents.Blood 1996, 88:358-365, Svane IM, Engel AM, Nielsen MB, Ljunggran HG, Rygsard J, Werdelin O: Chemically induced sarcomas from nude mice • m more immunogonic than similar sarcomas from congenic normal mice` Eur J Imrnunol t 996, 26:1844-1850. Tanaka Y, Kimata K, Wake A, Mine S, Morimoto I, Yernakawa N, Habuchi H, Ashikeri S, Yam•mot• H, Sakurai K, Yoshida K, Suzuki S, Eto S: Hedamn sulfate proteoglycan on leukemic cells is pdmadly involved in Integdn triggering end its mediated adhesion to endothelial cells. J Exp Mad 1996, 184:1987-1997. Taylor RL, England JM, Kopen GC, Christou AA, Heipem MS: Sequence v•datlon in the SRC game product affects met•strode formation: The central, but not exclusiv•, role of th• tumor immune response. Int J Cancer 1996, 68:228-231. Uyttanhove C, Godfraind C, Lethe B, Amercosteaec A, Reneuld JC, Gajewski TF, Duffour MT, Warnier G, Boon T, Vandeneynde BJ: The •xpraesinn of mouse genii P1A in testis does not prevent safe induction of cytolytic T cells against • PlA-encodad tumor antigen. Int J Cancer 1997, 70:349-356. Vacoher E, Tirelli U: HIV infection and neopiasia [Letter]. Lancet 1996, 348:1317-1318. Vanhei NLW, Vandongan GAMS, Roodknippeia EMC, Vandervalk P, Snow GB, Brakenhoff RH: Monoclonat antibody U36, • suitable candid•t• for clinical immunotherapy of square•us-cell carcinoma, recognizes • CD44 is•form. Int J Cancer 1996, 68:520-527. Virgilio L, Shuster M, Gollin SM, Veroneae ML, Ohta M, Huebner K, Croce CM: PHIT gone eltaratlone in head and neck square•us cell carcinomas - Inaugural paper. Proc Natl Acad Sci USA 1996, 93:97?0-9775. Wakaneil PS, Miller MM, Got• RM, Gauderman WJ, Briles WE: Association between the Rfp-Y haplotype and the inddenca of Marak's disease in chickens. Immunogenetics 1996, 44:242-245. Watson SA, Michaeli D, Grimes S, Morris TM, Robinson G, Verro A, Justin TA, Hardcastle JD: Gestrimmurm raises antibodies that neutralize amid•ted end glydne-extanded gastrln-17 end inhibit the growth of colon cancer. Cancer Res 1996, 56:880-885. Wsttel E, Guercl A, Hecquet B, Economopoulos 1", Copplestone A, Mahe B, Couteaux ME, Rasegotti L, Voglovl V, Foussard C, Pegourie B, Michsux JJ, Deconinck F., Stoppa AM, Mufti G, Oscier D, Fenaux P: A randomized trial of hydroxyures versus VP16 in adult chronic myelomonocytlc leukemia. Blood t 996, 88:2480-2487, Williams IR, Ort PJ, Delay D, Manning L, Karaoli 1", Bernhill RL Kupper TS: Constitutive expression of B7-1 (CD80) on mouse keratinocytes does nut prevent development of chemically induced skin papillomas and cardnornas. J Immuno/1996, 156:3382-3388. Yam•mot• N, Neraparaju VR, Asbell SO: Deglycosyiatlon of serum vitamin D-3-binding protein leads to Immunosupprosslon in cancer patients. Cancer Res 1996, 56:2827-2831. Yang GC, Mizuno MT, Hellstrom KE, Chen LP: BT-negaSve versus B7-positive P815 tumor o Differential requirements for pdmlng of an antltumor Immune response in lymph nodes. J Immuno/1997, 158:851-888. Yi AK, Hornbeck P, Lefranz DE, Kdeg AM: CpG DNA rescue of mudn• B lymph•me cells from antl-lgM-induced growth arrest end programmed cell death is associated with increased expression of c-myc end bcl-x(I.). J Immuno/1996, 157:4918-4925. Yen DX, Schimke RT: Inhibition of •poptesiz by ovarexpressing B¢1-2 enhances germ •mpllticatlon by • mechanism independent of •phidicolin pretreatmenL Proc Nat/Acad Sci USA 1996, 93:3394-3398. Zlvmg JF, Hu CJ, Geng YP, Selm J, Klein SB, •raze A. Taylor MW: Treatment of • human breast cancer xenograft with an aden•vires vector containing an interferon gerte results in rapid regression due to viral oncolysls and gone therapy. Proc Nat/Aced Sci USA 1996, 93:4513-4518. Zhu XL Kumer R, Mendel M, Bharma N, Sharma HW, Dhingra U, Sokolceld JA, Hsiao RS, Narayanan R: Cell cycle-dependent muduiatlon of tel•meres• activity in tumor cells. Proc Nat/Acad Sci USA 1996, 93:6091-6095.